INFORMATION TO USERS

This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer.

The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction.

In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion.

Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand corner and continuing from left to right in equal sections with small overlaps.

ProQuest Information and Learning
300 North Zeeb Road, Ann Arbor, MI 48106-1346 USA
800-521-0600

University of Alberta

IDENTIFICATION AND CHARACTERIZATION OF MULTIDRUG EFFLUX PUMPS IN THE *BURKHOLDERIA CEPACIA* COMPLEX

by

Cynthia Lynn Handford 

A thesis submitted to the Faculty of Graduate Studies and Research in partial fulfillment of the requirements for the degree of Master of Science

in

Microbiology and Biotechnology

Department of Biological Sciences

Edmonton, Alberta

Fall 2005

ABSTRACT

Infections caused by the *Burkholderia cepacia* complex, an opportunistic pathogen best known for infecting cystic fibrosis patients, are notoriously difficult to treat due to widespread antibiotic resistance. The objective of this study was to determine the role of multidrug efflux pumps in the overall antibiotic resistance of these organisms. In this study, six putative efflux pumps belonging to the resistance nodulation division (RND) family were identified. Several attempts were made to characterize the efflux systems by deletion and overexpression analysis. RT-PCR experiments showed that only one of the efflux systems was expressed in wild-type cells. Potential inducers of efflux pumps were tested with RT-PCR experiments. The presence of salicylate and chloramphenicol had no effect on efflux pump expression. However, one efflux system appeared to be induced during late-logarithmic growth. In addition, a Flp/FRT system was developed for the creation of markerless mutations in the *B. cepacia* complex.

TABLE OF CONTENTS

LIST OF TABLES

LIST OF FIGURES

LIST OF ABBREVIATIONS

α	Alpha
β	Beta
Δ	Delta (used to represent deletion)
λ	Lambda
Φ	Phi
ABC	ATP-binding cassette
BLAST	Basic local alignment search tool
BLASTP	Protein-protein basic local alignment search tool
bp	base pair
cDNA	Complementary or copy DNA
CF	Cystic fibrosis
DEPC	Diethyl pyrocarbonate
DMSO	Dimethyl sulfoxide
DNA	Deoxyribonucleic acid
DNase	Deoxyribonuclease
dNTP	Deoxynucleoside triphosphate
EDTA	Ethylenediaminetetraacetic acid
EPEC	Enteropathogenic *Escherichia coli*
Flp	Flippase
FRT	Flp-recombinase target
HK	Sensor histidine kinase
HSL	Homoserine lactone
kb	Kilobase
LPS	Lipopolysaccharide
MATE	Multidrug and toxic compound extrusion
MFS	Major facilitator superfamily
MIC	Minimum inhibitory concentration
mRNA	Messenger ribonucleic acid
NCCLS	National Commmittee for Clinical Laboratory Standards

OD	Optical density
ORF	Open reading frame
PCR	Polymerase chain reaction
RNA	Ribonucleic acid
RNase	Ribonuclease
RND	Resistance nodulation cell division
RR	Response Regulator
RT-PCR	Reverse-transcriptase polymerase chain reaction
SCP	Small cryptic plasmid
SDS	Sodium dodecyl sulfate
SMR	Small multidrug resistance
TAE	Tris-acetate EDTA

Chapter 1: Introduction

1. INTRODUCTION

1.1 The *Burkholderia cepacia* complex

The *Burkholderia cepacia* complex refers to a group of closely related species of Gram-negative, non-spore forming bacilli. Originally known as *Pseudomonas cepacia* (Burkholder, 1950), the organism has undergone many changes in taxonomy. The genus *Burkholderia* was created in 1992 (Yabuuchi *et al.*, 1992) and later divided into five genomovars representing groups of genetically distinct, phenotypically similar isolates (Vandamme *et al.*, 1997). Once differential tests became available, the genomovars were assigned species names. There are currently nine species in the *B. cepacia* complex: *B. cepacia* (genomovar I) (Vandamme *et al.*, 1997), *B. multivorans* (genomovar II) (Vandamme *et al.*, 1997), *B. cenocepacia* (genomovar III) (Vandamme *et al.*, 1997; Vandamme *et al.*, 2003), *B. stabilis* (genomovar IV) (Vandamme *et al.*, 1997; Vandamme *et al.*, 2000), *B. vietnamiensis* (genomovar V) (Vandamme *et al.*, 1997), *B. dolosa* (genomovar VI) (Coenye *et al.*, 2001a; Vermis *et al.*, 2004), *B. ambifaria* (genomovar VII) (Coenye *et al.*, 2001b), *B. anthina* (genomovar VIII) (Vandamme *et al.*, 2002), and *B. pyrrocinia* (genomovar IX) (Vandamme *et al.*, 2002).

Since its original discovery as a plant pathogen (Burkholder, 1950), the *B. cepacia* complex has emerged as an organism of interest in the fields of agriculture, bioremediation, and medicine. Members of the *B. cepacia* complex cause sour skin disease of onions (Burkholder, 1950). This pathogenicity involves a plasmid-encoded pectate hydrolase responsible for tissue maceration (Gonzalez *et al.*, 1997) and a type IV secretion system involved in secretion of plant cytotoxic factors (Engledow *et al.*, 2004). However, in many ways, the *B. cepacia* complex is beneficial to agriculture. Members of

the *B. cepacia* complex are associated with the roots of commercial crops such as maize, rice, and wheat, sometimes even colonizing internal root tissue (Gillis *et al.*, 1995; Hebbar *et al.*, 1992b; Nacamulli *et al.*, 1997; Viallard *et al.*, 1998). Interaction with the *B. cepacia* complex can enhance crop growth (Bevivino *et al.*, 1998; Clark and Parke, 1996; Germida and Walley, 1996; Tran Van *et al.*, 2000). For example, inoculation of rice with *B. vietnamiensis* increases yield by 13-22% (Tran Van *et al.*, 2000). *B. cepacia* complex strains are also useful biocontrol agents against fungal pathogens such as *Pythium* spp. (Bowers and Parke, 1993; Heungens and Parke, 2000; King and Parke, 1993; Mao *et al.*, 1998), *Rhizoctonia solani* (Homma *et al.*, 1989; Kang *et al.*, 1998), and *Fusarium* spp. (Bevivino *et al.*, 1998; Hebbar *et al.*, 1992a). The mechanism of biocontrol is often attributed to production of antifungal metabolites such as antibiotics (Burkhead *et al.*, 1994; Cartwright *et al.*, 1995; Homma *et al.*, 1989; Jiao *et al.*, 1996; Kang *et al.*, 1998; Lee *et al.*, 1994; Meyers *et al.*, 1987; Moon *et al.*, 1996; Parker *et al.*, 1984; Roitman *et al.*, 1990) and siderophores (Bevivino *et al.*, 1994; Meyer *et al.*, 1995; Sokol *et al.*, 1999). In addition to agricultural uses, the *B. cepacia* complex is a potential bioremediation agent. *B. cepacia* complex members are able to use a wide array of carbon sources, including soil and groundwater contaminants such as phthalates, herbicides and chlorinated hydrocarbons (Krumme *et al.*, 1993; Ribbons *et al.*, 1984; Sangodkar *et al.*, 1988; Shields and Reagin, 1992). Despite beneficial applications in agriculture and bioremediation, there is concern about potential harm to people susceptible to infections by the organism (Holmes *et al.*, 1998).

Although there are some examples of *B. cepacia* complex infections in immunocompetent individuals (Ledson *et al.*, 1998; Pujol *et al.*, 1992; Taplin *et al.*,

1971; Wong *et al.*, 1991), the organism primarily poses a severe danger to immunocompromised patients. Members of the *B. cepacia* complex can be recovered from people with human immunodeficiency virus (HIV) and cancer (Pegues *et al.*, 1993; Verghese *et al.*, 1994; Zinner, 1999). *B. cepacia* complex septicemia and pneumonia is the second-leading cause of death in people with chronic granulomatous disease (CGD), a disorder of the polymorphonuclear leukocytes (Johnston, 2001). Depending on the clinic, 10 to 40% of cystic fibrosis (CF) patients are colonized with the *B. cepacia* complex (Govan and Deretic, 1996). This colonization has variable outcomes. The majority of people are asymptomatic carriers or develop chronic infections. However, approximately 20% of CF patients infected with *B. cepacia* develop "*cepacia* syndrome," a severe necrotizing pneumonia and septicemia resulting in rapid clinical deterioration and early death (Isles *et al.*, 1984). Evidence of person-to-person transmission (LiPuma *et al.*, 1990) has resulted in segregation of CF patients colonized with the *B. cepacia* complex from the rest of the CF community. Although *B. cenocepacia* (genomovar III) and *B. multivorans* (genomovar II) are the most common infectious agents, members of all genomovars have been isolated from infected CF patients (Mahenthiralingam *et al.*, 2005). Members of the *B. cepacia* complex possess a vast array of virulence factors, recently reviewed by Mahenthiralingam *et al.* (2005), however, not all have a verified role in human disease. Current treatment of CF patients focuses on antibiotic therapy to decrease inflammation and bacterial numbers. However, treatment of *B. cepacia* complex infections is notoriously difficult due to widespread antibiotic resistance.

1.2 Antibiotic resistance in the *B. cepacia* complex

B. cepacia complex isolates generally have high resistance to β-lactams and aminoglycosides along with variable levels of resistance to quinolones (Burns and Saiman, 1999). Some strains of the *B. cepacia* complex are so resistant that no two-drug combination is effective against them. Therefore, triple antibiotic combinations may be needed to treat infections (Aaron *et al.*, 2000; Burns and Saiman, 1999). Clinically, antibiotic resistance of the *B. cepacia* complex is of great concern. A study of CF centres in northern Ireland found that 81% of adult patients were infected with pan-resistant genomovar III strains (Moore *et al.*, 2001). Many factors contribute to the extreme levels of resistance observed in the *B. cepacia* complex, including outer membrane impermeability, biofilm growth, β-lactamase enzymes, resistant drug targets, and multidrug efflux pumps.

Before the discovery of biofilms and efflux pumps, outer membrane impermeability was thought of as the primary drug resistance mechanism of the *B. cepacia* complex. Entry of hydrophilic compounds through water-filled porins is limited by the size and physiological properties of the solute (Hancock, 1984). Entry of hydrophobic compounds depends on diffusion across the outer membrane itself (Plesiat and Nikaido, 1992). The *B. cepacia* complex outer membrane provides a considerable barrier to the entry of hydrophilic compounds. The measured outer membrane permeability to the β-lactam antibiotic nitrocefin is 10-fold lower than that of *Escherichia coli* (Parr *et al.*, 1987). In addition, purified porin from the *B. cepacia* complex is small in size compared to *E. coli* porins (Parr *et al.*, 1987). Decreased expression of a 36-kDa outer membrane protein and no expression of a 27-kDA outer membrane protein are associated with decreased permeability and resistance to β-lactams (Aronoff, 1988). Low

outer membrane permeability also contributes to aminoglycoside resistance in the *B. cepacia* complex (Moore and Hancock, 1986).

Another factor adding to the antibiotic resistance of the *B. cepacia* complex is growth in a biofilm. Biofilms are microbial communities attached to a surface and encased in a polysaccharide matrix. Growth in a biofilm is commonly associated with enhanced resistance to antimicrobial agents and the host immune system. Biofilm resistance is most likely due to a combination of different mechanisms that have been reviewed recently (Drenkard, 2003). Possibilities include: reduced penetration of drugs through the exopolysaccharide matrix, local differences in metabolic activity of cells, physiological changes caused by the activation of genetic systems, the presence of persister cells, activation of the general stress response, involvement of quorum sensing systems, and the activation of multidrug efflux pumps (Drenkard, 2003). Evidence suggests that efflux pumps do not play a significant role in biofilm resistance. Genes encoding resistance nodulation cell division (RND) efflux systems are not induced during microarray analysis of mature *Pseudomonas aeruginosa* biofilms (Whiteley *et al.*, 2001). Overexpression of MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY does not contribute significantly to increased drug resistance in *P. aeruginosa* biofilms (De Kievit *et al.*, 2001). However, genome analysis reveals the existence of 12 possible RND systems in *P. aeruginosa* (Stover *et al.*, 2000), so the involvement of other efflux systems in biofilm resistance cannot be ruled out.

Members of the *B. cepacia* complex are capable of biofilm growth *in vitro* (Buhler *et al.*, 1998; Lo *et al.*, 1996; Nivens *et al.*, 1993; Tomlin *et al.*, 2001). There is some evidence to suggest that *B. cepacia* complex biofilm formation is controlled by the

cepIR quorum sensing system (Huber *et al.*, 2001; Huber *et al.*, 2002). However, under some growth conditions, biofilm formation is independent of quorum sensing (Conway *et al.*, 2002). Although it has not been established what form the *B. cepacia* complex is found in during infections of the CF lung, some interesting correlations exist between biofilm growth and pathogenesis. Infection with the *B. cepacia* complex usually occurs in CF patients who are already colonized with *P. aeruginosa* (Govan and Deretic, 1996). *In vitro* evidence of mixed biofilm growth and interspecies communication with *P. aeruginosa* raises the possibility that they could co-regulate virulence factors in the CF lung (Lewenza *et al.*, 2002; Riedel *et al.*, 2001). Genomovar II and III *B. cepacia* complex isolates, which are the most invasive (Cieri *et al.*, 2002; Keig *et al.*, 2002) and most frequently isolated from CF patients (Mahenthiralingam *et al.*, 2005), also form the most abundant biofilms *in vitro* (Conway *et al.*, 2002). If these isolates do form biofilms in the CF lung, it could contribute to antibiotic resistance since *B. cepacia* biofilm cells are 15 times less susceptible to ceftazidime and ciprofloxacin than planktonic bacteria at an equivalent stage of growth (Desai *et al.*, 1998).

Other mechanisms of resistance in the *B. cepacia* complex include the ability to degrade certain antibiotics. For example, members of the *B. cepacia* complex are able to use penicillin G as a sole carbon source (Beckman and Lessie, 1979). Some strains, including CF isolates, have inducible β-lactamases (Chiesa *et al.*, 1986). For example, *B. multivorans* strain 249, has two inducible β-lactamases: a cephalosporinase (Beckman and Lessie, 1980) and a penicillinase (Prince *et al.*, 1988). The *penA* and *penR* genes, encoding the penicillinase and its regulator respectively, have been cloned and

sequenced. Expression of *penA* in *E. coli* confers resistance to benzylpenicillin, carbenicillin, and cefuroxime, but not imipenem (Trepanier *et al.*, 1997).

Resistance of the *B. cepacia* complex to some antimicrobials is the result of resistant drug targets. At least some trimethoprim resistance is explained by production of a trimethoprim-resistant dihydrofolate reductase (Burns *et al.*, 1989b). Specific penicillin-binding proteins (PBP) are less susceptible to the actions of β-lactam antibiotics (Mahenthiralingam *et al.*, 2005). The specific structure of *B. cepacia* complex LPS confers resistance to cationic antimicrobial peptides and polymyxin. *B. cepacia* complex LPS contains D-glycero-D-talo-2-octulosonic acid (KO) and 4-amino-4-deoxy-L-arabinose (Ara4N) (Isshiki *et al.*, 1998), both of which are expected to reduce the binding affinity of LPS for cationic antibiotics. However, although *B. cepacia* complex LPS is somewhat resistant to the actions of polymyxin B, the LPS does bind polymyxin B with high affinity (Shimomura *et al.*, 2003). In addition to the mechanisms of resistance discussed above, active efflux systems are also involved in *B. cepacia* complex antimicrobial resistance (Burns *et al.*, 1996; Fehlner-Gardiner and Valvano, 2002; Wigfield *et al.*, 2002).

1.3 Multidrug efflux pumps

1.3.1 Classes of bacterial drug efflux pumps

Antibacterial efflux pumps fall into five larger classes of transporters. Members of the ATP-binding cassette (ABC) superfamily use ATP-hydrolysis to drive transport of sugars, amino acids, ions, drugs, iron complexes, polysaccharides, and proteins (Fath and Kolter, 1993). ABC pumps consist of two subunits: an integral membrane protein with

six transmembrane helices and an ATP-binding subunit located at the cytoplasmic face of the membrane. The two proteins may be non-covalently associated or linked in a single polypeptide chain. The complete system usually functions as a dimer (Fath and Kolter, 1993). Although ABC-type drug efflux pumps are not common in bacteria (Li and Nikaido, 2004), some examples include *Lactococcus lactis* multidrug pump LmrA (van Veen *et al.*, 1996) and *Escherichia coli* drug-specific pump MacAB (Kobayashi *et al.*, 2001b).

The major facilitator superfamily (MFS) pumps are driven by electro-chemical gradients, usually proton-motive force, in the transport of sugars, metabolites, anions, and drugs (Saier *et al.*, 1998). Two families within this group are involved with drug efflux. Pumps with 12 transmembrane helices have a large cytoplasmic loop between helices six and seven. Pumps with 14 transmembrane domains have a smaller cytoplasmic loop. MFS systems function as either dimers or trimers (Saier *et al.*, 1998). A well characterized example of an MFS pump is EmrAB of *E. coli* (Lomovskaya and Lewis, 1992).

The multidrug and toxic compound extrusion (MATE) family is a newly discovered class of efflux pumps. Members of this family have 12 transmembrane domains with a similar topology, but not homology, to MFS efflux pumps (Brown *et al.*, 1999). Two known bacterial multidrug efflux pumps of this class are NorM of *Vibrio parahaemolyticus* and YdhE of *E. coli*, both conferring resistance to cationic dyes, aminoglycosides, and fluoroquinolones (Morita *et al.*, 1998).

The small multidrug resistance (SMR) family of efflux pumps contains drug:proton antiporters. The protein is small, approximately 110 amino acids, and

contains four transmembrane domains (Arkin *et al.*, 1996). SMR pumps likely function as trimers (Yerushalmi *et al.*, 1996). Two well known SMR pumps are *Staphylococcus aureus* Smr and *E. coli* EmrE. Although these are considered multidrug pumps, their substrate ranges are limited to lipophilic cations such as antiseptics and disinfectants (Grinius *et al.*, 1992; Schuldiner *et al.*, 2001).

The resistance-nodulation-cell division (RND) family was named after the functions of its original members: transporters involved in metal resistance, proteins required for nodulation of alfalfa roots by *Rhizobium meliloti*, and EnvD (now known as multidrug transporter AcrF) which was originally thought to be involved in *E. coli* cell division (Saier *et al.*, 1994). RND transporters have a unique topology with 12 transmembrane segments and two large periplasmic loops. The efflux system functions as a trimer (Poole, 2004). All known RND drug pumps are multi-drug transporters. Proton motive force drives efflux of a broad range of structurally unrelated compounds including most classes of antibiotics, biocides, dyes, detergents, metabolic inhibitors, aromatic hydrocarbons, cationic antimicrobial peptides, toxic fatty acids, bile salts, and quorum sensing signals (Poole, 2004). As such, they play a major role in the resistance of Gram-negative organisms to a variety of clinically relevant antimicrobials. Numerous examples exist in Gram-negative organisms (Table 1.1).

1.3.2 Tripartite structure of Gram-negative efflux pumps

Drug efflux pumps in Gram-negative organisms face the challenge of transporting the substrate across the outer membrane. Such pumps often work in complex with an outer membrane protein and a membrane fusion protein (Saier *et al.*, 1998). The best

Table 1.1 A selection of resistance nodulation cell division (RND) family multidrug efflux pumps from Gram-negative bacteria

Organism	Efflux system component			Regulator	Substrates	References
	MFP	IMT	OMP			
Burkholderia cenocepacia	CeoA	CeoB	OpcM	CeoR	CM, CP, TP	(Burns *et al.*, 1996; Nair *et al.*, 2004)
Escherichia coli	AcrA	AcrB	TolC	AcrR, MarA, SoxS, Rob, SdiA	AC, AH, BA, BL, BS, CM, CV, EB, ER, FA, FU, FQ, LN, MX, NV, PO, RF, SDS,TC, TS, TX	(Fralick, 1996; Jellen-Ritter and Kern, 2001; Kopytek *et al.*, 2000; Ma *et al.*, 1993; O'Neill *et al.*, 2002; Tsukagoshi and Aono, 2000)
	AcrA	AcrD	TolC	SdiA, BaeR, CpxR, OmpR	AG, BL, DC, FU, NV, SDS	(Elkins and Nikaido, 2002; Hirakawa *et al.*, 2003; Rosenberg *et al.*, 2000)
	AcrE	AcrF	TolC	AcrS, SdiA	AC, AH, BL, BS, FQ, LN, ML, RD, SDS, TC, TP	(Jellen-Ritter and Kern, 2001; Kobayashi *et al.*, 2001a; Ma *et al.*, 1994; Nishino and Yamaguchi, 2001b)
	MdtA (YegM)	MdtBC (YegNO)	TolC	BaeSR	BL, BS, DC, NV, SDS	(Baranova and Nikaido, 2002; Nagakubo *et al.*, 2002; Nishino and Yamaguchi, 2001b)
	YhiU	YhiV	TolC	EvgAS	BA, BL, BS, CV, DC, DOX, EB, ER, RD, SDS	(Masuda and Church, 2002; Nishino and Yamaguchi, 2001b, 2002; Sulavik *et al.*, 2001)
Neisseria gonorrhoeae	MtrC	MtrD	MtrE	MtrR, MtrA	AZ, CV, EB, FA, ML, PN, RF, TX	(Hagman *et al.*, 1995; Hagman *et al.*, 1997; Pan and Spratt, 1994; Veal *et al.*, 1998; Zarantonelli *et al.*, 1999)
Pseudomonas aeruginosa	MexA	MexB	OprM	MexR, NalC (PA3721)	AC, AG, AH, BL, CL, CM, CV, EB, FQ, HL, IR, ML, NV, RD, SDS, SM, TC, TL, TG, TP, TPP, TS	(Dean *et al.*, 2003; Li *et al.*, 1995; Masuda *et al.*, 2000a; Okamoto *et al.*, 2002a, b; Poole *et al.*, 1993a; Poole *et al.*, 1996b)
	MexC	MexD	OprJ	NfxB	AC, AH, BL, CL, CM, CP, EB, FQ, NV, RD, SDS, SM, TC, TG, TP, TPP, TS	(Masuda *et al.*, 2000a; Okamoto *et al.*, 2002a, b; Poole *et al.*, 1996a)
	MexE	MexF	OprN	MexT	AH, CM, FQ, TP, TS	(Kohler *et al.*, 1997)
	MexX	MexY	OprM	MexZ	AG, BL, ER, FQ, TC, TG	(Aires *et al.*, 1999; Masuda *et al.*, 2000b; Mine *et al.*, 1999; Okamoto *et al.*, 2002a; Westbrock-Wadman *et al.*, 1999)
	MexH	MexI	OpmD	PA4203?	VA, EB, NV, RD, AC	(Aendekerk *et al.*, 2002; Sekiya *et al.*, 2003)
	MexJ	MexK	OprM	MexL	AC, CM, EB, ER, FQ, TC, TS	(Chuanchuen *et al.*, 2002; Li *et al.*, 2003)

AC = acriflavine; **AG** = aminogylcosides; **AH** = aromatic hydrocarbons; **AZ** = azithromycin; **BA** = benzalkonium; **BL** = β-lactams; **BS** = bile salts; **CL** = cerulenin; **CM** = chloramphenicol; **CP** = ciprofloxacin; **CV** = crystal violet; **DC** = deoxycholate; **DOX** = doxyrubicin; **EB** = ethidium bromide; **ER** = erythromycin; **FA** = fatty acids; **FU** = fusidic acid; **FQ** = fluoroquinolones; **HL** = homoserine lactones; **IMT** = inner membrane transporter; **IR** = irgasan; **LN** = linezolid; **MFP** = membrane fusion protein; **ML** = macrolides; **MX** = methotrexate; **NV** = novobiocin; **OMP** = outer membrane protein; **PN** = penicillin; **PO** = pine oil; **RD** = rhodamine; **RF** = rifampicin; **SDS** = sodium dodecyl sulphate; **SM** = sulphonamides; **TC** = tetracycline; **TG** = tigecycline; **TP** = trimethoprim; **TPP** = tetraphenyl phosphonium; **TS** = triclosan; **TX** = Triton X-100; **VA** = vanadium. In instances where only one member of an antimicrobial class has been tested, that member is identified. Where several members of an antimicrobial class are known to be substrates, the class is identified.

studied examples of tripartite efflux structures are *E. coli* AcrAB-TolC and *P. aeruginosa* MexAB-OprM, both members of the RND superfamily.

Inner membrane transporter. The inner membrane transporter is responsible for binding substrates and energizing active transport out of the cell. The crystal structure of *E. coli* transporter AcrB has been determined at high resolution (Figure 1.1) (Murakami *et al.*, 2002). The structure revealed that AcrB functions as a trimer. The trimer contains two domains, a transmembrane region and a periplasmic headpiece. The transmembrane domain consists of the 12 transmembrane helices of each monomer, arranged in a ring with a central hole. The hole is large and likely filled with phospholipids of the cytoplasmic membrane (Murakami *et al.*, 2002). The periplasmic headpiece contains three vestibules that are open to the periplasm, forming channels into a central cavity inside the pump. The cavity contains numerous aromatic, polar, and charged residues possibly involved in substrate interaction. Located above the central cavity is a closed pore formed by three helices (Murakami *et al.*, 2002). Conformational change of this pore is important since mutations fixing the pore in a closed state result in almost complete loss of transport (Murakami *et al.*, 2004). The top of the periplasmic headpiece resembles a funnel. The diameter of the funnel is approximately equal to the diameter of TolC, suggesting that it could act as a docking-site for the outer membrane protein (Murakami *et al.*, 2002).

The crystal structure of AcrB also suggests a possible proton translocation pathway. Three charged residues in the middle of transmembrane helices four and ten form ion pairs (Murakami *et al.*, 2002). The amino acids involved in these pairs are highly conserved and essential for the function of several RND pumps including MexB



Figure 1.1 Model of the AcrAB-TolC complex. Taken directly from Murakami *et al.*, 2002. The inner membrane transporter, AcrB, is responsible for proton translocation and substrate binding. The outer membrane protein TolC, shown docked into the AcrB structure, allows transport across the outer membrane.

(Guan and Nakae, 2001) and MexF (Aires *et al.*, 2002) of *P. aeruginosa* as well as CzcA of *Ralstonia* spp. (Goldberg *et al.*, 1999).

In addition to proton translocation, the inner membrane transporter is responsible for binding efflux substrates. The majority of evidence suggests that substrates are captured in the periplasm (Li and Nikaido, 2004). However, recent evidence suggests that some RND pumps are capable of both cytoplasmic and periplasmic capture. Reconstituted *E. coli* efflux pump AcrD is able to transport aminoglycosides from the outside (representing the cytoplasm) and inside (representing the periplasm) of proteoliposomes (Aires and Nikaido, 2005). A great deal of research has focused on which components of RND transporters are involved in substrate binding. The importance of the periplasmic loops in substrate recognition has been well established by the construction of chimeric transporters (Eda *et al.*, 2003; Elkins and Nikaido, 2002; Tikhonova *et al.*, 2002) and mutagenesis experiments (Franke *et al.*, 2003; Mao *et al.*, 2002; Middlemiss and Poole, 2004). However, X-ray crystallography of AcrB in the presence of structurally diverse ligands also provides convincing evidence that the transmembrane domain is responsible for substrate specificity (Yu *et al.*, 2003). Three molecules of ligand bind simultaneously in the central cavity via hydrophobic, aromatic stacking, and van der Waals interactions. Slightly different subsets of residues are involved in binding different ligands. The binding sites are near the proposed location of the cytoplasmic membrane within the central cavity. Surprisingly, most residues identified as drug binding sites are located in the transmembrane domain, not the periplasmic loops. However, if drugs use the periplasmic vestibules to enter the central

cavity, the periplasmic domains could still limit which substrates have access to the binding sites (Yu *et al.*, 2003).

Outer membrane protein. The outer membrane protein facilitates drug efflux across the outer membrane of Gram-negative organisms. The crystal structure of well-characterized outer membrane protein TolC of *E. coli* has been obtained (Figure 1.1) (Koronakis *et al.*, 2000). TolC functions as a trimer with two major domains. A β-barrel is embedded in the outer membrane and opens to the extracellular space. The trimer also has an α-helical cylinder that extends into the periplasm, gradually narrowing until it tapers to a close. The cylinder has a large interior cavity, a likely route for substrate passage. The bottom of the cylinder is sealed by a set of coiled helices, suggesting that these helices must open in order for substrates to pass (Koronakis *et al.*, 2000). Later, the crystal structure of another RND efflux pump outer membrane protein, *P. aeruginosa* OprM, was also solved (Akama *et al.*, 2004a). The structure is very similar to that of TolC, with some notable differences. The diameter of the outer membrane β-barrel was smaller than its *E. coli* counterpart and is restricted by the presence of three short loops protruding into the centre of the pore. In order for substrates to pass through OprM, the top β-barrel pore must open as well as the closed tip of the periplasmic cylinder (Akama *et al.*, 2004a).

Support for the necessity of a conformational change in outer membrane proteins comes from reconstitution experiments. *P. aeruginosa* OprM reconstituted in liposome membranes has some channel-forming abilities, allowing diffusion of amino acids and peptides but not antibiotics (Yoshihara *et al.*, 2002). Weak pore-forming activity results from reconstitution of TolC and OprM lipid bilayers (Benz *et al.*, 1993; Wong and

Hancock, 2000). Together, these results are consistent with the idea that outer membrane proteins are gated-channels that must be opened to allow drug efflux. The TonB protein is involved in the opening of many gated outer membrane receptors (Postle, 1993). Recently, it has been suggested that TonB may also play a role in active efflux. TonB is required for full efflux activity of *P. aeruginosa* multidrug efflux pump MexAB-OprM (Zhao *et al.*, 1998). Similarly, TonB is involved in efflux systems in *Pseudomonas putida* (Godoy *et al.*, 2001) and *Neisseria gonorrhoeae* (Rouquette-Loughlin *et al.*, 2002). However, TonB is not required for the function of *E. coli* AcrAB-TolC (Li and Nikaido, 2004).

Membrane fusion protein. The third member of the tripartite complex is the membrane fusion protein, also known as the periplasmic linker protein. Recently, the crystal structure of *P. aeruginosa* MexA, a well-characterized membrane fusion protein, was determined by two research groups (Akama *et al.*, 2004b; Higgins *et al.*, 2004). The MexA monomer is an elongated structure with three domains. First, a β-barrel domain is formed by β-strands and an α-helix and bears an overall resemblance to ligand binding domains. Second, a lipoyl/biotinyl domain is conserved in membrane fusion proteins. Third, there is an α-helical hairpin that contains both N-terminal and C-terminal helices. Both groups also note a fourth, disordered domain that was not resolved by the crystal structure. This domain contains the N-terminal and C-terminal residues of MexA (Akama *et al.*, 2004b; Higgins *et al.*, 2004).

The MexA crystal contained two twisted funnel shapes (a 7-mer and a 6-mer) united to form a 13-mer cylinder with an internal space and open ends. However, this structure is unlikely to be formed *in vivo*. Both research groups used an altered form of

MexA lacking the N-terminal fatty acyl moiety (Akama *et al.*, 2004b; Higgins *et al.*, 2004). Although the altered protein is fully functional in regards to antibiotic efflux, it no longer attaches to the inner membrane (Yoneyama *et al.*, 2000). *In vivo*, the attachment of MexA to the inner membrane would prevent head-to-head arrangement of the 7-mer and 6-mer. Based on the crystal structure, three suggestions have been made regarding the true form of MexA multimers. One possibility is that nine molecules of MexA could form a ring attached to the inner membrane and surrounding the other efflux components (Higgins *et al.*, 2004). A second suggestion states that 12 MexA molecules could wind around the MexB-OprM interaction site (Akama *et al.*, 2004b). Another possibility is that three MexA dimers could interact with the periplasmic end of OprM by means of α-helices. The C-terminal region could then interact with MexB (Akama *et al.*, 2004b). There is still no conclusive evidence for the actual *in vivo* state of MexA. Quantification of MexA, MexB, and OprM by immunoblotting, suggests that there are six molecules of MexA for every trimer of MexB and OprM (Narita *et al.*, 2003). Chemical cross-linking studies of membrane fusion proteins AcrA (Zgurskaya and Nikaido, 2000) and HlyD (Thanabalu *et al.*, 1998) support a trimeric form. Low resolution crystallography of AcrA shows the appearance of two identical rings, taken to be an AcrA dimer (Avila-Sakar *et al.*, 2001).

Another question remains about the function of membrane fusion proteins. Numerous studies have shown they are essential for efflux in intact cells (Aires and Nikaido, 2005; Elkins and Nikaido, 2002; Li *et al.*, 1995; Ma *et al.*, 1995; Poole *et al.*, 1993a). Suggestions include bringing the inner and outer membranes together, assembly and stabilization of the tripartite complex, activation of efflux, and drug-binding.

In the membrane fusion model, the membrane fusion protein brings the inner and outer membranes into close contact, facilitating substrate transfer between the inner membrane transporter and the outer membrane protein. Evidence for this model is mostly circumstantial. Sequence similarity to a viral membrane fusion protein and the presence of two conserved hydrophobic regions near the N and C terminal ends of periplasmic adaptors suggest that terminal ends could interact with the membranes (Dinh *et al.*, 1994). Furthermore, membrane fusion protein AcrA is attached to the inner membrane via an N-terminal lipid moiety (Ma *et al.*, 1993) and the AcrA monomer exists as an elongated shape that could span the periplasm (Zgurskaya and Nikaido, 1999a). Structural predictions reveal the presence of two coiled-coils separated by a gap and flanked on each side by two copies of a lipoyl motif. This structure suggests a mechanism for membrane fusion whereby this region could fold back on itself to form an α-helical hairpin (Johnson and Church, 1999). Direct evidence for the membrane fusion model comes from the observation that AcrA alone causes transfer of lipids between two vesicle populations without mixing the aqueous contents (Zgurskaya and Nikaido, 1999b). However, recent studies strongly suggest that the role of membrane fusion proteins is not to bring together the inner and outer membranes. The crystal structure of MexA demonstrates that the N- and C-terminal domains are in close contact with each other, precluding the attachment of one terminus to each membrane (Akama *et al.*, 2004b; Higgins *et al.*, 2004). Also, evidence that the C-terminus of AcrA contacts the inner membrane transporter excludes it from interaction with the outer membrane (Elkins and Nikaido, 2003; Touze *et al.*, 2004).

Other evidence suggests that membrane fusion proteins play an important role in assembly of the Gram-negative tripartite efflux complex. Numerous *in vivo* cross-linking studies show interaction of membrane fusion proteins HlyD (Thanabalu *et al.*, 1998), AcrA (Touze *et al.*, 2004; Zgurskaya and Nikaido, 2000), and MexA (Nehme *et al.*, 2004) with their corresponding transporters. This interaction is fairly specific, since AcrA functions with non-cognate transporters AcrD (Elkins and Nikaido, 2002), AcrF (Kobayashi *et al.*, 2001b), and YhiV but not MdtBC (Elkins and Nikaido, 2003). Similarly, membrane fusion proteins AcrA (Husain *et al.*, 2004; Touze *et al.*, 2004) and MexA (Mokhonov *et al.*, 2004) interact with outer membrane proteins in the absence of the inner membrane transporter. Additional support for an interaction between membrane fusion proteins and outer membrane proteins is that most extragenic suppressors of *tolC* mutants are found in *acrA* (Gerken and Misra, 2004). Furthermore, most evidence suggests that inner membrane transporters and outer membrane proteins are unable to interact independently. Without the membrane fusion protein MexA, MexB and OprM do not co-purify in a pull-down assay (Mokhonov *et al.*, 2004). Although AcrB and TolC can be chemically cross-linked independently of AcrA, isothermal titration calorimetry (ITC) suggests that there is no stable interaction between AcrB and TolC. Thus, cross-linking results merely represent close physical proximity within the cell (Touze *et al.*, 2004). Attempts to construct chimeric efflux pumps confirms the importance of membrane fusion proteins (Mokhonov *et al.*, 2004; Yoneyama *et al.*, 1998). The above evidence suggests that membrane fusion proteins are essential for stable assembly of the tripartite complex.

In addition to a role in assembly of the tripartite complex, a variety of more active roles have been proposed for the membrane fusion protein. The periplasmic end of outer membrane protein TolC is sealed by sets of coiled helices. In order for efflux to occur, TolC must transition into an open state (Koronakis *et al.*, 2000). It is possible that such a transition could be triggered by protein-protein interaction between TolC and the membrane fusion protein (Andersen *et al.*, 2002). Membrane fusion proteins may also activate inner membrane transporters. RND transporter AcrD reconstituted in proteoliposomes is unable to transport aminoglycosides without membrane fusion protein AcrA (Aires and Nikaido, 2005). Previously, AcrA was shown to stimulate AcrB activity. At the time, this was attributed to AcrA bringing the vesicles into close contact (Zgurskaya and Nikaido, 1999b). However, this result can be reinterpreted as AcrA activating efflux by AcrB. Interestingly, AcrA undergoes pH-induced oligomerization and conformational change *in vitro*, providing a link to the proton-gradient driven activity of AcrB (Ip *et al.*, 2003). Although AcrA seems to stimulate efflux activity, the same may not be true for all membrane fusion proteins. Reconstituted CzcA, an RND transporter from *Ralstonia* sp., has considerable activity in the absence of its cognate membrane fusion protein (Goldberg *et al.*, 1999). Another possible role for membrane fusion proteins is suggested by direct involvement of EmrA (Borges-Walmsley *et al.*, 2003) and HlyD (Balakrishnan *et al.*, 2001; Thanabalu *et al.*, 1998) in substrate binding. Although the importance of membrane fusion proteins in efflux systems is well-established, their *in vivo* state and function remain a mystery.

1.3.3 Regulation of drug efflux pumps

The expression of many drug efflux pumps is subject to elaborate regulatory control. The wide range of molecules that can be transported by some multidrug pumps raises the possibility that normal metabolites may be extruded. One study demonstrated that mutations in the adenine, glutamate, methionine, and cysteine biosynthetic pathways cause an increase in transcription of the *acrAB* efflux system and a corresponding increase in resistance to nalidixic acid (Helling *et al.*, 2002). This could explain the finding that overexpression of efflux pumps AcrAB (Ma *et al.*, 1993) and TetA (Eckert and Beck, 1989; Hickman *et al.*, 1990) can be toxic for cells. Similar difficulties are found for the *E. coli* AcrEF (Klein *et al.*, 1991) and *Neisseria gonorrhoeae* MtrCD (Pan and Spratt, 1994) efflux systems. Overexpression of multidrug efflux pumps in *P. aeruginosa* is associated with decreased virulence and decreased survival, emphasizing the importance of efflux pump regulation (Kohler *et al.*, 2001; Linares *et al.*, 2005; Sanchez *et al.*, 2002a). The majority of bacterial drug efflux pumps are controlled by transcriptional regulatory proteins. Regulation can occur at the global or local level by repressors, activators, or two component systems.

Expression of *E. coli* efflux operon *acrAB* responds to at least four global regulators. The *E. coli mar* (multiple antibiotic resistance) locus consists of two units expressed divergently from operator *marO*: the *marC* gene and the *marRAB* operon. The functions of MarB and MarC remain unknown (Alekshun and Levy, 1997). MarA belongs to the XylS/AraC family of transcription activators and is known to control the expression of more than 60 chromosomal genes (Barbosa and Levy, 2000). Among these targets is efflux operon *acrAB*. MarA activates transcription from the *acrAB* operon, increasing drug efflux (Martin *et al.*, 1996). Expression of *marRAB* is regulated in turn

by the repressor protein MarR (Alekshun and Levy, 1997). Induction of *marRAB* responds to a number of antibiotics, weak aromatic acids, uncoupling agents, and redox-cycling compounds, presumably by alleviating MarR repression of the operon (Ariza *et al.*, 1994; Cohen *et al.*, 1993; Seoane and Levy, 1995). However, direct binding to MarR has only been demonstrated for one inducer, salicylate (Alekshun *et al.*, 2001; Martin and Rosner, 1995).

MarA homologues SoxS (Ma *et al.*, 1996; McMurry *et al.*, 1998; White *et al.*, 1997) and Rob (Ariza *et al.*, 1995; Nakajima *et al.*, 1995; White *et al.*, 1997) also increase transcription of *acrAB*. Increases in SoxS occur when its repressor, SoxR, is inactivated in response to superoxides (Hidalgo *et al.*, 1997). Activation of Rob occurs via the binding of inducers such as dipyridyl (Jair *et al.*, 1996), fatty acids, and bile salts (Rosenberg *et al.*, 2003). Although overexpression of MarA, SoxS, and Rob each increase *acrAB* transcription, none of these regulators are responsible for *acrAB* induction in response to general stress conditions (Ma *et al.*, 1996). Therefore, some other regulatory factors must be involved. The recent finding that expression of *acrAB* is higher in slow-growing cells provides a link between quorum sensing and efflux pump regulation (Rand *et al.*, 2002). Additionally, the protein SdiA, which has homology to receptors of acyl homoserine lactone quorum sensing molecules, positively regulates *acrAB* (Rahmati *et al.*, 2002).

Local regulation is also involved in expression of the *acrAB* operon. The gene encoding a TetR family repressor protein, AcrR, is divergently transcribed from *acrAB* (Ma *et al.*, 1995; Pan and Spratt, 1994). AcrR binds to and represses expression from the *acrR* and *acrAB* promoters (Ma *et al.*, 1996). However, AcrR serves only to fine tune

expression of *acrAB* because general stress conditions increase *acrAB* expression in the absence of functional AcrR. Also, general stress conditions increase transcription of *acrR* as well as *acrAB* (Ma *et al.*, 1996).

Local regulators play an important role in regulation of *P. aeruginosa* efflux operons. Each of the RND multidrug efflux systems is linked to a regulatory gene encoding a repressor or activator. MexR, a repressor belonging to the MarR family, is encoded by a gene upstream and divergently transcribed from efflux operon *mexAB-oprM.* Although *mexAB-oprM* is constitutively expressed in wild-type cells (Li *et al.*, 1995; Yoneda *et al.*, 2005), inactivation of *mexR* results in overexpression of *mexAB-oprM* and a corresponding increase in resistance to several antimicrobial agents (Adewoye *et al.*, 2002; Poole *et al.*, 1996b; Saito *et al.*, 1999; Srikumar *et al.*, 2000; Ziha-Zarifi *et al.*, 1999) as well as organic solvents (Li and Poole, 1999). MexR negatively autoregulates its own expression (Poole *et al.*, 1996b) and binds directly to the overlapping *mexR* and *mexAB-oprM* promoters (Evans *et al.*, 2001). The natural conditions that alleviate MexR repression are unknown. Unlike its homologue MarR, MexR does not interact with salicylate (Lim *et al.*, 2002). Expression of *oprM* is induced by the antibiotic imipenem, but only in one strain of *P. aeruginosa* (Kolayli *et al.*, 2004). The crystal structure of MexR suggests that the unknown ligand could be a peptide signaling molecule (Lim *et al.*, 2002).

MexR is not the only regulator of *mexAB-oprM* expression. Growth phase also regulates *mexAB-oprM* expression, with levels increasing in late logarithmic and stationary phase (Evans and Poole, 1999; Maseda *et al.*, 2004; Sanchez *et al.*, 2002b). Growth phase regulation does not require *mexR* (Evans and Poole, 1999; Sawada *et al.*,

2004), nor the *las* quorum sensing cascade (Evans and Poole, 1999; Maseda *et al.*, 2004). However, the *rhl* quorum sensing system is likely involved in growth phase regulation since autoinducer C4-HSL enhances expression of *mexAB-oprM* (Sawada *et al.*, 2004). Surprisingly, MexT, an activator of the *mexEF-oprN* efflux operon, represses C4-HSL-mediated regulation of *mexAB-oprM* (Sawada *et al.*, 2004). MexT-mediated regulation of *mexAB-oprM* expression occurs directly, through the regulatory function of MexT, and indirectly, through the action of the MexEF-OprN efflux pump which is activated by MexT (Maseda *et al.*, 2004). Numerous studies show that some mutations altering *mexAB-oprM* transcription are located outside of the *mexR* gene and intergenic region, suggesting the presence of another regulatory gene, *nalC* (Llanes *et al.*, 2004; Pumbwe and Piddock, 2000; Srikumar *et al.*, 2000; Ziha-Zarifi *et al.*, 1999). Recent studies indicate that mutations in a putative TetR family repressor are involved in the *nalC* phenotype (Cao *et al.*, 2002; Llanes *et al.*, 2004). Still, some strains of *P. aeruginosa, nalD*-type mutants, overexpress *mexAB-oprM* although they contain no mutations in any known regulatory genes (Llanes *et al.*, 2004).

Unlike MexAB-OprM, *P. aeruginosa* efflux pump MexCD-OprJ is not expressed in wild-type cells under normal growth conditions (Morita *et al.*, 2003; Poole *et al.*, 1996a). Expression of this pump is regulated by the NfxB repressor, encoded by a gene upstream of the *mexCD-oprJ* operon. NfxB is similar to proteins in the LacI-GalR repressor family (Poole *et al.*, 1996a). In addition to repressing *mexCD-oprJ* transcription, NfxB also negatively autoregulates its own expression (Shiba *et al.*, 1995). Using mutants possessing only one of the four major *P. aeruginosa* RND pumps, MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY, Morita *et al.* demonstrated

that *mexCD-oprJ* expression is inducible. Some MexCD-OprJ substrates, tetraphenylphosphonium, ethidium bromide, rhodamine 6G, acriflavine, and disinfectants, induce expression of the pump. Other substrates of MexCD-OprJ, such as norfloxacin, erythromycin, tetracycline, chloramphenicol, streptomycin, and carbenicillin, do not induce expression (Morita *et al.*, 2001b; Morita *et al.*, 2003).

Regulation of the *mexXY* operon of *P. aeruginosa* also occurs via a repressor protein. The *mexZ* gene, encoding a putative TetR family repressor, is upstream and divergently transcribed from the *mexXY* operon (Aires *et al.*, 1999; Westbrock-Wadman *et al.*, 1999). MexZ down-regulates *mexXY* expression, because transformation of wild-type *P. aeruginosa* with *mexZXY* has no effect on resistance, but transformation with only *mexXY* substantially increases resistance (Aires *et al.*, 1999). In some cases, overexpression of *mexXY* has been observed in strains with mutations in the *mexZ* gene (Islam *et al.*, 2004; Llanes *et al.*, 2004; Vogne *et al.*, 2004). MexZ regulates *mexXY* directly, since purified MexZ protein binds the *mexZ-mexX* intergenic region (Matsuo *et al.*, 2004). Expression of *mexXY* is thought to be constitutive in wild-type cells, as mutations disrupting *mexX* result in hypersusceptibility to aminoglycosides, erythromycin, and tetracycline (Aires *et al.*, 1999). However, expression of *mexXY* was not found in wild-type cells using either real-time PCR or Western immunoblot analysis (Vogne *et al.*, 2004; Yoneda *et al.*, 2005). When cells are first exposed to sub-inhibitory levels of tetracycline, erythromycin, or gentamicin, MexX is observed in immunoblotting experiments (Masuda *et al.*, 2000b). Therefore, these three efflux pump substrates are inducers of *mexXY* expression (Masuda *et al.*, 2000b). These inducers do not appear to act via MexZ, since the presence of substrate antibiotics does not change the DNA-

binding ability of MexZ (Matsuo *et al.*, 2004). Some antibiotic resistant, *mexXY*-overexpressing strains of *P. aeruginosa* have wild-type *mexZ* genes (Islam *et al.*, 2004; Llanes *et al.*, 2004; Vogne *et al.*, 2004). Therefore, it seems likely that an unidentified locus plays a role in regulating *mexXY* expression.

In contrast to other negatively controlled *P. aeruginosa* RND pumps, expression of *mexEF-oprN* is controlled by MexT, a transcription activator of the LysR family. The *mexT* gene is located upstream of the *mexEF-oprN* operon (Kohler *et al.*, 1997). In wild-type cells grown under normal conditions, *mexEF-oprN* is not expressed (Kohler *et al.*, 1997). However, overexpression of *mexT* from a plasmid leads to increased levels of MexEF-OprN and increased antibiotic resistance (Kohler *et al.*, 1997; Kohler *et al.*, 1999). Although the majority of LysR-type regulators are not active until they bind an effector molecule (Schell, 1993), a MexT ligand has not been identified. Salicylate, flavone, trigonellin, naringenin, and vanilline, which are effectors of other LysR-type regulators, are unable to induce expression of the pump. Likewise, MexEF-OprN substrates chloramphenicol, norfloxacin, and trimethoprim also fail to induce expression (Kohler *et al.*, 1999). Expression of *mexEF-oprN* is induced by imipenem (Kolayli *et al.*, 2004) and a quorum sensing inhibitor (Hentzer *et al.*, 2003). However, it has not been demonstrated that this induction occurs via MexT. In many wild-type *P. aeruginosa* strains, induction of *mexEF-oprN* may be impossible due to inactivating mutations in *mexT* (Maseda *et al.*, 2000). Evidence is consistent with the existence of an unidentified suppressor, MexS, which prevents MexT from activating *mexEF-oprN* expression. According to this model, expression of *mexEF-oprN* requires mutations both to activate MexT and inactivate its suppressor MexS (Maseda *et al.*, 2000).

A possible candidate for MexS is the oxidoreductase/dehydrogenase homologue Qrh (Sobel *et al.*, 2005). The gene *qrh* (PA2491) is adjacent to *mexT*, but transcribed in the opposite direction. Expression of PA2491 is constitutive but can be further activated by MexT (Kohler *et al.*, 1999). Furthermore, disruption of PA2491 leads to an increase in MexEF-OprN and multidrug resistance (Sobel *et al.*, 2005). It is possible that PA2491 and MexEF-OprN play a common role in detoxification of cellular metabolites, and that such metabolites could be the MexT effector molecule (Sobel *et al.*, 2005).

MexT is also involved in the regulation of other genes including *mexAB-oprM* (Maseda *et al.*, 2004) and *oprD* (encoding a porin that facilitates uptake of basic amino acids and the antibiotic imipenem) (Kohler *et al.*, 1999; Ochs *et al.*, 1999). MexT may also play a role in expression of quorum sensing regulated genes. Overexpression of the MexEF-OprN efflux system results in decreased production of pyocyanin, elastase, and rhamnolipids as well as decreased swarming (Kohler *et al.*, 2001). Additionally, loss of the VsqR quorum sensing and virulence regulator causes a decrease in *mexEF-oprN* expression in conditions of oxidative stress (Juhas *et al.*, 2004).

As more information emerges about regulation of the *P. aeruginosa* efflux systems, the picture becomes increasingly complex. In fact, expression of the pumps may be subject to coordinate regulation (Li *et al.*, 2000). Expression of the *mexCD-oprJ* and *mexEF-oprN* operons is inversely related to *mexAB-oprM* expression. However, increased production of MexCD-OprJ and MexEF-OprN cannot compensate for the loss of MexAB-OprM. At this point, it is unclear if there is global regulation of the efflux pumps or if loss of MexAB-OprM leads to accumulation of compounds that trigger expression of the other multidrug efflux pumps (Li *et al.*, 2000).

Many organisms use two component systems to regulate expression of efflux systems. Two component systems involve a sensor histidine kinase and a response regulator that activates or represses target genes in response to environmental conditions (Stock *et al.*, 2000). The *Staphylococcus aureus* AlsSR system regulates NorA, a MFS pump (Fournier *et al.*, 2000). AdeSR, a two component system in *Acinetobacter baumanii*, regulates RND pump AdeABC (Magnet *et al.*, 2001). Similarly, the *E. coli* RND efflux system MdtABC is regulated by the BaeSR two component system (Baranova and Nikaido, 2002; Nagakubo *et al.*, 2002). The EvgAS system of *E. coli* regulates two efflux pumps: RND pump YhiUV (Nishino and Yamaguchi, 2002) and MFS pump EmrKY (Nishino and Yamaguchi, 2001a). *Stenotrophomonas maltophilia* RND efflux pump SmeABC is regulated by the SmeSR two component system. Except for NorA of *S. aureus* and YhiUV of *E. coli*, the genes encoding all of the above two component systems are located upstream or downstream of the efflux operon. Two component systems may regulate a range of genes in addition to efflux systems. For example, increased SmeSR expression is also associated with increased β-lactamase production in *S. maltophilia* (Li *et al.*, 2002). Also, *E. coli* two component system BaeSR is involved in regulation of the *yicO* and *ygcL* genes (Baranova and Nikaido, 2002). Regulation of bacterial drug efflux pumps is subject to many levels of control by transcriptional regulatory proteins at the global and local levels. Examining how an efflux pump is regulated may provide insight into its natural function.

1.4 Multidrug efflux pumps in the *B. cepacia* complex

Only recently has there been evidence that active efflux is responsible for some of the multidrug resistance observed in members of the *B. cepacia* complex. Burns *et al.* described a strain of *B. cenocepacia*, isolated from a CF patient, that is resistant to chloramphenicol, trimethoprim, ciprofloxacin, β-lactams, and aminoglycosides (Burns *et al.*, 1989a). Later, the DNA fragment conferring resistance to three of these antibiotics, chloramphenicol, trimethoprim, and ciprofloxacin, was subcloned and the nucleotide sequence was analyzed (Burns *et al.*, 1996). Now, the entire efflux gene cluster has been sequenced and found to contain five open reading frames (Nair *et al.*, 2004). The *opcM* gene is homologous to *oprM*, which encodes the outer membrane component of the *P. aeruginosa* MexAB-OprM RND efflux system. Like OprM, OpcM appears to localize to the outer membrane (Burns *et al.*, 1996). Upstream of *opcM* are two efflux genes *ceoB* and *ceoA* (Nair *et al.*, 2004). The *ceoA* and *ceoB* genes show the highest degree of homology to *mexE* and *mexF* respectively, the membrane fusion and inner membrane transporter components of a *P. aeruginosa* RND efflux system. Upstream of the efflux genes is an open reading frame named *llpE* (lipase-like protein for efflux) and a divergent LysR-type transcriptional regulator named *ceoR* (Nair *et al.*, 2004). LlpE is a novel discovery as there are currently no counterparts involved in characterized efflux systems. The sequence of *llpE* suggests it is a member of the α/β hydrolase enzyme family, which includes lipases, esterases, carboxypeptidases and haloperoxidases (Nair *et al.*, 2005). LlpE is clearly not essential for drug efflux, since deletion of *llpE* does not influence antibiotic susceptibility (Nair *et al.*, 2005). RT-PCR results confirmed that *llpE*, *ceoA*, *ceoB*, and *opcM* are cotranscribed (Nair *et al.*, 2004).

Expression of the three structural genes *ceoAB-opcM* in *B. cenocepacia* strain CEP511 confers resistance to chloramphenicol, trimethoprim, and ciprofloxacin, but not ceftazidime or gentamicin. In addition to antibiotics, when expressed in *B. multivorans* 249-2, the CeoAB-OpcM efflux system can also extrude the siderophore salicylate (Nair *et al.*, 2004). In fact, *ceoA* expression in *B. cenocepacia* clinical isolate PC121 is induced by the presence of pump substrates chloramphenicol and salicylate. Expression of a *ceoR-lacZ* promoter fusion also increases in the presence of chloramphenicol and salicylate (Nair *et al.*, 2004). Perhaps the coregulation of *ceoR* and *ceoAB-opcM* prevents levels of the efflux pump from getting too high.

The CeoAB-OpcM efflux system appears to be somewhat widespread in the *B. cepacia* complex. At least some of the components were amplified from genomovars I, II, III, and IV while none of the components were amplified from genomovar V strains (Nair *et al.*, 2004). Homologues of *llpE* are present in genomovars I, III, IV, and VI (Nair *et al.*, 2005).

Wigfield *et al.* discovered a second efflux system in the *B. cepacia* complex. They identified BcrA, an immunodominant antigen of *B. cenocepacia*, which belongs to the 14-transmembrane domain subfamily of MFS efflux pumps (Wigfield *et al.*, 2002). Overexpression of *bcrA* in *E. coli* cells causes a four-fold increase in resistance to tetracycline and an eight-fold increase in resistance to nalidixic acid. Two potential transcriptional regulators of *bcrA* were identified: a downstream gene encoding a LysR-type transcriptional regulator and an upstream gene encoding a member of the multiple antibiotic resistance (*mar*) family (Wigfield *et al.*, 2002).

A MATE family efflux pump was recently found in *B. vietnamiensis* (Fehlner-Gardiner and Valvano, 2002). Following transposon mutagenesis, a polymyxin B-sensitive strain was found to have an insertion in the *norM* gene. Surprisingly, polymyxin B sensitivity occurs only in presence of tetracycline. The mechanism for the tetracycline-dependent increase in sensitivity remains unknown (Fehlner-Gardiner and Valvano, 2002). Although polymyxin B is the only identified substrate in *B. vietnamienis*, *norM* expression is sufficient to restore norfloxacin resistance in an *E. coli* mutant. NorM is conserved in at least genomovars I through VI (Fehlner-Gardiner and Valvano, 2002). Together, the discovery of the NorM, BcrA, and CeoAB-OpcM efflux systems suggests that active efflux has been overlooked as an important resistance mechanism in the *B. cepacia* complex.

1.5 Research Objectives

The *Burkholderia cepacia* complex is best known for its ability to infect the lungs of cystic fibrosis patients. The widespread antibiotic resistance of the *B. cepacia* complex raises great concern regarding the treatment of such infections. The long-held belief that membrane impermeability is the major mechanism of resistance has been challenged by the discovery of multidrug efflux pumps (Burns *et al.*, 1996; Fehlner-Gardiner and Valvano, 2002; Wigfield *et al.*, 2002). We hypothesize that multidrug efflux pumps play a large role in this resistance. The goal of this research project is to assess the contribution of multidrug efflux pumps to the overall resistance of *B. cenocepacia* clinical isolates.

The identification of putative efflux systems in the *B. cepacia* complex was accomplished by searching the genome of *B. cenocepacia* strain J2315 (http://www.sanger.ac.uk/Projects/B_cenocepacia/) using the sequences of efflux genes from closely related organisms. By this method, six open reading frames (ORFs) with homology to RND transporters were found. Several strategies were employed to characterize the contribution of each RND system.

The ability to knock-out genes through insertion of an antibiotic resistance cassette is limited by the *B. cepacia* complex's intrinsic resistance. Also, the presence of a resistance marker could interfere with detection of an antibiotic sensitive phenotype. Therefore, a Flp-FRT recombinase system was developed and used to create a markerless deletion in one of the RND transporters. The minimum inhibitory concentrations (MICs) of various antibiotics were determined to compare the deletion mutant and wild-type cells. However, no change in antimicrobial susceptibility was observed, leading us to believe that this pump may not be expressed under normal laboratory conditions.

RT-PCR experiments revealed that this efflux system was not expressed. Therefore, we attempted to identify pump substrates by overexpressing the efflux system and looking for a corresponding increase in antibiotic resistance. The structural genes, encoding the membrane fusion, RND transporter, and outer membrane proteins, were cloned and introduced into *E. coli* and *B. cenocepacia*. We also cloned the putative transcription activator of this efflux system and introduced it into *B. cenocepacia* hoping to increase expression of the structural genes.

Expression of the six putative RND efflux systems was characterized using RT-PCR. We examined the effect of potential inducers, salicylate and chloramphenicol, on

expression levels. We also looked for changes in efflux pump expression at various stages of growth.

Chapter 2: Materials and Methods

2. MATERIALS AND METHODS

2.1 Bacterial strains, plasmids and growth conditions

2.1.1 Burkholderia cepacia and Escherichia coli strains

A variety of *E. coli* and *B. cepacia* complex strains were used in this study. Strains and their relevant characteristics are given in Table 2.1.

2.1.2 Plasmid vectors

Cloning vectors and recombinant plasmids constructed are listed in Table 2.2, along with their relevant properties.

2.1.3 Growth Conditions

Bacteria were grown in Luria-Bertani (LB) or ½ LB medium (Sambrook *et al.*, 1989). *E. coli* cells were grown at 37°C with shaking at 250 rpm. *B. cepacia* complex cells were grown at 30°C with shaking at 250 rpm. When necessary for selection, antibiotics were added to the growth medium (liquid and solid) in the following concentrations: for *E. coli*: 100 μg/mL ampicillin, 30 μg/mL chloramphenicol, 50 μg/mL kanamycin, and 100 μg/mL trimethoprim; for *B. cenocepacia* J2315: 300 μg/mL chloramphenicol and 500 μg/mL trimethoprim; for *B. cenocepacia* CEP511, K56-2, and 715j and for *B. vietnamiensis* DB01: 80 μg/mL chloramphenicol and 100 μg/mL trimethoprim.

2.1.4 Preparation of frozen bacterial stocks

Table 2.1 Bacterial strains used in this study

Strain	Description	Reference or Source
E. coli		
DH5α	F⁻ Φ80d*lac*ZΔM15 Δ(*lac*ZYA-*arg*F) U169 *rec*A1 *end*A1 *hsd*R17(r_k^-, m_k^+) *pho*A *sup*E44 λ⁻ *thi*-1 *gyr*A96 *rel*A1	Invitrogen
One Shot TOP10	F⁻ *mcr*A Δ(*mrr-hsd*RMS-*mcr*BC) Φ80*lac*ZΔM15 Δ*lac*X74 *rec*A1 *ara*Δ139 Δ(*ara-leu*)7697 *gal*U *gal*K *rps*L (Str^R) *end*A1 *nup*G	Invitrogen
B. cepacia complex		
715j	*B. cenocepacia* CF isolate	(McKevitt and Woods, 1984)
CEP511	*B. cenocepacia* CF isolate	(Mahenthiralingam *et al.*, 1996)
DB01	*B. vietnamiensis* phthalate degrading isolate	(Bull and Ballou, 1981)
J2315	*B. cenocepacia* CF isolate	(Govan *et al.*, 1993)
K56-2	*B. cenocepacia* CF isolate	(Darling *et al.*, 1998)
Δefflux 5	Derivative of CEP511 with a 978 bp (*Sal*I – *Sal*I) deletion within the efflux 5 transporter	This study

Table 2.2 Plasmids and cloning vectors used in this study

Plasmid	Relevant Characteristics*	Reference
pBAD33	Low copy number, arabinose-inducible promoter, chloramphenicol resistance marker, does not replicate in *B. cepacia* complex strains	(Guzman *et al.*, 1995)
pBAD33 + efflux 1 FRT	Efflux 1.4 L, R PCR product cloned into pBAD33 (*Hind*III - *Sac*I) and with insertion of the FRT cassette from pPS854-Tp (*Sal*I)	This study
pBAD33 + efflux 3 FRT	Efflux 3.1 L, R PCR product cloned into pBAD33 (*Hind*III - *Sac*I) and with insertion of the FRT cassette from pPS854-Tp (*Sal*I)	This study
pBAD33 + efflux 5 FRT	Efflux 5.2 2L, 2R PCR product cloned into pBAD33 (*Xba*I - *Sph*I) and with insertion of the FRT cassette from pPS854-Tp (*Sal*I)	This study
pBBR1MCS	Broad host-range, mobilizable, medium copy number, blue/white screening, chloramphenicol resistance marker	(Kovach *et al.*, 1994)
pBBR1MCS + efflux 5	Efflux 5 stuctural genes and ~1000 bp upstream cloned into pBBR1MCS (*Bam*HI – *Bam*HI)	This study
pBBR1MCS + efflux 5 reg	Efflux 5 putative regulator cloned into pBBR1MCS (*Pst*I - *Xba*I)	This study
pBBR1MCS-Tp	Derivative of pBBR1MCS with a trimethoprim resistance cassette	(DeShazer and Woods, 1996)
pBBR1MCS-Tp + efflux 5	Efflux 5 stuctural genes and ~1000 bp upstream cloned into pBBR1MCS-Tp (*Bam*HI - *Bam*HI)	This study
pBBR1MCS-Tp + efflux 5 reg	Efflux 5 putative regulator cloned into pBBR1MCS-Tp (*Pst*I - *Xba*I)	This study
pCR 2.1 TOPO	TOPO TA cloning vector for direct insertion of PCR products, blue/white screening, ampicillin and kanamycin resistance markers	Invitrogen
pFLP2	Flippase gene under control of λ promoter, Ts cI repressor, *sacB*, ampicillin resistance marker	(Hoang *et al.*, 1998)
pFLP2Cm	*Kpn*I - *Pst*I fragment of pFLP2 (including *Flp*, *cI*, *sacB*) cloned into pBBR1MCS	This study
pPS854	Ampicillin resistance marker, FRT cassette	(Hoang *et al.*, 1998)
pPS854Tp	Derivative of pPS854 with trimethoprim resistance marker from pBBR1MCS-Tp inserted into *Eco*RI site within FRT cassette	This study

* Primers used in the construction of the plasmids are described in Table 2.3.

Bacteria were grown overnight on LB agar with appropriate antibiotics, then suspended in 1 mL of LB + 20% glycerol (vol/vol). Once prepared, strains were stored at -80°C.

2.2 Transformation methods

2.2.1 Transformation of E. coli

E. coli DH5α subcloning efficiency and One Shot TOP10 chemically competent cells were commercially obtained (Invitrogen, Carlsbad, CA) and heat-shocked according to product specifications.

2.2.2 Transformation of B. cepacia complex

B. cepacia complex strains were grown overnight on LB agar. Then, cells were suspended in 500 μL of 10% glycerol (vol/vol), transferred into a sterile 1.5 mL microfuge tube, and centrifuged at 4800 rpm. This wash was repeated two additional times with 250 μL and 100 μL of 10% glycerol. Following the washes, cells were resuspended in 80 μL of 10% glycerol, mixed with an appropriate amount of plasmid DNA, and electroporated using BIO-RAD (Hercules, CA) MicroPulser setting Ec1 (0.1 cm cuvette, 1.8 kV). After electroporation, cells were resuspended immediately in 500 μL SOC medium (Sambrook *et al.*, 1989) and incubated for one hour at 30°C with shaking at 250 rpm. Following incubation, cells were plated in 100 μL volumes on LB agar with selective antibiotics.

2.3 DNA analysis

2.3.1 Isolation of plasmid DNA

For isolation of plasmid DNA from *E. coli* and the *B. cepacia* complex, the QIAprep Spin Miniprep Kit (QIAGEN, Valencia, CA) was used as specified by the manufacturer's recommendations.

2.3.2 Isolation of chromosomal DNA

Genomic DNA was isolated from the *B. cepacia* complex using a previously described phenol/chloroform extraction (Ausubel *et al.*, 1999).

2.3.3 Polymerase chain reaction

Polymerase chain reaction (PCR) was used to amplify DNA fragments for cloning and sequencing reactions. PCR was also used to confirm the insertion or excision of antibiotic resistance cassettes during mutagenesis. Oligonucleotide primers used in this study were purchased from Sigma (St. Louis, MO) and are listed in Table 2.3. Reactions were performed in 20 μL volumes in 0.2 mL tubes using the Eppendorf Mastercycler gradient thermocycler (Westbury, NY). A standard PCR reaction contained 1X PCR reaction buffer (Invitrogen, Carlsbad, CA), 1.5 mM $MgCl_2$, 0.2 mM dNTPs, 0.5 μM forward and reverse primers, and *Taq* polymerase (gift from M.A. Pickard, University of Alberta). When necessary, 0-10% dimethyl sulfoxide (DMSO) was added to the reaction mixture. For template DNA, 5 μL of a 1/50 chromosomal DNA dilution or 1 μL of a 1/50 dilution of plasmid DNA was used. A typical PCR program consisted of a 2 minute denaturation at 94°C followed by 30 cycles of a 45 second denaturation step at 94°C, a 30

Table 2.3 Oligonucleotide primers used in this study

Primer	Sequence (5'-3')*	PCR Conditions	Use
Efflux 1 1596R**	GTGGTTCACGCCGCTCGT	60°C, 2% DMSO	RT-PCR within efflux 1 transporter
Efflux 1 443F	GATGTCGAAGGAGGACCTGA	60°C, 2% DMSO	RT-PCR within efflux 1 transporter
Efflux 1.4 L	AAAAGCTTGCAGGTCACGAAGTCG	60°C, 2% DMSO	Construction of efflux 1 transporter deletion
Efflux 1.4 R	AAGAGCTCCGTCTCGCCGCTGA	60°C, 2% DMSO	Construction of efflux 1 transporter deletion
Efflux 2 1775F	ACATTTCCGACTACCTGTTG	54°C, 8% DMSO	RT-PCR within efflux 2 transporter
Efflux 2 2874R**	CCCCATCTTCTCCGTCG	54°C, 8% DMSO	RT-PCR within efflux 2 transporter
Efflux 3 1071R**	AACAGCCACATCACGCAA	60°C, 6% DMSO	RT-PCR within efflux 3 transporter
Efflux 3 471F	CGATTACCTGAACCGCTAC	60°C, 6% DMSO	RT-PCR within efflux 3 transporter
Efflux 3.1 L	ATAAGCTTGTGCTGACCGCCGTATT	60°C, 2% DMSO	Construction of efflux 3 transporter deletion
Efflux 3.1 R	TTGAGCTCATAACACCCCTCTGTC	60°C, 2% DMSO	Construction of efflux 3 transporter deletion
Efflux 4 1682F	AATTCATCCCGAGCCTCAA	60°C, 8% DMSO	RT-PCR within efflux 4 transporter
Efflux 4 2737R	GCCCGTCCTTCACGTTGTT	60°C, 8% DMSO	RT-PCR within efflux 4 transporter
Efflux 5 1627F	CAGTTCCGACCGCTACCA	60°C, 2% DMSO	RT-PCR within efflux 5 transporter
Efflux 5 2211R	GGTACGAGCTGACGGGATAG	60°C, 2% DMSO	RT-PCR within efflux 5 transporter
Efflux 5.2 2L	AATCTAGACCGCTGGAAGAGGCGA	60°C, 5% DMSO	Construction of efflux 5 transporter deletion
Efflux 5.2 2R**	AAGCATGCGAGCGTCACCGACATC	60°C, 5% DMSO	Construction of efflux 5 transporter deletion, RT-PCR within efflux 5 transporter
Efflux 5.2 3L	TAGGATCCTGAAAAGCCTGTTCC	60°C, Buffer 3, 6% DMSO	Overexpression of efflux 5 structural genes
Efflux 5.2 4R	TTGGATCCGTCTACTACTACATCA	60°C, Buffer 3, 6% DMSO	Overexpression of efflux 5 structural genes
Efflux 5reg 2L	TACTGCAGCATGGAAGGTATCGCAT	60°C, Failsafe PreMix H	Overexpression of efflux 5 regulator
Efflux 5reg 2R	ATTCTAGAGTTCACGTCGTTGCCGA	60°C, Failsafe PreMix H	Overexpression of efflux 5 regulator
Efflux 6 1143F	CACGTTCTCGCTGCTGCT	60°C, Failsafe PreMix H	RT-PCR within efflux 6 transporter
Efflux 6 2002R**	CTTCATCGCGCCGTACTT	60°C, Failsafe PreMix H	RT-PCR within efflux 6 transporter
FRT 1.L	GAGCTCGAATTGGGGATCTTG	60°C	PCR verification of FRT insertion and excision
FRT 1.R	GAGCTCGAATTAGCTTCAAAAG	60°C	PCR verification of FRT insertion and excision
RecA 130F	ATCCAGGTCGTCTCCACG	60°C, 2% DMSO	RT-PCR positive control within *recA*
RecA 921R**	GATCTTCTCGCCGTTGTAG	60°C, 2% DMSO	RT-PCR positive control within *recA*

L and F refer to the 5' primer

R refers to the 3' primer

* underlined sequences indicate engineered resistriction endonuclease sites

** indicates the oligonucleotide primer used for first strand cDNA synthesis

second annealing step at 50-65°C, and a 1 minute extension period at 72°C. Finally, 2 minutes at 68°C provided additional extension time.

In some cases, the Failsafe PCR PreMix Selection Kit (Epicentre Biotechnologies, Madison, WI) was used. Each reaction contained 1.5 μL of a 1/50 dilution of chromosomal DNA, and 0.25 μL (0.625 units) of a PCR enzyme mix containing a proof reading enzyme or 1 μL of *Taq* polymerase. After an initial denaturation at 94°C for 2 minutes, 0.5 μL of each 50 μM primer was added. Then, a standard PCR reaction was used as described above.

For amplification of long regions of DNA (>3kb), the Expand Long Template PCR System was used (Roche Diagnostics, Indianapolis, IN). This system uses a mix of *Taq* DNA polymerase and a proofreading polymerase. Reactions were prepared using the supplied PCR buffer 3 according to the manufacturer's specifications. Thermal cycling was performed as directed in the product guide. An initial elongation time of 8 minutes was used and this extension time was increased gradually over the course of the reaction to ensure maximum amplification of target DNA.

2.3.4 Gel electrophoresis of DNA

DNA samples were suspended in loading buffer containing 0.25% bromophenol blue and 40% sucrose (Sambrook *et al.*, 1989). Samples were subjected to electrophoresis in 0.8% agarose, 1X TAE gels. Electrophoresis was carried out at 100 – 130 V. The 1 kb Plus DNA ladder from Invitrogen (Carlsbad, CA) was used as a molecular weight marker. Following electrophoresis, gels were stained in ethidium bromide for visualization with ultraviolet light.

2.3.5 Purification of DNA from agarose gels

For isolation and purification of DNA from agarose gels, the Geneclean II Kit was used (Q-BIOgene, Irvine, CA). Briefly, an agarose gel fragment was melted in NaI at 55°C. Then a silica matrix was added to bind DNA out of the solution. The silica-DNA complex was pelleted by centrifugation and washed with a solution of NaCl, Tris, EDTA, and ethanol. Again, the silica-DNA complex was pelleted and dried to remove the ethanol. At this point, the silica-DNA complex was suspended in sterile water to elute the DNA. After centrifugation, the supernatant, containing the DNA, was removed and transferred into a clean tube for immediate use or storage at 4°C.

2.3.6 Cloning of DNA

General molecular techniques were performed as detailed by Sambrook *et al.* (1989). Restriction endonuclease digestion was performed using enzymes from Invitrogen (Carlsbad, CA) according to the manufacturer's instructions. For ligation reactions, an insert to vector ratio of approximately 3:1 was used. Reactions were carried out in 10-15 μL volumes using T4 DNA ligase (Promega, Madison, WI) at room temperature (directional cloning) or 16°C (non-directional cloning) for 4-16 hours. In some cases, PCR products amplified with *Taq* polymerase were first cloned into the pCR2.1-TOPO vector (Invitrogen, Carlsbad, CA) and subsequently cloned into suitable vectors for use in the *B. cepacia* complex.

2.3.7 DNA sequence analysis

Automated DNA sequencing was carried out using the DYEnamic ET kit (Amersham Biosciences, Piscataway, NJ). The sequencing reaction contained 1-3 μL of template DNA (plasmid or purified PCR product), 4 μL of ET reagent, 1 μL of 5 μM primer, and sequencing buffer (20 mM Tris, pH 9.0, 5mM $MgCl_2$) to a final volume of 20 μL. The standard reaction program consisted of 35 cycles of a 20 second denaturation step at 95°C, a 15 second primer annealing step at 50°C, and a 60 second extension step at 60°C. Reactions were stopped by the addition of 2 μL sodium acetate/EDTA. DNA was precipitated at -20°C for 15 minutes after the addition of 80 μL 95% ethanol. After centrifugation, the resulting pellets were washed with 500 μL 70% ethanol, stored at -80°C, and provided to the Molecular Biology Service Unit (MBSU, University of Alberta) for electrophoresis on an ABI PRISM 377 or 3100 DNA sequencer (Applied Biosystems, Foster City, CA).

2.4 RNA analysis

2.4.1 RNA isolation

One mL of an overnight culture of *B. cenocepacia* was used to inoculate 25 mL of LB medium. The cultures were grown at 30°C with shaking at 250 rpm to an OD_{600} of 0.5-0.7. At this point, 3 mL of culture were removed for RNA isolation. The MasterPure RNA Purification Kit (Epicentre, Madison, WI) was used according to manufacturer's instructions with one modification. Following the first precipitation of nucleic acids, the pellet was resuspended and digested with 5 units of DNaseI for 30 minutes at 37°C. Then, an additional 5 units of DNaseI were added for a second 30 minute digestion at 37°C. Upon completion of the RNA isolation procedure, RNA was suspended in 30 μL

of sterile DEPC-treated water and kept at -20°C overnight to allow the RNA to go into solution. RNA was then quantified by spectrophotometry, measuring absorbance at 260 nm (1 absorbance unit = 40 μg/mL RNA) (Sambrook *et al.*, 1989). The quality of RNA was determined by the ratio of A_{260}/A_{280}. Pure RNA has an A_{260}/A_{280} ratio of 2.0. A ratio of < 2.0 indicates that the RNA sample is contaminated with protein or phenol (Sambrook *et al.*, 1989). For long-term storage, RNA was stored in sterile DEPC-treated water and frozen at -80°C. Isolation of RNA from cells in late-logarithmic or stationary phase occurred as described above with the following exceptions: cells were grown in ½ LB medium at 30°C with shaking at 250 rpm, and 1 mL aliquots were removed when the culture reached an OD_{600} of 1.2 (late-logarithmic phase) and again after growth overnight (stationary phase).

2.4.2 Reverse-transcriptase PCR (RT-PCR)

The primers for first strand cDNA sythesis and PCR were designed to bind specifically to each of the six putative RND transporter genes. Specificity was confirmed by sequencing the PCR products as described above. As a positive control, the *recA* gene was amplified. The oligonucleotide primers used for cDNA synthesis and PCR are described in Table 2.3.

Superscript III First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA) was used to generate cDNA. Reaction mixtures contained 1 μg of total RNA, 2 μM of gene specific primer, 1 μL of DMSO, 1 μL of 10 mM dNTPs, and DEPC-treated water to a final volume of 10 μL. This reaction was heated at 65°C for 5 minutes in an Eppendorf Mastercycler gradient thermocycler, then cooled to 4°C for at least 1 minute.

Next, appropriate amounts of 10X RT buffer, 25 mM $MgCl_2$, 0.1M DTT, RNase Out, and Superscript III reverse transcriptase were added according to the manufacturer's instructions. A negative control was prepared as described above, except without the addition of Superscript III. Synthesis occurred for 1 hour at 55°C (or 2 hours for efflux 5 cDNA synthesis) and was terminated by heating to 85°C for 5 minutes. The cDNA was used immediately for PCR or stored at 4°C.

The yield of RNA isolated from late log or stationary phase cells was much lower than that of the mid-log phase cell. As a result, first strand cDNA synthesis for these growth conditions was performed using only 0.75μg total RNA. The cDNA synthesis reaction for all transporter genes was extended to 2 hours at 55°C.

Following synthesis, 2 μL of cDNA was used as the template for a PCR reaction. PCR was performed as described above except that primers were added after the initial 2 minute, 94°C denaturation step and that the amplification continued for 28 cycles instead of 30.

2.5 Minimum inhibitory concentration (MIC) assay

Antibiotics were purchased from various commercial sources, including Sigma (St. Louis, MO) and Fisher (Fairlawn, NJ). Stock solutions of antibiotics were prepared according to the solubilities listed in the MERCK index (Budavari *et al.*, 1996) to concentrations of 4 mg/mL and 8 mg/mL. Antibiotics were serially diluted into 96 well plates containing 100 μL of LB per well. After dilution, each well contained 100 μL of antibiotic solution, with half the concentration of the previous well.

A single colony of *B. cenocepacia* was used to inoculate 5 mL of LB and grown overnight at 30°C. One mL of the overnight culture was used to inoculate 25 mL of LB and incubated at 30°C until reaching a final OD_{600} of approximatey 1.0. Then, 5 μL of culture was used to inoculate each well containing antibiotic solution. Plates were incubated on a shaker at 30°C for approximately 24 hours. The minimum inhibitory concentration (MIC), or the lowest antibiotic concentration that completely inhibited bacterial growth, was determined by measuring OD_{600} with a Wallac Victor^2 multilabel counter (Perkin Elmer, Shelton, CT).

2.6 Computer-assisted sequence analysis

For raw sequence handling, the GeneJockey Sequence Processor (BIOSOFT, Ferguson, MO) was used. Oligonucleotide primers were designed using Primer3 (http://frodo.wi.mit.edu/cgi-bin/primer3_www.cgi) and Primers (Anderson and Bristol, UCLA, Los Angeles, CA). For automated sequence viewing and assembly, both ABI PRISM EditView (Perkin Elmer) and GeneTool 2.0 (BioTools, Edmonton, AB) were used. Putative RND transporters were identified by performing BLAST (Altschul *et al.*, 1990) searches of the *B. cenocepacia* database (http://www.sanger.ac.uk/Projects/B_cenocepacia/) with the sequences of known efflux systems in related organisms. The homology of the putative *B. cenocepacia* RND efflux systems to other known RND efflux pumps was determined using BLASTP searches of the NCBI database (http://www.ncbi.nlm.nih.gov/BLAST).

Chapter 3: Results

3. RESULTS

3.1 Identification of putative RND transporters in *B. cenocepacia*

We wanted to assess the contribution of multidrug efflux pumps to the overall antibiotic resistance of *B. cenocepacia*. RND family transporters are considered the most relevant multidrug efflux pumps in terms of resistance to clinically important agents (Poole, 2004). Therefore a logical starting point for the study of *B. cenocepacia* multidrug resistance was to search for members of the RND family. To identify putative RND efflux systems, the genome of *B. cenocepacia* J2315 was searched using sequences from known efflux pumps in related organisms such as *E. coli*, *P. aeruginosa*, and *N. gonorrhoeae*. Six ORFs were found with homology to RND transporters. Since these putative efflux systems have not been given official names, they will be referred to as efflux system numbers 1 through 6. With the exception of efflux system 3, each of the putative RND transporters was located along with ORFs encoding putative membrane fusion proteins, outer membrane proteins, and transcription regulators (Figure 3.1). To identify which known efflux pumps the putative *B. cenocepacia* ORFs were most similar to, BLASTP searches were performed.

Efflux system 1 contained each member of a tripartite efflux system similar to the *P. aeruginosa* MexAB-OprM multidrug efflux pump (Poole *et al.*, 1993b). The RND transporter was 77% similar and 63% identical at the protein level to MexB (accession number AAG03815). Immediately downstream of the transporter gene was an ORF encoding an outer membrane protein that was 69% similar and 54% identical to *P. aeruginosa* OprM (accession number AAG03816). Immediately upstream of the transporter, a gene encoding a membrane fusion protein that was 69% similar and 55%



Figure 3.1 Six putative RND efflux systems in *B. cenocepacia* J2315. Potential efflux pumps were identified by searching the genome sequence of *B. cepacia* J2315 with DNA sequences from known efflux pump genes. ORFs encoding RND transporters (light gray), membrane fusion proteins (white), outer membrane proteins (black), transcription regulators (diagonal lines) were found. For efflux system 4, a putative outer membrane-associated protein was encoded (horizontal lines). For efflux system 6, an *llpE*-homologue was also identified (vertical lines). The closest homologues of each predicted protein product, determined by BLASTP searches, are shown above each ORF (% similarity/identity).

identical to *P. aeruginosa* MexA was identified (accession number AAG03814). A putative regulator, with homology to members of the AraC family (Egan, 2002), is transcribed upstream and in the opposite orientation of the membrane fusion component. The AraC-type regulators are usually activators, but the family also includes some repressors of transcription (Gallegos *et al.*, 1993).

Like efflux system 1, efflux system 2 showed homology to the MexAB-OprM RND pump of *P. aeruginosa* (Poole *et al.*, 1993b). The transporter component of efflux system 2 was homologous to MexB (accession number AAG03815), showing 79% similarity and 64% identity. The membrane fusion component was 69% similar and 54% identical to MexA (accession number AAG03814). An outer membrane protein with 68% similarity and 53% identity to OprM (accession number AAG03816) was encoded downstream of the transporter gene. Unlike efflux system 1, efflux system 2 had two putative regulatory genes nearby, one belonging to the TetR family of repressors (Grkovic *et al.*, 2002) and the other belonging to the AraC family (Egan, 2002).

Efflux system 3 was different than the other five putative RND systems because the transporter gene was not found near ORFs encoding putative membrane fusion and outer membrane proteins. The putative RND transporter was 67% similar and 50% identical to MexD (accession number AAG07986), another multidrug transporter from *P. aeruginosa* (Poole *et al.*, 1996a). Upstream of efflux system 3 was a gene encoding a putative ABC transporter. A putative TonB-dependent outer membrane receptor was located downstream of efflux system 3 (data not shown).

Efflux system 4 did not show homology to a multidrug transporter, but rather the *Ralstonia metallidurans* (*Alcaligenes eutrophus*) heavy metal cation RND transporter

CzcA (85% similarity, 73% identity, accession number CAA67084). A membrane fusion component showing 68% similarity and 51% identity to CzcB (accession number CAA67083) was encoded directly upstream of the CzcA-homolog. Upstream of the membrane fusion component, a protein was encoded with 56% similarity and 39% identity to CzcC (accession number CAA67082). CzcC is an outer membrane-associated protein that may facilitate transport across the outer membrane by recruiting a hypothetical outer membrane protein (Rensing *et al.*, 1997). Encoded downstream of the RND transporter was a sensor histidine kinase (HK) and response regulator (RR) pair homologous to the *R. metallidurans* two component system CzcS (60% similarity, 38% identity, accession number CAA67087) and CzcR (77% similarity, 60% identity, accession number CAA67086). The Czc efflux system is involved in resistance to cobalt, zinc, and cadmium in *R. metallidurans* (Nies *et al.*, 1989; Nies, 1992; van der Lelie *et al.*, 1997).

The efflux system 5 transporter was most homologous to *P. aeruginosa* multidrug transporter MexF (71% similarity, 56% identity, accession number AAG05882) (Kohler *et al.*, 1997). It was located between a membrane fusion component with homology to MexE (64% similar, 46% identical, accession number AAG05881) and an outer membrane component with homology to OprN (54% similar, 37% identical, accession number AAG05883). Upstream of this putative efflux operon was a divergently transcribed regulator. The predicted product of this regulatory gene was homologous to members of the LysR family of transcription activators (Schell, 1993).

The RND transporter from efflux system 6 was also very similar to MexF (80% similar and 64% identical, accession number AAG05882) of *P. aeruginosa* (Kohler *et al.*,

1997), but was most homologous to the CeoB RND pump (93% similarity and identity, accession number AAB58161) of *B. cenocepacia* K61-3 (Nair *et al.*, 2004). The outer membrane component of efflux system 6 was also homologous to the *B. cenocepacia* K61-3 system (Burns *et al.*, 1996), with 93% similarity and 92% identity to OpcM (accession number AAC43969). Continuing this trend, the putative LysR-type regulator encoded upstream of efflux system 6 was 100% identical at the protein level to CeoR (accession number AAG21824) and the putative membrane fusion protein belonging to efflux system 6 was 100% identical to *B. cenocepacia* K61-3 CeoA (accession number AAB58160) (Nair *et al.*, 2004). Efflux system 6 also contains an ORF with a product that is 100% identical to LlpE (accession number AAG21825), a gene that is cotranscribed with the *ceoAB-opcM* efflux pump and encodes a lipase-like protein of unknown function (Nair *et al.*, 2004).

3.2 Construction of a Flp/FRT system for use in the *B. cepacia* complex

Once the six putative efflux pumps were identified, we wanted to determine the contribution of each pump to the overall antibiotic resistance of *B. cenocepacia* J2315. This contribution was to be assessed by creating deletions in the transporter genes, alone and in combination. Then, the minimum inhibitory concentrations (MICs) of various antibiotics against the wild-type and deletion strains could be compared. However, members of the *B. cepacia* complex are known to be extremely antibiotic resistant, which limits the availability of markers for selection of mutants. We were also concerned that the presence of antibiotic resistance markers in the genome could mask an antibiotic sensitive phenotype in the deletion mutants. Therefore, a Flp/FRT system was developed

for the creation of markerless mutations in *B. cenocepacia*. Flp/FRT systems make use of the Flp enzyme, a site specific recombinase that promotes recombination at specific 13 bp sites, termed Flp recombinase target (FRT) sites (Cox, 1983). Therefore, a selectable marker carried between two FRT sites can be used to mark a deletion and later be excised by the introduction of the Flp enzyme. These systems require a gene delivery vector, an FRT cassette, and a Flp recombinase producing plasmid.

To deliver the interrupted mutant allele into *B. cenocepacia*, pBAD33 was used (Guzman *et al.*, 1995). This vector was chosen because it does not replicate in members of the *B. cepacia* complex, facilitating selection of homologous recombination events. Also, pBAD33 has a multiple cloning site and a chloramphenicol resistance marker that are useful for cloning and maintaining a gene of interest in *E. coli*.

The previously described plasmid pPS854 (Hoang *et al.*, 1998) was used as the source of the FRT cassette. This plasmid contains the FRT sites flanked with eight restriction endonuclease sites in inverted order, allowing the FRT cassette to be easily inserted into a gene of interest. The FRT cassette contains two FRT sites separated by 68 bp. Between the two FRT sites are *Eco*RI and *Eco*RV restriction endonuclease sites. For use in *B. cenocepacia*, we cloned the trimethoprim resistance marker from pBBR1MCS-Tp into the *Eco*RI site of the pPS854 FRT cassette. The resulting plasmid, pPS854Tp (Figure 3.2 A), was used as the source of the FRT cassette in this study since trimethoprim resistance is one of the few markers that can be easily selected in the *B. cepacia* complex.

High intrinsic β-lactam resistance in the *B. cepacia* complex prevents the use of the Flp recombinase-producing plasmid pFLP2 (Hoang *et al.*, 1998). To address this



Figure 3.2 Physical maps of plasmids used in the *B. cepacia* complex Flp/FRT system. (A) The FRT cassette vector pPS854Tp was constructed as described in Section 3.2. The sequence of the FRT cassette has been previously described (Hoang *et al.*, 1998). Only selected restriction enzyme cleavage sites are shown. *Hind*III → *Sac*I, *Hind*III-*Sph*I-*Pst*I-*Sal*I-*Xba*I-*Bam*HI-*Sma*I-*Kpn*I-*Sac*I. (B) The pFLP2Cm plasmid was derived as described in Section 3.2. DNA shown in white originates from pBBR1MCS and DNA shown in gray is from pFLP2. Expression of Flp is driven by the strong, rightward λ promoter and is controlled by the cI_{857}-encoded, temperature sensitive λ repressor.

problem, pFLP2Cm was constructed (Figure 3.2 B). A *Kpn*I – *Pst*I fragment from pFLP2 was ligated to pBBR1MCS. This new Flp recombinase-producing plasmid contains the Flp gene expressed from the strong λ promoter. Expression of Flp is regulated by the temperature sensitive cI_{857} λ repressor. The pFLP2Cm plasmid has the broad host range origin of replication from pBBR1MCS, allowing its use in members of the *B. cepacia* complex. It also contains the chloramphenicol resistance marker from pBBR1MCS, which is useful for selection in some *B. cepacia* complex strains. Finally, pFLP2Cm has the *sacB* gene from pFLP2, encoding a levansucrase enzyme that releases glucose from sucrose, creating a byproduct that is toxic for Gram-negative bacteria. Therefore, loss of the plasmid can be selected for following excision of the FRT cassette.

3.3 Isolation of an unmarked *B. cenocepacia* efflux transporter deletion

The application of this Flp/FRT system in *B. cenocepacia* was tested by creating a markerless deletion in the efflux system 5 RND transporter. The general procedure is outlined in Figure 3.3. Approximately 3 kb of the efflux 5 transporter was amplified from *B. cenocepacia* J2315 and cloned into the pBAD33 vector by means of *Xba*I and *Sph*I restriction sites engineered into oligonucleotide primers Efflux 5.2 2R and 2L (Table 2.3). *Sal*I digestion of this plasmid resulted in a 978 bp deletion within the transporter gene. Simultaneously, the FRT cassette from pPS854Tp was inserted into the *Sal*I site to mark the deletion. The resulting construct contained the FRT cassette flanked on each side by 1 kb of *B. cenocepacia* DNA. Similar constructs were made for the efflux 1 (963 bp deletion flanked by 837 bp and 931 bp of DNA) and efflux 3 (968 bp deletion flanked by 584 bp and 1115 bp of DNA) transporter genes as described in Table 2.2.



Figure 3.3 Strategy for isolation of markerless deletions. This system utilizes a trimethoprim resistance cassette flanked by two Flp recombinase target (FRT) sites that can be inserted into any target gene. The interrupted gene, carried by pBAD33, is delivered into the *B. cepacia* complex where it may undergo homologous recombination with the host chromosome. Since pBAD33 does not replicate in the *B. cepacia* complex, any trimethoprim resistant, chloramphenicol sensitive colonies indicate a double recombination event. Once the wild-type copy of the gene has been replaced with the interrupted copy, the flippase gene is provided *in trans* on the broad host range plasmid pFLP2Cm in order to excise the trimethoprim resistance cassette. Loss of pFLP2Cm can be selected for by growth on LB medium containing 5% sucrose.

The next step was to introduce the marked deletion into *B. cenocepacia* via homologous recombination. Since pBAD33 does not replicate in members of the *B. cepacia* complex, any resistant colonies must be recombinants. Colonies that are resistant to both trimethoprim and chloramphenicol represent a single recombination event, resulting in the integration of pBAD33 and the marked deletion into the host chromosome. Colonies that are trimethoprim resistant but chloramphenicol sensitive indicate that a double recombination event has occurred in which the wild-type transporter gene has been replaced by the marked deletion.

Originally, we planned to introduce efflux deletions into *B. cenocepacia* J2315. This organism is a clinical isolate that is well known for having extremely high levels of antibiotic resistance. Also, the genome of this organism has been sequenced and was used to identify and clone the putative efflux genes. However, we have never been able to observe integration of DNA into the J2315 chromosome by homologous recombination. This may be due to difficulties in introducing pBAD33 into J2315. The transformation efficiency of *B. cenocepacia* J2315 is negligible compared to other strains (Mahenthiralingam *et al.*, 2000b). The decreased amount of pBAD33 getting into the cells may have limited the chance of recombination events. An additional complication is strain J2315's high level of background resistance to trimethoprim, which made it difficult to select recombinants. As such, we experimented with the use of other members of the *B. cepacia* complex that may be more amenable to the Flp/FRT system. Our lab has had previous success creating mutants in *B. vietnamiensis* DB01. Some progress was made in creating a deletion of the efflux 3 transporter in this strain. A deleted copy of the gene was integrated into the host genome. However, we were unable

to introduce the Flp-carrying plasmid pFLP2Cm due to the inducible chloramphenicol resistance of DB01. Similarly, inducible chloramphenicol resistance also interfered with the use of pFLP2Cm after integration of the efflux 5 deletion in *B. cenocepacia* K56-2. *B. cenocepacia* 715j was compatible with the antibiotic resistance markers used in the Flp/FRT system. An efflux 3 transporter deletion was integrated into the chromosome of this strain. However, work in strain 715j was not continued because success was achieved using *B. cenocepacia* CEP511. CEP511 is a clinical isolate that is susceptible to both trimethoprim and chloramphenicol and is readily transformed (Mahenthiralingam *et al.*, 2000b). A marked deletion of the efflux 5 transporter was introduced into CEP511 via pBAD33. Selection for trimethoprim resistant and chloramphenicol sensitive colonies yielded a double recombination event in which the wild-type transporter was replaced by the deleted gene. Integration of the marked deletion into the host chromosome was verified by PCR amplification of the FRT cassette (Figure 3.4 B).

Once the deletion was returned to the host chromosome, the FRT cassette was excised. The cells were transformed with Flp-producing plasmid pFLP2Cm. After shaking at 30°C for 1 hour, the cells were transferred to 37°C for 1 hour. During the 37°C incubation, the temperature sensitive cI repressor was inactivated, allowing expression of the Flp gene. After incubation, cells containing pFLP2Cm were selected by growth on LB agar with 80 μg/mL chloramphenicol. In order to identify cells that had undergone Flp-mediated excision of the FRT cassette, chloramphenicol resistant colonies were assessed for growth on LB agar with 100 μg/mL trimethoprim. PCR amplification with oligonucleotide primers specific to the FRT cassette was performed to confirm absence of the FRT cassette (Figure 3.4 B). Following excision of the FRT cassette,



Figure 3.4 PCR confirmation of a markerless deletion in a *B. cenocepacia* CEP511 efflux transporter. Lanes: 1) 1 kb Plus DNA ladder, 2) wild-type CEP511, 3 and 4) CEP511 Δefflux 5 after excision of the FRT cassette, 5) CEP511 Δefflux 5 before excision of the FRT cassette. (A) PCR amplification within the efflux 5 RND transporter using primers Efflux 5.2 2L and 2R (Table 2.3) demonstrates a deletion of 978 bp (in lanes 3 and 4) compared to the wild-type PCR product of ~ 3 kb (lane 2). In lane 5, the efflux 5 PCR product is approximately the same size as the wild-type product. This reflects the simultaneous deletion of 978 bp and insertion of the ~ 900 bp FRT cassette. (B) PCR amplification using primers FRT 1.L and 1.R, which flank the entire FRT cassette (Hoang *et al.*, 1998), verifies that the FRT cassette has been removed from Δefflux 5 strains (lanes 3 and 4) following transformation with pFLP2Cm. As expected, the FRT cassette is amplified from the Δefflux 5 mutant prior to excision of the FRT cassette (lane 5). Wild-type CEP511 (lane 2) was included as a negative control.

pFLP2Cm must be removed from cells. This was accomplished by growth on LB + 5% sucrose plates because cells containing pFLP2Cm, and thus the *sacB* gene, are unable to survive under these conditions. Loss of pFLP2Cm was verified by the inability to grow on 80 μg/mL chloramphenicol and by failure to isolate plasmid DNA. PCR amplification using oligonucleotide primers flanking the deletion was performed to verify the loss of 978 bp from the efflux 5 transporter (Figure 3.4 A).

3.4 Characterization of a *B. cenocepacia* efflux transporter deletion

Having isolated a markerless deletion in the efflux 5 RND transporter gene, we then wanted to compare the mutant to wild-type CEP511 in terms of antibiotic resistance. It was expected that the mutant would show increased sensitivity to certain antimicrobial agents that were substrates of efflux system 5. The minimum inhibitory concentrations (MICs) of 14 antibiotics were determined (Table 3.1). A variety of antimicrobial agents were chosen, including β-lactams, fluoroquinolones, tetracycline, macrolides, aminoglycosides, and other classes. Although there is not necessarily a correlation between homology and substrate range, sensitivity to some *P. aeruginosa* MexEF-OprN substrates, chloramphenicol, fluoroquinolones, and trimethoprim, was determined. For most of the antibiotics tested, there was no difference between wild-type CEP511 and Δefflux 5. Slight differences were observed for some antibiotics. The mutant strain was two times less resistant to novobiocin and two times more resistant to norfloxacin than wild-type CEP511. However, these differences are not necessarily significant as they correspond to only a one or two well difference in the 96 well assay.

Table 3.1 Minimum inhibitory concentrations of various antibiotics against wild-type *B. cenocepacia* CEP511and Δefflux 5. The table below shows the results from one experiment. Susceptibility to ampicillin (AP), carbenicillin (CA), chloramphenicol (CM), erythromycin (ER), fusidic acid (FU), kanamycin (KN), nalidixic acid (NL), norfloxacin (NR), novobiocin (NV), polymyxin B (PB), streptomycin (ST), tetracycline (TC), tobramycin (TB), and trimethoprim (TP) was assessed.

	MIC (μg/mL)											
	AP	**ER**	**FU**	**KN**	**NL**	**NR**	**NV**	**PB**	**ST**	**TC**	**TB**	**TP**
CEP511	8000	250	125	4000	4000	125	31.25	4000	>4000	125	2000	7.8
Δefflux 5	8000	250	125	4000	4000	250	15.6	4000	>4000	125	2000	7.8

3.5 Expression of the putative RND efflux pumps in *B. cenocepacia*

One possible explanation for the lack of antibiotic sensitivity in the deletion mutant is that efflux system 5 may not be constitutively expressed in wild-type cells. To address this possibility, expression of the six putative efflux systems was analyzed by RT-PCR. We prepared cDNA from *B. cenocepacia* J2315 grown to mid-logarithmic phase in LB broth. PCR amplification was performed using primers designed within each transporter gene (Figure 3.5). The specificity of the primers was verified by DNA sequencing. Primers within the constantly expressed *recA* gene were used as a positive control. As expected, the *recA* gene was expressed, resulting in a 791 bp band. Efflux system 2 was also expressed, as demonstrated by the 1099 bp product. However, the absence of RT-PCR bands from efflux 1, 3, 4, 5, and 6 specific primers indicates that these efflux systems are not expressed under normal laboratory conditions. There was a lower molecular weight product in the RT-PCR of efflux system 5. The procedure was modified to eliminate this non-specific product. Since *B. cenocepacia* CEP511 was used in the creation of the Δefflux 5 mutant, expression of the RND systems in this strain was also assessed (Figure 3.6). As in J2315, the *recA* positive control was expressed in CEP511. For the most part, none the six putative RND efflux systems were amplified under normal laboratory conditions. However, there may be a faint RT-PCR product corresponding to efflux system 3. To determine if this efflux system is expressed, optimization of the RT-PCR conditions by using various ratios of betaine and DMSO is required. The lack of expression of efflux system 5 in both *B. cenocepacia* strains explains why Δefflux 5 was no different than CEP511 in terms of antibiotic



Figure 3.5 Expression of RND efflux pumps in *B. cenocepacia* J2315. RT-PCR amplification was performed on RNA isolated from mid-logarithmic phase cells grown in LB medium. Putative RND efflux transporters 1 – 6 were amplified for 28 cycles with gene specific primers (+). RT-PCR of the constantly expressed *recA* was performed as a positive control. For each set of oligonucleotide primers, amplification of cDNA synthesized without reverse transcriptase (-) was performed to determine the extent of amplification from contaminating chromosomal DNA. As an additional control, PCR amplification from J2315 chromosomal DNA (D) was carried out to ensure that all reaction reagents and conditions were functioning.



Figure 3.6 Expression of RND efflux pumps in *B. cenocepacia* CEP511. RT-PCR amplification was performed on RNA isolated from mid-logarithmic phase cells grown in LB medium. Putative RND efflux transporters 1 – 6 were amplified for 28 cycles with gene specific primers (+). RT-PCR of the constantly expressed *recA* gene was performed as a positive control. Amplification from cDNA synthesized without reverse transcriptase (-) was included as a negative control for contaminating DNA. PCR amplification from CEP511 chromosomal DNA (D) was performed as a control for PCR conditions and reagents.

susceptibility. An alternate approach was needed to determine the contribution of these efflux systems to *B. cenocepacia* antibiotic resistance.

3.6 Overexpression of efflux 5 structural genes

Overexpression of efflux structural genes from cosmids or plasmids has been associated with increased resistance to antimicrobials for many efflux systems, including *P. aeruginosa mexXY* (Aires *et al.*, 1999), *mexEF-oprN* (Kohler *et al.*, 1997), and *B. cenocepacia ceoAB-opcM* (Nair *et al.*, 2004). A similar approach was attempted for *B. cenocepacia* J2315 efflux system 5. The putative promoter region, as well as the membrane fusion, RND transporter, and outer membrane components, were PCR amplified from J2315 chromosomal DNA. Using *Bam*HI restriction endonuclease sites engineered into the oligonucleotide primers, the structural genes and promoter were cloned into medium copy number plasmids pBBR1MCS and pBBR1MCS-Tp. Two plasmid vectors were chosen because they carry different antibiotic resistance markers (chloramphenicol and trimethoprim, respectively). Using two vectors ensured that increased resistance to either antibiotic could be attributed to overexpression of the efflux system rather than to the vector.

The constructs were electroporated into *B. cenocepacia* CEP511. MICs of various antibiotics were determined for the wild-type, vector control, and overexpression strains (Table 3.2). There was no difference in the MICs of carbenicillin, chloramphenicol, erythromycin, norfloxacin, and trimethoprim other than that due to the vector. A two fold decrease in kanamycin resistance was observed in the pBBR1MCS overexpression strain. A two fold increase in tetracycline resistance was seen in the

Table 3.2 Overexpression of efflux 5 structural genes in *B. cenocepacia* CEP511. The efflux 5 structural genes were cloned into pBBR1MCS and pBBR1MCS-Tp. The minimum inhibitory concentration (MIC) of various antibiotics on wild-type, vector controls, and overexpression strains was compared. The values below are an average of two replicates, with the exception of carbenicillin. Antibiotics carbenicillin (CA), chloramphenicol (CM), erythromycin (ER), kanamycin (KN), norfloxacin (NR), tetracycline (TC), and trimethoprim (TP) were used.

	MIC (μg/mL)						
	CA	**CM**	**ER**	**KN**	**NR**	**TC**	**TP**
CEP511	4000	31.25	125	4000	250	62.5	7.8
+ pBBR1MCS	4000	250	125	4000	250	62.5	7.8
+ pBBR1MCS + efflux 5	4000	250	125	4000	250	125	7.8
+ pBBR1MCS-Tp	4000	31.25	125	4000	250	62.5	250
+ pBBR1MCS-Tp + efflux 5	4000	31.25	125	2000	250	62.5	250

pBBR1MCS overexpression strain. Since these differences were not seen in both pBBR1MCS and pBBR1MCS-Tp overexpression strains, they are not significant. A similar experiment performed in *E. coli* DH5α also showed no significant difference in resistance between wild-type strains and strains overexpressing efflux system 5 (data not shown). Introduction of the efflux 5 structural genes in *B. cenocepacia* CEP511 and in *E. coli* did not increase resistance to any antimicrobial agents tested.

To verify that the efflux genes were expressed from the plasmid system, RT-PCR experiments were performed using primers within the efflux 5 RND transporter gene. In order to eliminate possible expression of the chromosomal copy, the plasmids containing the efflux 5 structural genes were electroporated into Δefflux 5. RNA isolated from both Δefflux 5 and Δefflux 5 containing the plasmid-borne structural genes was subjected to RT-PCR using efflux 5 transporter specific primers. Results of the RT-PCR experiment show that, at the RNA level, the efflux 5 genes are expressed from the plasmid vectors (Figure 3.7). Although the 584 bp band in the minus reverse transcriptase control indicated that some amplification is the result of DNA contamination, the band from the reaction with reverse transcriptase was noticeably brighter. Therefore, there is efflux system 5 mRNA present.

3.7 Overexpression of a putative regulator of efflux system 5

Another approach to increasing the levels of an efflux pump is to overexpress its corresponding activator. Located near the genes for *B. cenocepacia* efflux system 5 is a putative LysR-type regulatory gene. LysR-type proteins are usually transcription activators that require an inducing molecule for their function (Schell, 1993). However,



Figure 3.7 Expression of efflux 5 structural genes from pBBR1MCS and pBBR1MCS-Tp. In order to confirm expression of the efflux 5 structural genes from the overexpression vectors, RT-PCR experiments were performed. RNA was isolated from mid-logarithmic phase cells of (1) Δefflux 5, (2) Δefflux 5 plus efflux 5 structural genes on pBBR1MCS, and (3) Δefflux 5 plus efflux 5 structural genes on pBBR1MCS-Tp. First strand synthesis and 28 cycles of PCR amplification were performed using gene specific primers within the efflux 5 RND transporter (+) and within *recA* (positive control). As a control, amplification was performed using cDNA synthesized without reverse transcriptase (-).

overexpression of *P. aeruginosa mexT*, encoding a LysR-type regulator, from a plasmid is sufficient to induce expression of the *mexEF-oprN* efflux operon and increase antibiotic resistance (Kohler *et al.*, 1997; Kohler *et al.*, 1999). As such, it was hoped that overexpression of the putative regulator of *B. cenocepacia* efflux system 5 would have a similar effect.

The putative LysR-type activator was PCR amplified without its promoter and cloned into the pBBR1MCS vector by means of *Pst*I and *Xba*I sites engineered into the oligonucleotide primers. The resulting construct was electroporated into CEP511 wild-type and Δefflux 5 strains and the MICs of various antibiotics were determined (Table 3.3). Overexpression of the activator did not increase resistance to any of the antibiotics tested. The observed increase in chloramphenicol resistance is due to the presence of a chloramphenicol resistance marker on pBBR1MCS. The two fold increase in resistance to fusidic acid shown by Δefflux 5 is not significant. However, expression of the LysR-type activator from pBBR1MCS has not been verified.

3.8 Expression of *B. cenocepacia* efflux pumps in response to chloramphenicol and salicylate

Given that none of the putative efflux systems were expressed in CEP511, we wanted to find conditions that may turn on efflux pump expression in *B. cenocepacia*. Identifying inducers of efflux pump expression would provide clues to the possible function of the efflux system. Also, being able to induce expression of an efflux system would allow us to examine the phenotype of efflux pump deletion mutants. Both salicylate and chloramphenicol have been identified as inducers of the *ceoAB-opcM*

Table 3.3 The effect of overexpression of the putative LysR-type regulator of efflux system 5 on antibiotic resistance. The putative regulatory gene was cloned into pBBR1MCS and expressed in wild-type CEP511 and Δefflux 5. The data below are the results of one experiment. Minimum inhibitory concentrations (MICs) of chloramphenicol (CM), erythromycin (ER), fusidic acid (FU), norfloxacin (NR), polymyxin B (PB), sulfamethoxaxole (SX), tetracycline (TC), and trimethoprim (TP) were determined.

	MIC (μg/mL)						
	CM	**ER**	**FU**	**PB**	**SX**	**TC**	**TP**
CEP511	15.6	125	125	>2000	125	62.5	15.6
+ pBBR1MCS	250	125	125	>2000	125	62.5	15.6
+ pBBR1MCS + regulator	250	125	125	>2000	125	62.5	15.6
Δ efflux 5	15.6	125	250	>2000	125	62.5	15.6
+ pBBR1MCS	250	125	125	>2000	125	62.5	15.6
+ pBBR1MCS + regulator	250	125	125	>2000	125	62.5	15.6

efflux system in *B. cenocepacia* PC121 (Nair *et al.*, 2004). To determine if salicylate and chloramphenicol were inducers of any of the six putative *B. cenocepacia* J2315 efflux systems, RT-PCR experiments were performed (Figure 3.8). Cells were grown to mid-logarithmic phase in LB medium with or without 1 mM salicylate or 5 μg/mL chloramphenicol. The expression of the *recA* positive control was not changed by the presence of salicylate or chloramphenicol. Efflux systems 1, 3, 4, 5, and 6 were not expressed under any of the conditions examined. Although efflux system 6 is a close homologue of *ceoAB-opcM*, its expression was not induced by chloramphenicol or salicylate. This could be a strain dependent difference. *B. cenocepacia* PC121, the strain used by Nair *et al.* (2004), is a salicylate producing clinical isolate in which antibiotic resistance is known to increase in low iron environments. *B. cenocepacia* J2315 efflux system 2 was expressed in all three conditions but seemed to be expressed at a higher level in the presence of 1 mM salicylate. In order to verify that efflux system 2 is induced by salicylate, the experiment was repeated using a range of salicylate concentrations (Figure 3.9). This time, there was no noticeable difference in expression levels between the 0 and 1 mM salicylate conditions. The RT-PCR product in the 2.5 mM and 5 mM conditions were only marginally brighter than that in 0 mM salicylate. This indicates that efflux system 2 is not induced strongly by salicylate.

3.9 Expression of *B. cenocepacia* efflux pumps in response to growth phase

Expression of some RND efflux systems is linked to growth. Expression of *E. coli* multidrug transporter *acrAB* increases in slow-growing cells (Rand *et al.*, 2002). In *P. aeruginosa*, expression of the *mexAB-oprM* multidrug efflux system increases during



Figure 3.8 Effect of salicylate and chloramphenicol on efflux pump expression in *B. cenocepacia* J2315. RT-PCR amplification of the six putative RND transporter genes (+) was performed using RNA from J2315 cells grown under three conditions: cells grown in LB medium (LB), cells grown in LB with 1 mM salicylate (SAL), and cells grown in LB with 5 μg/mL chloramphenicol (CM). Amplification using *recA* primers was performed as a loading control. A negative control was performed, amplifying cDNA that was synthesized without reverse transcriptase (-). As an additional control, PCR amplification from J2315 chromosomal DNA (D) was carried out to ensure that all reaction reagents and conditions were functioning.



Figure 3.9 Effect of salicylate on expression of efflux system 2 in *B. cenocepacia* J2315. J2315 was grown in the presence of various amounts of salicylate. RT-PCR amplification for 28 cycles was performed using oligonucleotide primers specific to the RND transporter of efflux system 2 (+). Amplification using *recA* primers was performed as a loading control. A minus reverse transcriptase control (-) was performed to assess amplification from contaminating DNA.

late logarithmic and stationary phase growth (Evans and Poole, 1999; Maseda *et al.*, 2004). It seemed likely that expression of some putative *B. cenocepacia* RND efflux systems might respond to growth phase in the same manner. RT-PCR experiments were performed using RNA isolated from J2315 cells grown to late-logarithmic phase and stationary phase (Figure 3.10). MexAB-like efflux system 2 was expressed during late-logarithmic phase but not during stationary phase. The other five putative RND efflux systems were not expressed in late-logarithmic or stationary phase. Following amplification of cDNA synthesized from stationary phase RNA preparations, there was considerable DNA contamination due to difficulties isolating pure RNA from these cells. A similar experiment was performed in *B. cenocepacia* CEP511 (Figure 3.11). In this strain, efflux system 2, which was not amplified from mid-logarithmic phase cells (Figure 3.6), was expressed in late-logarithmic and stationary phase cells. However, efflux systems 1, 3, 4, 5, and 6 were not expressed under any conditions tested.



Figure 3.10 Expression of *B. cenocepacia* J2315 efflux systems during late-logarithmic and stationary phase growth. RT-PCR amplification of the six putative RND efflux pumps was performed using 0.75 μg total RNA from (A) cells grown to late-logarithmic phase (OD_{600} = 1.2) or (B) cells grown to stationary phase (growth overnight). PCR amplification (28 cycles) was performed using primers specific to the six putative RND transporter genes (+). Amplification of *recA* was done as a loading control. A minus reverse transcriptase control (-) was used to determine amplification of contaminating DNA. To control for PCR reagents and conditions, amplification from J2315 chromosomal DNA was performed (D).



Figure 3.11 Expression of *B. cenocepacia* CEP511 efflux systems during late-logarithmic and stationary phase growth. RT-PCR amplification of the six putative RND efflux pumps was performed using 0.75 μg total RNA from (A) cells grown to late-logarithmic phase (OD_{600} = 1.2) or (B) cells grown to stationary phase (growth overnight). PCR amplification (28 cycles) was performed using primers specific to the six putative RND transporter genes (+). Amplification of *recA* was done as a loading control. A minus reverse transcriptase control (-) was used to determine amplification of contaminating DNA. To control for PCR reagents and conditions, amplification from CEP511 chromosomal DNA was performed (D).

Chapter 4: Discussion

4. DISCUSSION

Antibiotic resistance in the *B. cepacia* complex poses a considerable barrier to the treatment of opportunistic infections. In many cases, triple antibiotic combinations may be required for eradication of the *B. cepacia* complex from CF patients (Aaron *et al.*, 2000; Burns and Saiman, 1999). We hypothesize that this extensive resistance is largely due to uncharacterized multidrug efflux pumps that can bind antibiotics and toxic compounds and export them from the cell. Widespread antibiotic resistance is also a considerable challenge in performing mutational analysis of the *B. cepacia* complex. As such, the goal of this research project was two-fold: to determine the contribution of multidrug efflux pumps to antibiotic resistance in the *B. cepacia* complex, and to develop a Flp/FRT system by which markerless mutations can be created.

4.1 Identification and characterization of multidrug efflux systems in the *B. cepacia* complex

Multidrug efflux pumps have emerged as a major problem in the treatment of pathogenic bacteria. A great deal of research has focused on the role of such systems in *E. coli* and *P. aeruginosa*. However, knowledge of multidrug efflux pumps in the *B. cepacia* complex is limited. Currently, only three systems have been identified in members of the *B. cepacia* complex. An RND efflux system, *ceoAB-opcM*, contributes to chloramphenicol, ciprofloxacin, and trimethoprim resistance in *B. cenocepacia* (Burns *et al.*, 1996). BcrA, an MFS pump from *B. cenocepacia*, increases resistance to tetracycline and nalidixic acid in *E. coli*, suggesting it may play a similar role in the *B. cepacia* complex (Wigfield *et al.*, 2002). The third efflux system is a MATE family transporter that confers resistance to polymyxin B in *B. vietnamiensis* (Fehlner-Gardiner

and Valvano, 2002). However, these efflux systems do not account for the full extent of antibiotic resistance in the *B. cepacia* complex. The recent completion of the *B. cenocepacia* J2315 genome sequence (http://www.sanger.ac.uk/Projects/B_cenocepacia/) suggested a genomics approach to identifying additional RND-type systems in the *B. cepacia* complex. By searching the genome sequence of *B. cenocepacia* J2315 with DNA sequences from known efflux pumps in related bacteria, we have identified six putative resistance nodulation cell division (RND) efflux pumps (Figure 3.1). Five of these pumps had considerable homology to multidrug transporters of *P. aeruginosa* and therefore are possible contributors to the high intrinsic resistance of *B. cenocepacia*. The remaining RND-type system is homologous to a heavy metal cation transporter. It is not unusual for an organism to possess multiple efflux systems. The genome of *E. coli* contains at least 37 established and putative drug transporters, including seven of the RND family (Nishino and Yamaguchi, 2001b). Likewise, the *P. aeruginosa* genome contains 12 potential RND-type efflux systems, only six of which have been characterized (Stover *et al.*, 2000).

In terms of genetic organization, the *B. cenocepacia* efflux clusters typically consist of an inner membrane transporter, a membrane fusion subunit, and an outer membrane protein channel. The only exception is efflux system 3, which is an isolated RND transporter. In general, their genetic arrangement is similar to *P. aeruginosa* efflux operons in which the membrane fusion and RND components are always encoded together. Genes encoding regulators and outer membrane proteins are often, but not always present (Schweizer, 2003). Some *P. aeruginosa* efflux operons contain additional genes, such as an extra RND transporter or a membrane protein required for drug efflux

(Aendekerk *et al.*, 2002; Schweizer, 2003). This was not observed for the six putative RND systems in *B. cenocepacia*. Efflux system 3, the independent transporter gene, may be similar to *E. coli* transporter AcrD. The gene encoding AcrD is not found with corresponding membrane fusion and outer membrane proteins. However, AcrD is a functional efflux pump that exports aminoglycosides, bile salts, and novobiocin. It was recently discovered that AcrD works in conjunction with non-cognate membrane fusion protein AcrA and outer membrane protein TolC (Elkins and Nikaido, 2002; Rosenberg *et al.*, 2000). Therefore, *B. cenocepacia* efflux system 3 may utilize the membrane fusion protein and outer membrane protein from another RND system.

Although organisms may contain multiple RND systems, not all contribute to intrinsic resistance. For example, the constitutively expressed *E.coli* AcrAB-TolC efflux pump predominates in terms of resistance to commonly used antimicrobial agents (Nikaido, 1996). Similarly, of the six characterized *P. aeruginosa* RND-type systems, only MexAB-OprM (Li *et al.*, 1995; Poole *et al.*, 1993a; Poole *et al.*, 1993b), MexXY (Aires *et al.*, 1999), and MexGHI (Aendekerk *et al.*, 2002) are involved in intrinsic resistance under normal laboratory conditions. MexCD-OprJ (Poole *et al.*, 1996a; Srikumar *et al.*, 1997), MexEF-OprN (Kohler *et al.*, 1997), and MexJK (Chuanchuen *et al.*, 2002) are not expressed to a significant extent in wild-type cells.

In order to determine which of the putative RND systems were expressed in *B. cenocepacia*, RT-PCR analysis was performed using primers specific to the transporter components. As observed in *E. coli* and *P. aeruginosa*, few of the *B. cenocepacia* efflux systems are expressed under normal laboratory conditions in mid-logarithmic phase cells. In J2315, the source of the efflux sequences, only efflux system 2 was expressed.

Generally, the constitutively expressed efflux pumps, such as AcrAB of *E. coli* and MexAB-OprM of *P. aeruginosa*, are the most important in terms of intrinsic antibiotic resistance. Interestingly, the closest homologue of efflux system 2 was the MexAB-OprM RND system. This evidence strongly suggests that efflux system 2 may be of great importance to the intrinsic resistance of wild-type *B. cenocepacia*. Although efflux system 2 was expressed in *B. cenocepacia* J2315 during mid-logarithmic phase growth, it was not expressed in another *B. cenocepacia strain*, CEP511. This is an intriguing result as there are differences in the antibiotic susceptibilities of these two strains. J2135 is more resistant than CEP511 to ceftazidime, tobramycin, tetracycline, and trimethoprim (Nzula *et al.*, 2002). Our studies indicate that J2315 is also more resistant than CEP511 to chloramphenicol. Perhaps the difference in resistance to these antibiotics can be explained by the action of efflux system 2. Further experiments will be necessary to determine if these antibiotics are in fact efflux 2 substrates.

It was somewhat surprising that efflux system 6 was not expressed in either *B. cenocepacia* J2315 or CEP511. According to RT-PCR results, the *ceoAB-opcM* efflux system is constitutively expressed in two *B. cenocepacia* clinical isolates, K61-3 and PC121 (Nair *et al.*, 2004). Since efflux system 6 is 93% identical to the CeoB transporter at the protein level, we expected that efflux system 6 would be expressed in J2315 and CEP511, which are also *B. cenocepacia* clinical isolates (Mahenthiralingam *et al.*, 2000b). Nair *et al.* report that CEP511 does not contain the membrane fusion and outer membrane protein components of the *ceoAB-opcM* operon (Nair *et al.*, 2004), which could account for the lack of expression in this strain. However, their study relied on PCR amplification of the *ceo* components, using only a single pair of primers for each

gene. In this case, a difference of only a few nucleotides between strains could completely abolish PCR amplification. Southern hybridization may have provided more meaningful results. Another possible explanation for the lack of efflux 6 expression could lie in the natural function of the *ceoAB-opcM* efflux system. Based on the observation that CeoAB-OpcM is able to extrude salicylate, an important siderophore and signal molecule in plant pathogenesis, Nair *et al.* suggest that salicylate may be the true natural substrate for the pump (Nair *et al.*, 2004). If this is true, it could be that only salicylate secreting strains of the *B. cepacia* complex would express the *ceoAB-opcM* (or efflux system 6). In support of this theory, K61-3 and PC121 constitutively express the *ceoAB-opcM* efflux operon and secrete salicylate (Nair *et al.*, 2004). On the other hand, CEP511 does not secrete salicylate (Nair *et al.*, 2004) and, in our study, was shown not to express the CeoB-like efflux system 6. However, some strains are able to secrete salicylate even though some components of the *ceoAB-opcM* system could not be amplified from their genomes (Nair *et al.*, 2004).

Although five of the efflux systems were not expressed, they may still be clinically important. Multidrug resistant bacteria are often selected for *in vivo* during antimicrobial therapy. Many of these resistant bacteria overexpress multidrug efflux pumps. *P. aeruginosa nalB* mutants, overexpressing MexAB-OprM, have been found among resistant clinical isolates (Bert and Lambert-Zechovsky, 1996; Li *et al.*, 1994a; Li *et al.*, 1994b; Ziha-Zarifi *et al.*, 1999). Likewise, the MexCD-OprJ and MexEF-OprN efflux systems are expressed in clinical *nfxB* (Jakics *et al.*, 1992; Jalal and Wretlind, 1998) and *nfxC* (Beinlich *et al.*, 2001) mutants respectively. Increased expression of efflux systems in clinical multidrug resistant strains have also been reported in many

other Gram-negative organisms (Li and Nikaido, 2004). Therefore, it is possible that multidrug resistant *B. cepacia* complex strains overexpressing one or more of the RND systems could be selected for during antimicrobial therapy of CF patients.

Alternatively, the efflux systems may each play a unique role in the cell. In this case, the pumps may only be expressed in response to certain inducing molecules or environmental conditions. For example, expression of some RND efflux systems is linked to growth phase. Expression of *E. coli* multidrug transporter *acrAB* is inversely related to growth rate (Rand *et al.*, 2002). Similarly, in *P. aeruginosa*, expression of the *mexAB-oprM* multidrug efflux system increases during late-logarithmic and stationary phase growth (Evans and Poole, 1999; Maseda *et al.*, 2004; Sanchez *et al.*, 2002b). Several links connect expression of efflux pumps with quorum sensing. The *P. aeruginosa mexGHI-opmD* operon is induced by acyl homoserine lactones (Whiteley *et al.*, 1999) and mutation of *mexI* or *opmD* reduces the presence of quorum sensing regulated phenotypes (Aendekerk *et al.*, 2002). Loss of the LuxR-type quorum sensing regulator VsqR decreases expression of the MexEF-OprN efflux system (Juhas *et al.*, 2004).

We conducted RT-PCR experiments on *B. cenocepacia* strains J2315 and CEP511 to determine the extent of efflux pump expression during late-logarithmic and stationary phase growth. Efflux system 2 was expressed in late-logarithmic phase cells of J2315 (Figure 3.10). In CEP511, efflux system 2 was expressed strongly during late-logarithmic phase and to a lesser extent during stationary phase (Figure 3.11). Unfortunately, no comparisons can be made with the RT-PCR results from mid-logarithmic phase cells (Figures 3.5 and 3.6) since the growth medium and amount of

RNA template were not kept constant. Quantitative RT-PCR should be performed on RNA isolated from all three growth phases, in the same medium, in order to validate growth phase regulation of efflux system 2. The remaining five RND systems were not expressed in late-logarithmic or stationary phase cultures of J2315 or CEP511 (Figures 3.10 and 3.11).

Growth in the presence of salicylate is another factor that induces antibiotic resistance in many organisms, including *Klebsiella pneumoniae* (Domenico *et al.*, 1990), *Mycobacterium tubersulosis* (Schaller *et al.*, 2002), and *Staphylococcus aureus* (Gustafson *et al.*, 1999; Price *et al.*, 1999). In *E. coli*, salicylate interacts directly with MarR to alleviate repression of the *marRAB* operon and thus increase antibiotic resistance (Alekshun *et al.*, 2001; Cohen *et al.*, 1993). In *P. aeruginosa*, the presence of salicylate causes increased resistance to imipenem by decreasing the production of OprD, the outer membrane channel responsible for imipenem influx (Masuda *et al.*, 1995; Ochs *et al.*, 1999; Sumita and Fukasawa, 1993). Salicylate also increases antimicrobial resistance in *B. multivorans* 249-2 (Burns and Clark, 1992) and induces expression of the CeoAB-OpcM efflux system in *B. cenocepacia* PC121 (Nair *et al.*, 2004). Since salicylate is often associated with increased antimicrobial resistance, we tested its effect on the expression of the *B. cenocepacia* J2315 RND systems. RT-PCR with primers specific to each RND transporter was performed on RNA isolated from cells grown in the presence of 1 mM salicylate. Growth in the presence of salicylate did not affect the expression of most *B. cenocepacia* J2315 efflux pumps. Efflux systems 1, 3, 4, 5, and 6 were not expressed, regardless of the presence of salicylate. Initially, it appeared that expression of efflux system 2 was increased slightly by 1 mM salicylate (Figure 3.8). However,

when a larger range of salicylate concentrations was tested, 1 mM salicylate did not increase efflux 2 expression (Figure 3.9). There appeared to be a marginal increase in the expression of efflux 2 in the presence of 2.5 mM and 5.0 mM salicylate, however, the results are not conclusive. Quantitative real-time PCR must be performed to accurately detect a difference in expression of efflux system 2.

Chloramphenicol is also an inducer of the *ceoAB-opcM* efflux system in *B. cenocepacia* PC121 (Nair *et al.*, 2004). Accordingly, we performed RT-PCR to determine if the presence of 5 μg/mL chloramphenicol increased expression of the *B. cenocepacia* J2315 RND systems (Figure 3.8). Results were similar to those observed in the presence of salicylate. No increase in expression was detected for any of the putative efflux systems in the presence of chloramphenicol. There are many other possibilities for efflux pump inducers that have yet to be tested. For example, expression of *P. aeruginosa mexCD-oprJ* increases in response to some of its substrates, tetraphenylphosphonium, ethidium bromide, rhodamine 6G, acriflavine, and disinfectants (Morita *et al.*, 2003). Similarly, MexXY is induced by pump substrates tetracycline, erythromycin, and gentamicin (Masuda *et al.*, 2000b). Once the substrates of the *B. cenocepacia* efflux pumps are determined, we will have a better idea of potential inducers to test with RT-PCR.

Several strategies were employed in an attempt to determine the substrates of each *B. cenocepacia* RND efflux system. Much of the work focused on efflux system 5. First, a markerless deletion was created within the efflux 5 RND transporter gene of *B. cenocepacia* CEP511 (Δefflux 5). The deletion was verified by PCR amplification with primers flanking the deletion (Figure 3.4). However, MIC assays revealed no difference

in the susceptibility of wild-type CEP511 and Δefflux 5 to 14 antibiotics (Table 3.1). The lack of phenotype in Δefflux 5 was later explained when RT-PCR results revealed that efflux system 5 is not expressed in CEP511 under normal growth conditions (Figure 3.6). In fact, all of the efflux systems, except efflux system 2, were not expressed in *B. cenocepacia* J2315 or CEP511 (Figures 3.5 and 3.6). Therefore, the creation of deletions in wild-type cells is not an effective approach for the study of these systems. This problem has been encountered by other laboratories. Inactivation of *E. coli* efflux pumps AcrEF, YhiUV, and MdtABCD does not affect drug susceptibility (Baranova and Nikaido, 2002; Nishino and Yamaguchi, 2001b; Sulavik *et al.*, 2001). Likewise, mutation of *mexE*, the membrane fusion component of the MexEF-OprN efflux system, does not change the resistance profile of wild-type *P. aeruginosa* (Kohler *et al.*, 1997). Given that efflux system 2 is expressed at some point in *B. cenocepacia* J2315 and CEP511, a deletion of this transporter may produce a change in the antibiotic resistance profile.

In some cases, the introduction of extraneous copies of an efflux system on plasmids or cosmids confers antimicrobial resistance. For example, introduction of the *ceoAB-opcM* operon into *B. cenocepacia* CEP511 increases resistance to ciprofloxacin, chloramphenicol, and trimethoprim (Nair *et al.*, 2004). Similarly, expression of the *mexXY* genes from a plasmid increased the resistance of wild-type *P. aeruginosa* to MexXY substrates (Aires *et al.*, 1999). Since most of the *B. cenocepacia* efflux systems are not constitutively expressed, the only way to determine potential substrates would be to overexpress the pumps and look for a corresponding increase in resistance to certain antibiotics. Therefore, we cloned the efflux 5 structural genes (membrane fusion protein,

RND transporter, and outer membrane protein) along with the putative promoter region into the broad host range vectors pBBR1MCS and pBBR1MCS-Tp. When the resulting constructs were introduced into *B. cenocepacia* CEP511, there was no change in antimicrobial susceptibility (Table 3.2). There are many possible explanations as to why the overexpression of efflux 5 structural genes did not confer antibiotic resistance. RT-PCR analysis confirmed that the structural genes were expressed from the plasmid vectors at the RNA level (Figure 3.7). However, we did not determine whether this increase in mRNA correlated to an increase in protein levels. This could be tested by running SDS-PAGE gels and looking for the presence of three additional protein bands corresponding to the sizes of the efflux 5 gene products. Alternatively, the addition of a marker, such as a His-tag, into one of the open reading frames could be used to verify expression at the protein level. It is also possible that mutations could have been introduced during PCR amplification and cloning of the efflux genes. Although a proofreading polymerase was used during PCR to avoid such a problem, the clone should be sequenced to verify that no muations were introduced. Another explanation is that the overexpression did function as expected, but none of the seven antibiotics tested were substrates for efflux system 5.

Efflux systems can also be overexpressed indirectly by mutating the corresponding regulator. Deletion of *P. aeruginosa* TetR family repressors *mexR* and *mexZ* increase expression of *mexAB-oprM* and *mexXY* respectively (Poole *et al.*, 1996b; Westbrock-Wadman *et al.*, 1999). Overexpression of the *mexAB-oprM*, *mexCD-oprJ*, and *mexJK* efflux systems often results from mutations in the respective regulators (Chuanchuen *et al.*, 2002; Poole *et al.*, 1996a; Saito *et al.*, 1999; Srikumar *et al.*, 2000;

Ziha-Zarifi *et al.*, 1999). Therefore, we attempted to overexpress efflux system 5 by increasing levels of the putative LysR-type activator. The regulatory gene was cloned into pBBR1MCS and introduced into *B. cenocepacia* CEP511 and Δefflux 5. Unfortunately, no change in the resistance profile was observed (Table 3.3). It is possible that none of the tested antibiotics are substrates of efflux system 5. To address another potential problem, RT-PCR analysis should be performed to determine if the regulator is expressed and if the presence of the plasmid-encoded regulator produces the expected increase in efflux 5 expression. DNA sequencing verified that no mutations were introduced during PCR amplification. However, in many wild-type *P. aeruginosa* strains, the gene encoding LysR-type regulator MexT contains inactivating mutations preventing expression of *mexEF-oprN* (Maseda *et al.*, 2000). Since *mexEF-oprN* is the closest *P. aeruginosa* homologue of efflux system 5, it is possible that similar inactivating mutations are found in the efflux 5 regulator. Another possibility is that the efflux 5 regulator, like many LysR-type proteins, may require an effector molecule in order to activate gene expression (Schell, 1993). However, overexpression of *P. aeruginosa mexT*, encoding a LysR-type regulator, from a plasmid is sufficient to induce expression of the *mexEF-oprN* efflux operon and increase antibiotic resistance (Kohler *et al.*, 1997; Kohler *et al.*, 1999).

Similar attempts could be made to interfere with the regulators of the other RND efflux systems. Efflux system 1 and 2 are both located near genes encoding putative AraC-type proteins (Figure 3.1). AraC family members are usually transcriptional activators (Gallegos *et al.*, 1993). MarA, SoxS, and Rob are all AraC-type global activators known to positively regulate the *E. coli* AcrAB RND efflux system (Ma *et al.*,

1996; Martin *et al.*, 1996). Another AraC regulator, MtrA, activates expression of the *Neisseria gonorrhoeae mtrCDE* efflux system (Rouquette *et al.*, 1999). Therefore, efflux systems 1 and 2 may also be positively regulated by the AraC homologs. Like efflux system 5, efflux system 6 is also found near a putative LysR-type activator. If efflux systems 1, 2, 5, and 6 are indeed positively regulated, then overexpression of the activator genes could lead to increased resistance to substrate antibiotics. On the other hand, the gene immediately upstream and in the opposite orientation of efflux system 2 encodes a putative TetR-family repressor. The predicted amino acid sequence of this regulator was similar to *E. coli* AcrR, which negatively regulates expression of *acrAB* (Ma *et al.*, 1996). In this case, deletion of the putative efflux 2 repressor may cause an increase in expression of efflux system 2 and, therefore, an increase in antibiotic resistance.

Although the original goal of characterizing the putative *B. cenocepacia* RND systems in terms of efflux substrates was not achieved, valuable information was obtained that will facilitate future work in this area. Six putative RND systems were identified in the *B. cenocepacia* J2315 genome, five of which showed homology to *P. aeruginosa* multidrug transporters. One of these systems, efflux 2, was similar to MexAB-OprM and was shown to be expressed in strains J2315 and CEP511 at various stages of growth. Therefore, this efflux pump is likely important to the intrinsic resistance of *B. cenocepacia*. Accordingly, efflux system 2 should be the focus of future research. Quantitative real-time PCR will verify induction of efflux 2 expression in response to growth phase and salicylate. The substrate range of efflux 2 could be determined by deletion analysis or overexpression of this system by deleting its putative repressor. Additionally, deletion analysis of the RND efflux systems was shown to be

ineffective, as most of the pumps were not constitutively expressed. Overexpression of the efflux systems, either directly or indirectly, should prove more useful in determining the contribution of RND systems to the resistance of *B. cenocepacia*. In this way, substrates of each pump can be identified and their relative ability to induce efflux pump expression can be assessed.

4.2 Development of a Flp/FRT system for use in the *B. cepacia* complex

Flp/FRT systems have proven useful in the creation of markerless mutations of *P. aeruginosa pabC* (Hoang *et al.*, 1998), *mexAB-oprM* (Schweizer, 1998), and *mexXY* (Morita *et al.*, 2001a). In fact Flp/FRT systems have been used to create *P. aeruginosa* strains that lack all four major *mex* operons (Morita *et al.*, 2001b). During this study, we developed the first Flp/FRT system for use in the *B. cepacia* complex. In this system, a gene of interest is cloned into pBAD33, chosen because it does not replicate in members of the *B. cepacia* complex. A deletion is made using appropriate restriction endonucleases and the FRT cassette, containing a trimethoprim resistance marker flanked by two Flp recombinase target sites, replaces the deleted region. The construct is electroporated into a *B. cepacia* complex strain, where it can undergo homologous recombination with the host chromosome. A double recombination event occurs, identified by trimethoprim resistance (from the FRT cassette) and chloramphenicol sensitivity (from loss of pBAD33), replacing the wild-type copy with the marked deletion. At this point, the Flp-producing plasmid pFLP2Cm is introduced by electroporation. Induction of the flippase gene is obtained by incubation at 37°C, resulting in site-specific recombination between the two Flp recombinase targets to excise

the FRT cassette. Chloramphenicol resistant (containing pFLP2Cm), trimethoprim sensitive (having lost the FRT cassette) colonies are identified. These cells are then subjected to growth on LB + 5% sucrose, selecting for loss of the *sacB* containing pFLP2Cm. Deletion of the gene of interest and presence or absence of the FRT cassette can be verified by PCR amplification. This system was used successfully for the creation of a CEP511 deletion mutant of the efflux system 5 RND transporter.

While applying the Flp/FRT system, it became apparent that some members of the *B. cepacia* complex are more amenable to mutational analysis. Although the genome sequence of *B. cenocepacia* J2315 is available, this strain proved too difficult for use in laboratory studies as a result of high intrinsic resistance and a negligible transformation rate (Mahenthiralingam *et al.*, 2000b). The strain CEP511 proved much more useful. CEP511 differs from J2315 in that it lacks the *cblA* gene encoding the cable pilus (Mahenthiralingam *et al.*, 2000b). *B. cenocepacia* is divided into two lineages based on the sequence of *recA*. CEP511 belongs to the genomovar IIIB lineage while J2315 belongs to the genomovar IIIA lineage (Mahenthiralingam *et al.*, 2000a). Like J2315, CEP511 is a CF epidemic strain and contains the *B. cepacia* epidemic strain marker (BCESM). Its high transformation rate and susceptibility to trimethoprim and chloramphenicol are tremendous advantages in creating mutations with the Flp/FRT system (Mahenthiralingam *et al.*, 2000b). For the purpose of this study, the gene sequences of CEP511 and J2315 were similar enough that the same oligonoucleotide primers were effective for amplification of RND transporters and *recA* from both strains.

Although CEP511 is a useful lab strain, the applicability of the Flp/FRT system could be extended. By creating additional FRT cassettes and Flp-producing plasmids

with different antibiotic markers, the Flp/FRT system could also be used in other members of the *B. cenocepacia* complex. For example, selection for chloramphenicol resistance was problematic in *B. cenocepacia* K56-2 and *B. vietnamiensis* DB01 due to inducible resistance.

The Flp/FRT system developed in this study should prove extremely useful for mutational analysis of many genes in the *B. cepacia* complex. A system for creating markerless mutations is necessary in order to create multiple deletions in one strain; otherwise the limited number of useful antibiotic resistance markers precludes such studies in the *B. cepacia* complex. This Flp/FRT system is ideally suited for analysis of multidrug resistance since the use of antibiotic resistance markers could mask a drug sensitivity phenotype.

Chapter 5: Literature Cited

Aaron, S.D., Ferris, W., Henry, D.A., Speert, D.P., and Macdonald, N.E. (2000) Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with *Burkholderia cepacia*. *Am J Respir Crit Care Med* **161**: 1206-1212.

Adewoye, L., Sutherland, A., Srikumar, R., and Poole, K. (2002) The *mexR* repressor of the *mexAB-oprM* multidrug efflux operon in *Pseudomonas aeruginosa*: characterization of mutations compromising activity. *J Bacteriol* **184**: 4308-4312.

Aendekerk, S., Ghysels, B., Cornelis, P., and Baysse, C. (2002) Characterization of a new efflux pump, MexGHI-OpmD, from *Pseudomonas aeruginosa* that confers resistance to vanadium. *Microbiology* **148**: 2371-2381.

Aires, J.R., Kohler, T., Nikaido, H., and Plesiat, P. (1999) Involvement of an active efflux system in the natural resistance of *Pseudomonas aeruginosa* to aminoglycosides. *Antimicrob Agents Chemother* **43**: 2624-2628.

Aires, J.R., Pechere, J.C., Van Delden, C., and Kohler, T. (2002) Amino acid residues essential for function of the MexF efflux pump protein of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* **46**: 2169-2173.

Aires, J.R., and Nikaido, H. (2005) Aminoglycosides are captured from both periplasm and cytoplasm by the AcrD multidrug efflux transporter of *Escherichia coli*. *J Bacteriol* **187**: 1923-1929.

Akama, H., Kanemaki, M., Yoshimura, M., Tsukihara, T., Kashiwagi, T., Yoneyama, H., Narita, S., Nakagawa, A., and Nakae, T. (2004a) Crystal structure of the drug discharge outer membrane protein, OprM, of *Pseudomonas aeruginosa*: dual modes of membrane anchoring and occluded cavity end. *J Biol Chem* **279**: 52816-52819.

Akama, H., Matsuura, T., Kashiwagi, S., Yoneyama, H., Narita, S., Tsukihara, T., Nakagawa, A., and Nakae, T. (2004b) Crystal structure of the membrane fusion protein, MexA, of the multidrug transporter in *Pseudomonas aeruginosa*. *J Biol Chem* **279**: 25939-25942.

Alekshun, M.N., and Levy, S.B. (1997) Regulation of chromosomally mediated multiple antibiotic resistance: the *mar* regulon. *Antimicrob Agents Chemother* **41**: 2067-2075.

Alekshun, M.N., Levy, S.B., Mealy, T.R., Seaton, B.A., and Head, J.F. (2001) The crystal structure of MarR, a regulator of multiple antibiotic resistance, at 2.3 A resolution. *Nat Struct Biol* **8**: 710-714.

Altschul, S.F., Gish, W., Miller, W., Myers, E.W., and Lipman, D.J. (1990) Basic local alignment search tool. *J Mol Biol* **215**: 403-410.

Andersen, C., Koronakis, E., Bokma, E., Eswaran, J., Humphreys, D., Hughes, C., and Koronakis, V. (2002) Transition to the open state of the TolC periplasmic tunnel entrance. *Proc Natl Acad Sci U S A* **99**: 11103-11108.

Ariza, R.R., Cohen, S.P., Bachhawat, N., Levy, S.B., and Demple, B. (1994) Repressor mutations in the *marRAB* operon that activate oxidative stress genes and multiple antibiotic resistance in *Escherichia coli*. *J Bacteriol* **176**: 143-148.

Ariza, R.R., Li, Z., Ringstad, N., and Demple, B. (1995) Activation of multiple antibiotic resistance and binding of stress-inducible promoters by *Escherichia coli* Rob protein. *J Bacteriol* **177**: 1655-1661.

Arkin, I.T., Russ, W.P., Lebendiker, M., and Schuldiner, S. (1996) Determining the secondary structure and orientation of EmrE, a multi-drug transporter, indicates a transmembrane four-helix bundle. *Biochemistry* **35**: 7233-7238.

Aronoff, S.C. (1988) Outer membrane permeability in *Pseudomonas cepacia*: diminished porin content in a beta-lactam-resistant mutant and in resistant cystic fibrosis isolates. *Antimicrob Agents Chemother* **32**: 1636-1639.

Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A., and Struhl, K., (eds) (1999) *Short protocols in molecular biology.* New York: John Wiley and Sons, Inc.

Avila-Sakar, A.J., Misaghi, S., Wilson-Kubalek, E.M., Downing, K.H., Zgurskaya, H., Nikaido, H., and Nogales, E. (2001) Lipid-layer crystallization and preliminary three-dimensional structural analysis of AcrA, the periplasmic component of a bacterial multidrug efflux pump. *J Struct Biol* **136**: 81-88.

Balakrishnan, L., Hughes, C., and Koronakis, V. (2001) Substrate-triggered recruitment of the TolC channel-tunnel during type I export of hemolysin by *Escherichia coli*. *J Mol Biol* **313**: 501-510.

Baranova, N., and Nikaido, H. (2002) The *baeSR* two-component regulatory system activates transcription of the *yegMNOB* (*mdtABCD*) transporter gene cluster in *Escherichia coli* and increases its resistance to novobiocin and deoxycholate. *J Bacteriol* **184**: 4168-4176.

Barbosa, T.M., and Levy, S.B. (2000) Differential expression of over 60 chromosomal genes in *Escherichia coli* by constitutive expression of MarA. *J Bacteriol* **182**: 3467-3474.

Beckman, W., and Lessie, T.G. (1979) Response of *Pseudomonas cepacia* to beta-lactam antibiotics: utilization of penicillin G as the carbon source. *J Bacteriol* **140**: 1126-1128.

Beckman, W., and Lessie, T.G. (1980) Multiple forms of *Pseudomonas cepacia* B-lactamase, abstr. K-128. In *The Annual Meeting of the American Society for Microbiology*: American Society for Microbiology.

Beinlich, K.L., Chuanchuen, R., and Schweizer, H.P. (2001) Contribution of multidrug efflux pumps to multiple antibiotic resistance in veterinary clinical isolates of *Pseudomonas aeruginosa*. *FEMS Microbiol Lett* **198**: 129-134.

Benz, R., Maier, E., and Gentschev, I. (1993) TolC of *Escherichia coli* functions as an outer membrane channel. *Zentralbl Bakteriol* **278**: 187-196.

Bert, F., and Lambert-Zechovsky, N. (1996) Comparative distribution of resistance patterns and serotypes in *Pseudomonas aeruginosa* isolates from intensive care units and other wards. *J Antimicrob Chemother* **37**: 809-813.

Bevivino, A., Tabacchioni, S., Chiarini, L., Carusi, M.V., Del Gallo, M., and Visca, P. (1994) Phenotypic comparison between rhizosphere and clinical isolates of *Burkholderia cepacia*. *Microbiology* **140 (Pt 5)**: 1069-1077.

Bevivino, A., Sarrocco, S., Dalmastri, C., Tabacchioni, S., Cantale, C., and Chiarini, L. (1998) Characterization of a free-living maize-rhizosphere population of *Burkholderia cepacia*: effect of seed treatment on disease suppression and growth promotion of maize. *FEMS Microbiol Ecol* **27**: 225-237.

Borges-Walmsley, M.I., Beauchamp, J., Kelly, S.M., Jumel, K., Candlish, D., Harding, S.E., Price, N.C., and Walmsley, A.R. (2003) Identification of oligomerization and drug-binding domains of the membrane fusion protein EmrA. *J Biol Chem* **278**: 12903-12912.

Bowers, J.H., and Parke, J.L. (1993) Epidemiology of *Pythium* damping-off and *Aphanomyces* root rot of peas after seed treatment with bacterial agents for biological control. *Phytopathol* **83**: 1466-1473.

Brown, M.H., Paulsen, I.T., and Skurray, R.A. (1999) The multidrug efflux protein NorM is a prototype of a new family of transporters. *Mol Microbiol* **31**: 394-395.

Budavari, S., O'Neil, M.J., Smith, A., Heckelman, P.E., and Kinneary, J.F., (eds) (1996) *The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals.* Whitehouse Station: Merck Research Laboratories.

Buhler, T., Ballestero, S., Desai, M., and Brown, M.R. (1998) Generation of a reproducible nutrient-depleted biofilm of *Escherichia coli* and *Burkholderia cepacia*. *J Appl Microbiol* **85**: 457-462.

Bull, C., and Ballou, D.P. (1981) Purification and properties of protocatechuate 3,4-dioxygenase from *Pseudomonas putida*. A new iron to subunit stoichiometry. *J Biol Chem* **256**: 12673-12680.

Burian, J., Guller, L., Macor, M., and Kay, W.W. (1997) Small cryptic plasmids of multiplasmid, clinical *Escherichia coli*. *Plasmid* **37**: 2-14.

Burkhead, K.D., Schisler, D.A., and Slininger, P.J. (1994) Pyrrolnitrin production by biological control agent *Pseudomonas cepacia* B37w in culture and in colonized wounds of potatoes. *Appl Environ Microbiol* **60**: 2031-2039.

Burkholder, W.H. (1950) Sour skin: a bacterial rot of onion bulbs. *Phytopathol* **40**: 115-117.

Burns, J.L., Hedin, L.A., and Lien, D.M. (1989a) Chloramphenicol resistance in *Pseudomonas cepacia* because of decreased permeability. *Antimicrob Agents Chemother* **33**: 136-141.

Burns, J.L., Lien, D.M., and Hedin, L.A. (1989b) Isolation and characterization of dihydrofolate reductase from trimethoprim-susceptible and trimethoprim-resistant *Pseudomonas cepacia*. *Antimicrob Agents Chemother* **33**: 1247-1251.

Burns, J.L., and Clark, D.K. (1992) Salicylate-inducible antibiotic resistance in *Pseudomonas cepacia* associated with absence of a pore-forming outer membrane protein. *Antimicrob Agents Chemother* **36**: 2280-2285.

Burns, J.L., Wadsworth, C.D., Barry, J.J., and Goodall, C.P. (1996) Nucleotide sequence analysis of a gene from *Burkholderia (Pseudomonas) cepacia* encoding an outer membrane lipoprotein involved in multiple antibiotic resistance. *Antimicrob Agents Chemother* **40**: 307-313.

Burns, J.L., and Saiman, L. (1999) *Burkholderia cepacia* infections in cystic fibrosis. *Pediatr Infect Dis J* **18**: 155-156.

Cao, L., Srikumar, R., and Poole, K. (2002) Identification and characterization of *nalC* multidrug-resistant isolates of *Pseudomonas aeruginosa* [abstract no. C1-430]. In *The 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy* San Diego (CA): American Society for Microbiology, pp. 29.

Cartwright, D.K., Chilton, W.S., and Benson, D.M. (1995) Pyrrolnitrin and phenazine production by *Pseudomonas cepacia* strain 5.5B, a biocontrol agent of *Rhizoctonia solani*. *Appl Microbiol Biotechnol* **43**: 211-216.

Chiesa, C., Labrozzi, P.H., and Aronoff, S.C. (1986) Decreased baseline beta-lactamase production and inducibility associated with increased piperacillin susceptibility of

Pseudomonas cepacia isolated from children with cystic fibrosis. *Pediatr Res* **20**: 1174-1177.

Chuanchuen, R., Narasaki, C.T., and Schweizer, H.P. (2002) The MexJK efflux pump of *Pseudomonas aeruginosa* requires OprM for antibiotic efflux but not for efflux of triclosan. *J Bacteriol* **184**: 5036-5044.

Cieri, M.V., Mayer-Hamblett, N., Griffith, A., and Burns, J.L. (2002) Correlation between an *in vitro* invasion assay and a murine model of *Burkholderia cepacia* lung infection. *Infect Immun* **70**: 1081-1086.

Clark, A.D., and Parke, J.L. (1996) Biological control of *Pythium* damping-off of super-sweet corn by seed-applied *Burkholderia cepacia* AMMDR1. *Phytopathol* **86**.

Coenye, T., LiPuma, J.J., Henry, D., Hoste, B., Vandemeulebroecke, K., Gillis, M., Speert, D.P., and Vandamme, P. (2001a) *Burkholderia cepacia* genomovar VI, a new member of the *Burkholderia cepacia* complex isolated from cystic fibrosis patients. *Int J Syst Evol Microbiol* **51**: 271-279.

Coenye, T., Mahenthiralingam, E., Henry, D., LiPuma, J.J., Laevens, S., Gillis, M., Speert, D.P., and Vandamme, P. (2001b) *Burkholderia ambifaria* sp. nov., a novel member of the *Burkholderia cepacia* complex including biocontrol and cystic fibrosis-related isolates. *Int J Syst Evol Microbiol* **51**: 1481-1490.

Cohen, S.P., Levy, S.B., Foulds, J., and Rosner, J.L. (1993) Salicylate induction of antibiotic resistance in *Escherichia coli*: activation of the *mar* operon and a mar-independent pathway. *J Bacteriol* **175**: 7856-7862.

Conway, B.A., Venu, V., and Speert, D.P. (2002) Biofilm formation and acyl homoserine lactone production in the *Burkholderia cepacia* complex. *J Bacteriol* **184**: 5678-5685.

Cox, M.M. (1983) The FLP protein of the yeast 2-microns plasmid: expression of a eukaryotic genetic recombination system in *Escherichia coli*. *Proc Natl Acad Sci U S A* **80**: 4223-4227.

Darling, P., Chan, M., Cox, A.D., and Sokol, P.A. (1998) Siderophore production by cystic fibrosis isolates of *Burkholderia cepacia*. *Infect Immun* **66**: 874-877.

De Kievit, T.R., Parkins, M.D., Gillis, R.J., Srikumar, R., Ceri, H., Poole, K., Iglewski, B.H., and Storey, D.G. (2001) Multidrug efflux pumps: expression patterns and contribution to antibiotic resistance in *Pseudomonas aeruginosa* biofilms. *Antimicrob Agents Chemother* **45**: 1761-1770.

Dean, C.R., Visalli, M.A., Projan, S.J., Sum, P.E., and Bradford, P.A. (2003) Efflux-mediated resistance to tigecycline (GAR-936) in *Pseudomonas aeruginosa* PAO1. *Antimicrob Agents Chemother* **47**: 972-978.

Dennis, J.J., and Zylstra, G.J. (1998) Improved antibiotic-resistance cassettes through restriction site elimination using Pfu DNA polymerase PCR. *Biotechniques* **25**: 772-774, 776.

Desai, M., Buhler, T., Weller, P.H., and Brown, M.R. (1998) Increasing resistance of planktonic and biofilm cultures of *Burkholderia cepacia* to ciprofloxacin and ceftazidime during exponential growth. *J Antimicrob Chemother* **42**: 153-160.

DeShazer, D., and Woods, D.E. (1996) Broad-host-range cloning and cassette vectors based on the R388 trimethoprim resistance gene. *Biotechniques* **20**: 762-764.

Dinh, T., Paulsen, I.T., and Saier, M.H., Jr. (1994) A family of extracytoplasmic proteins that allow transport of large molecules across the outer membranes of gram-negative bacteria. *J Bacteriol* **176**: 3825-3831.

Domenico, P., Hopkins, T., and Cunha, B.A. (1990) The effect of sodium salicylate on antibiotic susceptibility and synergy in *Klebsiella pneumoniae*. *J Antimicrob Chemother* **26**: 343-351.

Drenkard, E. (2003) Antimicrobial resistance of *Pseudomonas aeruginosa* biofilms. *Microbes Infect* **5**: 1213-1219.

Eckert, B., and Beck, C.F. (1989) Overproduction of transposon Tn10-encoded tetracycline resistance protein results in cell death and loss of membrane potential. *J Bacteriol* **171**: 3557-3559.

Eda, S., Maseda, H., and Nakae, T. (2003) An elegant means of self-protection in gram-negative bacteria by recognizing and extruding xenobiotics from the periplasmic space. *J Biol Chem* **278**: 2085-2088.

Egan, S.M. (2002) Growing repertoire of AraC/XylS activators. *J Bacteriol* **184**: 5529-5532.

Elkins, C.A., and Nikaido, H. (2002) Substrate specificity of the RND-type multidrug efflux pumps AcrB and AcrD of *Escherichia coli* is determined predominantly by two large periplasmic loops. *J Bacteriol* **184**: 6490-6498.

Elkins, C.A., and Nikaido, H. (2003) Chimeric analysis of AcrA function reveals the importance of its C-terminal domain in its interaction with the AcrB multidrug efflux pump. *J Bacteriol* **185**: 5349-5356.

Engledow, A.S., Medrano, E.G., Mahenthiralingam, E., LiPuma, J.J., and Gonzalez, C.F. (2004) Involvement of a plasmid-encoded type IV secretion system in the plant tissue watersoaking phenotype of *Burkholderia cenocepacia*. *J Bacteriol* **186**: 6015-6024.

Enne, V.I., Livermore, D.M., Stephens, P., and Hall, L.M. (2001) Persistence of sulphonamide resistance in *Escherichia coli* in the UK despite national prescribing restriction. *Lancet* **357**: 1325-1328.

Enne, V.I., Bennett, P.M., Livermore, D.M., and Hall, L.M. (2004) Enhancement of host fitness by the *sul2*-coding plasmid p9123 in the absence of selective pressure. *J Antimicrob Chemother* **53**: 958-963.

Evans, K., and Poole, K. (1999) The MexA-MexB-OprM multidrug efflux system of *Pseudomonas aeruginosa* is growth-phase regulated. *FEMS Microbiol Lett* **173**: 35-39.

Evans, K., Adewoye, L., and Poole, K. (2001) MexR repressor of the *mexAB-oprM* multidrug efflux operon of *Pseudomonas aeruginosa*: identification of MexR binding sites in the *mexA-mexR* intergenic region. *J Bacteriol* **183**: 807-812.

Fath, M.J., and Kolter, R. (1993) ABC transporters: bacterial exporters. *Microbiol Rev* **57**: 995-1017.

Fehlner-Gardiner, C.C., and Valvano, M.A. (2002) Cloning and characterization of the *Burkholderia vietnamiensis norM* gene encoding a multi-drug efflux protein. *FEMS Microbiol Lett* **215**: 279-283.

Fournier, B., Aras, R., and Hooper, D.C. (2000) Expression of the multidrug resistance transporter NorA from *Staphylococcus aureus* is modified by a two-component regulatory system. *J Bacteriol* **182**: 664-671.

Fralick, J.A. (1996) Evidence that TolC is required for functioning of the Mar/AcrAB efflux pump of *Escherichia coli*. *J Bacteriol* **178**: 5803-5805.

Franke, S., Grass, G., Rensing, C., and Nies, D.H. (2003) Molecular analysis of the copper-transporting efflux system CusCFBA of *Escherichia coli*. *J Bacteriol* **185**: 3804-3812.

Gallegos, M.T., Michan, C., and Ramos, J.L. (1993) The XylS/AraC family of regulators. *Nucleic Acids Res* **21**: 807-810.

Gerken, H., and Misra, R. (2004) Genetic evidence for functional interactions between TolC and AcrA proteins of a major antibiotic efflux pump of *Escherichia coli*. *Mol Microbiol* **54**: 620-631.

Germida, J.J., and Walley, F.L. (1996) Plant growth-promoting rhizobacteria alter rooting patterns and arbuscular mycorrhizal fungi colonization of field-grown spring wheat. *Biol Fertil Soils* **23**: 113-120.

Gillis, M., Van Van, T., Bardin, R., Goor, M., Hebbar, P., Willems, A., Segers, P., Kersters, K., Heulin, T., and Fernandez, M. (1995) Polyphasic taxonomy in the genus *Burkholderia* leading to an emended description of the genus and proposition of *Burkholderia vietnamiensis* sp. nov. for N_2-fixing isolates from rice in Vietnam. *Int J Syst Bacteriol* **45**: 274 - 289.

Godoy, P., Ramos-Gonzalez, M.I., and Ramos, J.L. (2001) Involvement of the TonB system in tolerance to solvents and drugs in *Pseudomonas putida* DOT-T1E. *J Bacteriol* **183**: 5285-5292.

Goldberg, M., Pribyl, T., Juhnke, S., and Nies, D.H. (1999) Energetics and topology of CzcA, a cation/proton antiporter of the resistance-nodulation-cell division protein family. *J Biol Chem* **274**: 26065-26070.

Gonzalez, C.F., Pettit, E.A., Valadez, V.A., and Provin, E.M. (1997) Mobilization, cloning, and sequence determination of a plasmid-encoded polygalacturonase from a phytopathogenic *Burkholderia* (*Pseudomonas*) *cepacia. Mol Plant Microbe Interact* **10**: 840-851.

Govan, J.R., Brown, P.H., Maddison, J., Doherty, C.J., Nelson, J.W., Dodd, M., Greening, A.P., and Webb, A.K. (1993) Evidence for transmission of *Pseudomonas cepacia* by social contact in cystic fibrosis. *Lancet* **342**: 15-19.

Govan, J.R., and Deretic, V. (1996) Microbial pathogenesis in cystic fibrosis: mucoid *Pseudomonas aeruginosa* and *Burkholderia cepacia. Microbiol Rev* **60**: 539-574.

Grinius, L., Dreguniene, G., Goldberg, E.B., Liao, C.H., and Projan, S.J. (1992) A *staphylococcal* multidrug resistance gene product is a member of a new protein family. *Plasmid* **27**: 119-129.

Grkovic, S., Brown, M.H., and Skurray, R.A. (2002) Regulation of bacterial drug export systems. *Microbiol Mol Biol Rev* **66**: 671-701, table of contents.

Guan, L., and Nakae, T. (2001) Identification of essential charged residues in transmembrane segments of the multidrug transporter MexB of *Pseudomonas aeruginosa. J Bacteriol* **183**: 1734-1739.

Gustafson, J.E., Candelaria, P.V., Fisher, S.A., Goodridge, J.P., Lichocik, T.M., McWilliams, T.M., Price, C.T., O'Brien, F.G., and Grubb, W.B. (1999) Growth in the presence of salicylate increases fluoroquinolone resistance in *Staphylococcus aureus. Antimicrob Agents Chemother* **43**: 990-992.

Guzman, L.M., Belin, D., Carson, M.J., and Beckwith, J. (1995) Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. *J Bacteriol* **177**: 4121-4130.

Hagman, K.E., Pan, W., Spratt, B.G., Balthazar, J.T., Judd, R.C., and Shafer, W.M. (1995) Resistance of *Neisseria gonorrhoeae* to antimicrobial hydrophobic agents is modulated by the *mtrRCDE* efflux system. *Microbiology* **141 (Pt 3)**: 611-622.

Hagman, K.E., Lucas, C.E., Balthazar, J.T., Snyder, L., Nilles, M., Judd, R.C., and Shafer, W.M. (1997) The MtrD protein of *Neisseria gonorrhoeae* is a member of the resistance/nodulation/division protein family constituting part of an efflux system. *Microbiology* **143 (Pt 7)**: 2117-2125.

Hancock, R.E. (1984) Alterations in outer membrane permeability. *Annu Rev Microbiol* **38**: 237-264.

Hartman, A.B., Essiet, II, Isenbarger, D.W., and Lindler, L.E. (2003) Epidemiology of tetracycline resistance determinants in *Shigella* spp. and enteroinvasive *Escherichia coli*: characterization and dissemination of *tet*(A)-1. *J Clin Microbiol* **41**: 1023-1032.

Hebbar, K.P., Atkinson, D., Tucker, W., and Dart, P.J. (1992a) Suppression of *Fusarium moniliforme* by maize root-associated *Pseudomonas cepacia*. *Soil Biol Biochem* **24**: 1009-1020.

Hebbar, K.P., Davey, A.G., Merrin, J., McLoughlin, T.J., and Dart, P.J. (1992b) *Pseudomonas cepacia*, a potential suppressor of maize soil-borne diseases - seed inoculation and maize root colonization. *Soil Biol Biochem* **24**: 999-1007.

Helling, R.B., Kinney, T., and Adams, J. (1981) The maintenance of plasmid-containing organisms in populations of *Escherichia coli*. *J Gen Microbiol* **123**: 129-141.

Helling, R.B., Janes, B.K., Kimball, H., Tran, T., Bundesmann, M., Check, P., Phelan, D., and Miller, C. (2002) Toxic waste disposal in *Escherichia coli*. *J Bacteriol* **184**: 3699-3703.

Hentzer, M., Wu, H., Andersen, J.B., Riedel, K., Rasmussen, T.B., Bagge, N., Kumar, N., Schembri, M.A., Song, Z., Kristoffersen, P., Manefield, M., Costerton, J.W., Molin, S., Eberl, L., Steinberg, P., Kjelleberg, S., Hoiby, N., and Givskov, M. (2003) Attenuation of *Pseudomonas aeruginosa* virulence by quorum sensing inhibitors. *Embo J* **22**: 3803-3815.

Heungens, K., and Parke, J.L. (2000) Zoospore homing and infection events: effects of the biocontrol bacterium *Burkholderia cepacia* AMMDR1 on two oomycete pathogens of pea (*Pisum sativum* L.). *Appl Environ Microbiol* **66**: 5192-5200.

Hickman, R.K., McMurry, L.M., and Levy, S.B. (1990) Overproduction and purification of the Tn10-specified inner membrane tetracycline resistance protein Tet using fusions to beta-galactosidase. *Mol Microbiol* **4**: 1241-1251.

Hidalgo, E., Ding, H., and Demple, B. (1997) Redox signal transduction via iron-sulfur clusters in the SoxR transcription activator. *Trends Biochem Sci* **22**: 207-210.

Higgins, M.K., Bokma, E., Koronakis, E., Hughes, C., and Koronakis, V. (2004) Structure of the periplasmic component of a bacterial drug efflux pump. *Proc Natl Acad Sci U S A* **101**: 9994-9999.

Hirakawa, H., Nishino, K., Hirata, T., and Yamaguchi, A. (2003) Comprehensive studies of drug resistance mediated by overexpression of response regulators of two-component signal transduction systems in *Escherichia coli*. *J Bacteriol* **185**: 1851-1856.

Hoang, T.T., Karkhoff-Schweizer, R.R., Kutchma, A.J., and Schweizer, H.P. (1998) A broad-host-range Flp-FRT recombination system for site-specific excision of chromosomally-located DNA sequences: application for isolation of unmarked *Pseudomonas aeruginosa* mutants. *Gene* **212**: 77-86.

Hochhut, B., Lotfi, Y., Mazel, D., Faruque, S.M., Woodgate, R., and Waldor, M.K. (2001) Molecular analysis of antibiotic resistance gene clusters in *Vibrio cholerae* O139 and O1 SXT constins. *Antimicrob Agents Chemother* **45**: 2991-3000.

Holmes, A., Govan, J., and Goldstein, R. (1998) Agricultural use of *Burkholderia (Pseudomonas) cepacia*: a threat to human health? *Emerg Infect Dis* **4**: 221-227.

Homma, Y., Sato, Z., Hirayama, F., Konno, K., Shirahama, H., and Suzui, T. (1989) Production of antibiotics by *Pseudomonas cepacia* as an agent for biological control of soilborne plant pathogens. *Soil Biol Biochem* **21**: 723-728.

Huber, B., Riedel, K., Hentzer, M., Heydorn, A., Gotschlich, A., Givskov, M., Molin, S., and Eberl, L. (2001) The *cep* quorum-sensing system of *Burkholderia cepacia* H111 controls biofilm formation and swarming motility. *Microbiology* **147**: 2517-2528.

Huber, B., Riedel, K., Kothe, M., Givskov, M., Molin, S., and Eberl, L. (2002) Genetic analysis of functions involved in the late stages of biofilm development in *Burkholderia cepacia* H111. *Mol Microbiol* **46**: 411-426.

Husain, F., Humbard, M., and Misra, R. (2004) Interaction between the TolC and AcrA proteins of a multidrug efflux system of *Escherichia coli*. *J Bacteriol* **186**: 8533-8536.

Ip, H., Stratton, K., Zgurskaya, H., and Liu, J. (2003) pH-induced conformational changes of AcrA, the membrane fusion protein of *Escherichia coli* multidrug efflux system. *J Biol Chem* **278**: 50474-50482.

Islam, S., Jalal, S., and Wretlind, B. (2004) Expression of the MexXY efflux pump in amikacin-resistant isolates of *Pseudomonas aeruginosa. Clin Microbiol Infect* **10**: 877-883.

Isles, A., Maclusky, I., Corey, M., Gold, R., Prober, C., Fleming, P., and Levison, H. (1984) *Pseudomonas cepacia* infection in cystic fibrosis: an emerging problem. *J Pediatr* **104**: 206-210.

Isshiki, Y., Kawahara, K., and Zahringer, U. (1998) Isolation and characterisation of disodium (4-amino-4-deoxy-B-L-arabinopyranosyl)-(1--> 8)-(D-glycero-alpha-D-talo-oct-2-ulopyranosylonate)-(2-->4)-(methyl 3-deoxy-D-manno-oct-2-ulopyranosid) onate from the lipopolysaccharide of *Burkholderia cepacia. Carbohydr Res* **313**: 21-27.

Jair, K.W., Yu, X., Skarstad, K., Thony, B., Fujita, N., Ishihama, A., and Wolf, R.E., Jr. (1996) Transcriptional activation of promoters of the superoxide and multiple antibiotic resistance regulons by Rob, a binding protein of the *Escherichia coli* origin of chromosomal replication. *J Bacteriol* **178**: 2507-2513.

Jakics, E.B., Iyobe, S., Hirai, K., Fukuda, H., and Hashimoto, H. (1992) Occurrence of the *nfxB* type mutation in clinical isolates of *Pseudomonas aeruginosa. Antimicrob Agents Chemother* **36**: 2562-2565.

Jalal, S., and Wretlind, B. (1998) Mechanisms of quinolone resistance in clinical strains of *Pseudomonas aeruginosa. Microb Drug Resist* **4**: 257-261.

Jellen-Ritter, A.S., and Kern, W.V. (2001) Enhanced expression of the multidrug efflux pumps AcrAB and AcrEF associated with insertion element transposition in *Escherichia coli* mutants selected with a fluoroquinolone. *Antimicrob Agents Chemother* **45**: 1467-1472.

Jiao, Y., Yoshihara, T., Ishikuri, S., Uchino, H., and Ichihara, A. (1996) Structural identification of cepaciamide A, a novel fungitoxic compound from *Pseudomonas cepacia D-202. Tetrahedron Lett* **37**: 1039-1042.

Johnsen, P.J., Simonsen, G.S., Olsvik, O., Midtvedt, T., and Sundsfjord, A. (2002) Stability, persistence, and evolution of plasmid-encoded VanA glycopeptide resistance in enterococci in the absence of antibiotic selection *in vitro* and in gnotobiotic mice. *Microb Drug Resist* **8**: 161-170.

Johnson, J.M., and Church, G.M. (1999) Alignment and structure prediction of divergent protein families: periplasmic and outer membrane proteins of bacterial efflux pumps. *J Mol Biol* **287**: 695-715.

Johnston, R.B., Jr. (2001) Clinical aspects of chronic granulomatous disease. *Curr Opin Hematol* **8**: 17-22.

Juhas, M., Wiehlmann, L., Huber, B., Jordan, D., Lauber, J., Salunkhe, P., Limpert, A.S., von Gotz, F., Steinmetz, I., Eberl, L., and Tummler, B. (2004) Global regulation of quorum sensing and virulence by VqsR in *Pseudomonas aeruginosa*. *Microbiology* **150**: 831-841.

Kang, Y., Carlson, R., Tharpe, W., and Schell, M.A. (1998) Characterization of genes involved in biosynthesis of a novel antibiotic from *Burkholderia cepacia* BC11 and their role in biological control of *Rhizoctonia solani*. *Appl Environ Microbiol* **64**: 3939-3947.

Keig, P.M., Ingham, E., Vandamme, P.A., and Kerr, K.G. (2002) Differential invasion of respiratory epithelial cells by members of the *Burkholderia cepacia* complex. *Clin Microbiol Infect* **8**: 47-49.

King, E.B., and Parke, J.L. (1993) Biocontrol of *Aphanomyces* root rot and *Pythium* damping-off by *Pseudomonas cepacia* AMMD on four pea cultivars. *Plant Dis* **77**: 1185-1188.

Klein, J.R., Henrich, B., and Plapp, R. (1991) Molecular analysis and nucleotide sequence of the *envCD* operon of *Escherichia coli*. *Mol Gen Genet* **230**: 230-240.

Kobayashi, K., Tsukagoshi, N., and Aono, R. (2001a) Suppression of hypersensitivity of *Escherichia coli acrB* mutant to organic solvents by integrational activation of the *acrEF* operon with the IS1 or IS2 element. *J Bacteriol* **183**: 2646-2653.

Kobayashi, N., Nishino, K., and Yamaguchi, A. (2001b) Novel macrolide-specific ABC-type efflux transporter in *Escherichia coli*. *J Bacteriol* **183**: 5639-5644.

Kohler, T., Michea-Hamzehpour, M., Henze, U., Gotoh, N., Curty, L.K., and Pechere, J.C. (1997) Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of *Pseudomonas aeruginosa*. *Mol Microbiol* **23**: 345-354.

Kohler, T., Epp, S.F., Curty, L.K., and Pechere, J.C. (1999) Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of *Pseudomonas aeruginosa*. *J Bacteriol* **181**: 6300-6305.

Kohler, T., van Delden, C., Curty, L.K., Hamzehpour, M.M., and Pechere, J.C. (2001) Overexpression of the MexEF-OprN multidrug efflux system affects cell-to-cell signaling in *Pseudomonas aeruginosa*. *J Bacteriol* **183**: 5213-5222.

Kolayli, F., Karadenizli, A., Savli, H., Ergen, K., Hatirnaz, O., Balikci, E., Budak, F., and Vahaboglu, H. (2004) Effect of carbapenems on the transcriptional expression of the *oprD*, *oprM* and *oprN* genes in *Pseudomonas aeruginosa*. *J Med Microbiol* **53**: 915-920.

Kopytek, S.J., Dyer, J.C., Knapp, G.S., and Hu, J.C. (2000) Resistance to methotrexate due to AcrAB-dependent export from *Escherichia coli*. *Antimicrob Agents Chemother* **44**: 3210-3212.

Koronakis, V., Sharff, A., Koronakis, E., Luisi, B., and Hughes, C. (2000) Crystal structure of the bacterial membrane protein TolC central to multidrug efflux and protein export. *Nature* **405**: 914-919.

Kovach, M.E., Phillips, R.W., Elzer, P.H., Roop, R.M., 2nd, and Peterson, K.M. (1994) pBBR1MCS: a broad-host-range cloning vector. *Biotechniques* **16**: 800-802.

Krumme, M.L., Timmis, K.N., and Dwyer, D.F. (1993) Degradation of trichloroethylene by *Pseudomonas cepacia* G4 and the constitutive mutant strain G4 5223 PR1 in aquifer microcosms. *Appl Environ Microbiol* **59**: 2746-2749.

Ledson, M.J., Gallagher, M.J., and Walshaw, M.J. (1998) Chronic *Burkholderia cepacia* bronchiectasis in a non-cystic fibrosis individual. *Thorax* **53**: 430-432.

Lee, C.H., Kim, S., Hyun, B., Suh, J.W., Yon, C., Kim, C., and Lim, Y. (1994) Cepacidine A, a novel antifungal antibiotic produced by *Pseudomonas cepacia*. I. Taxonomy, production, isolation and biological activity. *J Antibiot (Tokyo)* **47**: 1402-1405.

Lenski, R.E., Simpson, S.C., and Nguyen, T.T. (1994) Genetic analysis of a plasmid-encoded, host genotype-specific enhancement of bacterial fitness. *J Bacteriol* **176**: 3140-3147.

Levine, M.M., Nataro, J.P., Karch, H., Baldini, M.M., Kaper, J.B., Black, R.E., Clements, M.L., and O'Brien, A.D. (1985) The diarrheal response of humans to some classic serotypes of enteropathogenic *Escherichia coli* is dependent on a plasmid encoding an enteroadhesiveness factor. *J Infect Dis* **152**: 550-559.

Lewenza, S., Visser, M.B., and Sokol, P.A. (2002) Interspecies communication between *Burkholderia cepacia* and *Pseudomonas aeruginosa*. *Can J Microbiol* **48**: 707-716.

Li, X.Z., Livermore, D.M., and Nikaido, H. (1994a) Role of efflux pump(s) in intrinsic resistance of *Pseudomonas aeruginosa*: resistance to tetracycline, chloramphenicol, and norfloxacin. *Antimicrob Agents Chemother* **38**: 1732-1741.

Li, X.Z., Ma, D., Livermore, D.M., and Nikaido, H. (1994b) Role of efflux pump(s) in intrinsic resistance of *Pseudomonas aeruginosa*: active efflux as a contributing factor to beta-lactam resistance. *Antimicrob Agents Chemother* **38**: 1742-1752.

Li, X.Z., Nikaido, H., and Poole, K. (1995) Role of *mexA-mexB-oprM* in antibiotic efflux in *Pseudomonas aeruginosa. Antimicrob Agents Chemother* **39**: 1948-1953.

Li, X.Z., and Poole, K. (1999) Organic solvent-tolerant mutants of *Pseudomonas aeruginosa* display multiple antibiotic resistance. *Can J Microbiol* **45**: 18-22.

Li, X.Z., Barre, N., and Poole, K. (2000) Influence of the MexA-MexB-OprM multidrug efflux system on expression of the MexC-MexD-OprJ and MexE-MexF-OprN multidrug efflux systems in *Pseudomonas aeruginosa. J Antimicrob Chemother* **46**: 885-893.

Li, X.Z., Zhang, L., and Poole, K. (2002) SmeC, an outer membrane multidrug efflux protein of *Stenotrophomonas maltophilia. Antimicrob Agents Chemother* **46**: 333-343.

Li, X.Z., and Nikaido, H. (2004) Efflux-mediated drug resistance in bacteria. *Drugs* **64**: 159-204.

Li, Y., Mima, T., Komori, Y., Morita, Y., Kuroda, T., Mizushima, T., and Tsuchiya, T. (2003) A new member of the tripartite multidrug efflux pumps, MexVW-OprM, in *Pseudomonas aeruginosa. J Antimicrob Chemother* **52**: 572-575.

Lim, D., Poole, K., and Strynadka, N.C. (2002) Crystal structure of the MexR repressor of the *mexRAB-oprM* multidrug efflux operon of *Pseudomonas aeruginosa. J Biol Chem* **277**: 29253-29259.

Linares, J.F., Lopez, J.A., Camafeita, E., Albar, J.P., Rojo, F., and Martinez, J.L. (2005) Overexpression of the multidrug efflux pumps MexCD-OprJ and MexEF-OprN is associated with a reduction of type III secretion in *Pseudomonas aeruginosa. J Bacteriol* **187**: 1384-1391.

LiPuma, J.J., Dasen, S.E., Nielson, D.W., Stern, R.C., and Stull, T.L. (1990) Person-to-person transmission of *Pseudomonas cepacia* between patients with cystic fibrosis. *Lancet* **336**: 1094-1096.

Llanes, C., Hocquet, D., Vogne, C., Benali-Baitich, D., Neuwirth, C., and Plesiat, P. (2004) Clinical strains of *Pseudomonas aeruginosa* overproducing MexAB-OprM and MexXY efflux pumps simultaneously. *Antimicrob Agents Chemother* **48**: 1797-1802.

Lo, W., Nelson, Y.M., Lion, L.W., Shuler, M.L., and Ghiorse, W.C. (1996) Determination of iron colloid size distribution in the presence of suspended cells:

application to iron deposition onto a biofilm surface. *Water Research* **30**: 2413-2423.

Lomovskaya, O., and Lewis, K. (1992) *Emr*, an *Escherichia coli* locus for multidrug resistance. *Proc Natl Acad Sci U S A* **89**: 8938-8942.

Ma, D., Cook, D.N., Alberti, M., Pon, N.G., Nikaido, H., and Hearst, J.E. (1993) Molecular cloning and characterization of *acrA* and *acrE* genes of *Escherichia coli*. *J Bacteriol* **175**: 6299-6313.

Ma, D., Cook, D.N., Hearst, J.E., and Nikaido, H. (1994) Efflux pumps and drug resistance in gram-negative bacteria. *Trends Microbiol* **2**: 489-493.

Ma, D., Cook, D.N., Alberti, M., Pon, N.G., Nikaido, H., and Hearst, J.E. (1995) Genes *acrA* and *acrB* encode a stress-induced efflux system of *Escherichia coli*. *Mol Microbiol* **16**: 45-55.

Ma, D., Alberti, M., Lynch, C., Nikaido, H., and Hearst, J.E. (1996) The local repressor AcrR plays a modulating role in the regulation of *acrAB* genes of *Escherichia coli* by global stress signals. *Mol Microbiol* **19**: 101-112.

Magnet, S., Courvalin, P., and Lambert, T. (2001) Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in *Acinetobacter baumannii* strain BM4454. *Antimicrob Agents Chemother* **45**: 3375-3380.

Mahenthiralingam, E., Campbell, M.E., Henry, D.A., and Speert, D.P. (1996) Epidemiology of *Burkholderia cepacia* infection in patients with cystic fibrosis: analysis by randomly amplified polymorphic DNA fingerprinting. *J Clin Microbiol* **34**: 2914-2920.

Mahenthiralingam, E., Bischof, J., Byrne, S.K., Radomski, C., Davies, J.E., Av-Gay, Y., and Vandamme, P. (2000a) DNA-based diagnostic approaches for identification of *Burkholderia cepacia* complex, *Burkholderia vietnamiensis*, *Burkholderia multivorans*, *Burkholderia stabilis*, and *Burkholderia cepacia* genomovars I and III. *J Clin Microbiol* **38**: 3165-3173.

Mahenthiralingam, E., Coenye, T., Chung, J.W., Speert, D.P., Govan, J.R., Taylor, P., and Vandamme, P. (2000b) Diagnostically and experimentally useful panel of strains from the *Burkholderia cepacia* complex. *J Clin Microbiol* **38**: 910-913.

Mahenthiralingam, E., Urban, T.A., and Goldberg, J.B. (2005) The multifarious, multireplicon *Burkholderia cepacia* complex. *Nat Rev Microbiol* **3**: 144-156.

Mao, W., Lumsden, R.D., Lewis, J.A., and Hebbar, P.K. (1998) Seed treatment using preinfiltration and biocontrol agents to reduce damping-off of corn caused by species of *Pythium* and *Fusarium*. *Plant Dis* **82**: 294-299.

Mao, W., Warren, M.S., Black, D.S., Satou, T., Murata, T., Nishino, T., Gotoh, N., and Lomovskaya, O. (2002) On the mechanism of substrate specificity by resistance nodulation division (RND)-type multidrug resistance pumps: the large periplasmic loops of MexD from *Pseudomonas aeruginosa* are involved in substrate recognition. *Mol Microbiol* **46**: 889-901.

Martin, R.G., and Rosner, J.L. (1995) Binding of purified multiple antibiotic-resistance repressor protein (MarR) to *mar* operator sequences. *Proc Natl Acad Sci U S A* **92**: 5456-5460.

Martin, R.G., Jair, K.W., Wolf, R.E., Jr., and Rosner, J.L. (1996) Autoactivation of the *marRAB* multiple antibiotic resistance operon by the MarA transcriptional activator in *Escherichia coli*. *J Bacteriol* **178**: 2216-2223.

Maseda, H., Saito, K., Nakajima, A., and Nakae, T. (2000) Variation of the *mexT* gene, a regulator of the MexEF-OprN efflux pump expression in wild-type strains of *Pseudomonas aeruginosa*. *FEMS Microbiol Lett* **192**: 107-112.

Maseda, H., Sawada, I., Saito, K., Uchiyama, H., Nakae, T., and Nomura, N. (2004) Enhancement of the *mexAB-oprM* efflux pump expression by a quorum-sensing autoinducer and its cancellation by a regulator, MexT, of the *mexEF-oprN* efflux pump operon in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* **48**: 1320-1328.

Masuda, N., Sakagawa, E., and Ohya, S. (1995) Outer membrane proteins responsible for multiple drug resistance in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* **39**: 645-649.

Masuda, N., Sakagawa, E., Ohya, S., Gotoh, N., Tsujimoto, H., and Nishino, T. (2000a) Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM efflux pumps in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* **44**: 3322-3327.

Masuda, N., Sakagawa, E., Ohya, S., Gotoh, N., Tsujimoto, H., and Nishino, T. (2000b) Contribution of the MexX-MexY-OprM efflux system to intrinsic resistance in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* **44**: 2242-2246.

Masuda, N., and Church, G.M. (2002) *Escherichia coli* gene expression responsive to levels of the response regulator EvgA. *J Bacteriol* **184**: 6225-6234.

Matsuo, Y., Eda, S., Gotoh, N., Yoshihara, E., and Nakae, T. (2004) MexZ-mediated regulation of *mexXY* multidrug efflux pump expression in *Pseudomonas aeruginosa* by binding on the *mexZ-mexX* intergenic DNA. *FEMS Microbiol Lett* **238**: 23-28.

McDermott, P.J., Gowland, P., and Gowland, P.C. (1993) Adaptation of *Escherichia coli* growth rates to the presence of pBR322. *Lett Appl Microbiol* **17**: 139-143.

McKevitt, A.I., and Woods, D.E. (1984) Characterization of *Pseudomonas cepacia* isolates from patients with cystic fibrosis. *J Clin Microbiol* **19**: 291-293.

McMurry, L.M., Oethinger, M., and Levy, S.B. (1998) Overexpression of *marA*, *soxS*, or *acrAB* produces resistance to triclosan in laboratory and clinical strains of *Escherichia coli*. *FEMS Microbiol Lett* **166**: 305-309.

Meyer, J.M., Van, V.T., Stintzi, A., Berge, O., and Winkelmann, G. (1995) Ornibactin production and transport properties in strains of *Burkholderia vietnamiensis* and *Burkholderia cepacia* (formerly *Pseudomonas cepacia*). *Biometals* **8**: 309-317.

Meyers, E., Bisacchi, G.S., Dean, L., Liu, W.C., Minassian, B., Slusarchyk, D.S., Sykes, R.B., Tanaka, S.K., and Trejo, W. (1987) Xylocandin: a new complex of antifungal peptides. I. Taxonomy, isolation and biological activity. *J Antibiot (Tokyo)* **40**: 1515-1519.

Middlemiss, J.K., and Poole, K. (2004) Differential impact of MexB mutations on substrate selectivity of the MexAB-OprM multidrug efflux pump of *Pseudomonas aeruginosa*. *J Bacteriol* **186**: 1258-1269.

Mine, T., Morita, Y., Kataoka, A., Mizushima, T., and Tsuchiya, T. (1999) Expression in *Escherichia coli* of a new multidrug efflux pump, MexXY, from *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* **43**: 415-417.

Mokhonov, V.V., Mokhonova, E.I., Akama, H., and Nakae, T. (2004) Role of the membrane fusion protein in the assembly of resistance-nodulation-cell division multidrug efflux pump in *Pseudomonas aeruginosa*. *Biochem Biophys Res Commun* **322**: 483-489.

Moon, S.S., Kang, P.M., Park, K.S., and Kim, C.H. (1996) Plant growth promoting and fungicidal 4-quinolones from *Pseudomonas cepacia*. *Phytochemistry* **42**: 365-368.

Moore, J.E., Crowe, M., Shaw, A., McCaughan, J., Redmond, A.O., and Elborn, J.S. (2001) Antibiotic resistance in *Burkholderia cepacia* at two regional cystic fibrosis centres in Northern Ireland: is there a need for synergy testing? *J Antimicrob Chemother* **48**: 319-321.

Moore, R.A., and Hancock, R.E. (1986) Involvement of outer membrane of *Pseudomonas cepacia* in aminoglycoside and polymyxin resistance. *Antimicrob Agents Chemother* **30**: 923-926.

Morita, Y., Kodama, K., Shiota, S., Mine, T., Kataoka, A., Mizushima, T., and Tsuchiya, T. (1998) NorM, a putative multidrug efflux protein, of *Vibrio parahaemolyticus*

and its homolog in *Escherichia coli*. *Antimicrob Agents Chemother* **42**: 1778-1782.

Morita, Y., Kimura, N., Mima, T., Mizushima, T., and Tsuchiya, T. (2001a) Roles of MexXY- and MexAB-multidrug efflux pumps in intrinsic multidrug resistance of *Pseudomonas aeruginosa* PAO1. *J Gen Appl Microbiol* **47**: 27-32.

Morita, Y., Komori, Y., Mima, T., Kuroda, T., Mizushima, T., and Tsuchiya, T. (2001b) Construction of a series of mutants lacking all of the four major *mex* operons for multidrug efflux pumps or possessing each one of the operons from *Pseudomonas aeruginosa* PAO1: MexCD-OprJ is an inducible pump. *FEMS Microbiol Lett* **202**: 139-143.

Morita, Y., Murata, T., Mima, T., Shiota, S., Kuroda, T., Mizushima, T., Gotoh, N., Nishino, T., and Tsuchiya, T. (2003) Induction of *mexCD-oprJ* operon for a multidrug efflux pump by disinfectants in wild-type *Pseudomonas aeruginosa* PAO1. *J Antimicrob Chemother* **51**: 991-994.

Murakami, S., Nakashima, R., Yamashita, E., and Yamaguchi, A. (2002) Crystal structure of bacterial multidrug efflux transporter AcrB. *Nature* **419**: 587-593.

Murakami, S., Tamura, N., Saito, A., Hirata, T., and Yamaguchi, A. (2004) Extramembrane central pore of multidrug exporter AcrB in *Escherichia coli* plays an important role in drug transport. *J Biol Chem* **279**: 3743-3748.

Nacamulli, C., Bevivino, A., Dalmastri, C., Tabacchioni, S., and Chiarini, L. (1997) Perturbation of maize rhizosphere microflora following seed bacterization with *Burkholderia cepacia* MC17. *FEMS Microbiol Ecol* **23**: 183-193.

Nagakubo, S., Nishino, K., Hirata, T., and Yamaguchi, A. (2002) The putative response regulator BaeR stimulates multidrug resistance of *Escherichia coli* via a novel multidrug exporter system, MdtABC. *J Bacteriol* **184**: 4161-4167.

Nair, B.M., Cheung, K.J., Jr., Griffith, A., and Burns, J.L. (2004) Salicylate induces an antibiotic efflux pump in *Burkholderia cepacia* complex genomovar III (*B. cenocepacia*). *J Clin Invest* **113**: 464-473.

Nair, B.M., Joachimiak, L.A., Chattopadhyay, S., Montano, I., and Burns, J.L. (2005) Conservation of a novel protein associated with an antibiotic efflux operon in *Burkholderia cenocepacia*. *FEMS Microbiol Lett* **245**: 337-344.

Nakajima, H., Kobayashi, K., Kobayashi, M., Asako, H., and Aono, R. (1995) Overexpression of the *robA* gene increases organic solvent tolerance and multiple antibiotic and heavy metal ion resistance in *Escherichia coli*. *Appl Environ Microbiol* **61**: 2302-2307.

Narita, S., Eda, S., Yoshihara, E., and Nakae, T. (2003) Linkage of the efflux-pump expression level with substrate extrusion rate in the MexAB-OprM efflux pump of *Pseudomonas aeruginosa*. *Biochem Biophys Res Commun* **308**: 922-926.

Nehme, D., Li, X.Z., Elliot, R., and Poole, K. (2004) Assembly of the MexAB-OprM multidrug efflux system of *Pseudomonas aeruginosa*: identification and characterization of mutations in *mexA* compromising MexA multimerization and interaction with MexB. *J Bacteriol* **186**: 2973-2983.

Nies, D.H., Nies, A., Chu, L., and Silver, S. (1989) Expression and nucleotide sequence of a plasmid-determined divalent cation efflux system from *Alcaligenes eutrophus*. *Proc Natl Acad Sci U S A* **86**: 7351-7355.

Nies, D.H. (1992) CzcR and CzcD, gene products affecting regulation of resistance to cobalt, zinc, and cadmium (*czc* system) in *Alcaligenes eutrophus*. *J Bacteriol* **174**: 8102-8110.

Nikaido, H. (1996) Multidrug efflux pumps of gram-negative bacteria. *J Bacteriol* **178**: 5853-5859.

Nishino, K., and Yamaguchi, A. (2001a) Overexpression of the response regulator *evgA* of the two-component signal transduction system modulates multidrug resistance conferred by multidrug resistance transporters. *J Bacteriol* **183**: 1455-1458.

Nishino, K., and Yamaguchi, A. (2001b) Analysis of a complete library of putative drug transporter genes in *Escherichia coli*. *J Bacteriol* **183**: 5803-5812.

Nishino, K., and Yamaguchi, A. (2002) EvgA of the two-component signal transduction system modulates production of the *yhiUV* multidrug transporter in *Escherichia coli*. *J Bacteriol* **184**: 2319-2323.

Nivens, D.E., Chambers, J.Q., Anderson, T.R., and White, D.C. (1993) Long-term, on-line monitoring of microbial biofilms using a quartz crystal microbalance. *Analytical Chemistry* **65**: 65-69.

Nzula, S., Vandamme, P., and Govan, J.R. (2002) Influence of taxonomic status on the *in vitro* antimicrobial susceptibility of the *Burkholderia cepacia* complex. *J Antimicrob Chemother* **50**: 265-269.

Ochs, M.M., McCusker, M.P., Bains, M., and Hancock, R.E. (1999) Negative regulation of the *Pseudomonas aeruginosa* outer membrane porin OprD selective for imipenem and basic amino acids. *Antimicrob Agents Chemother* **43**: 1085-1090.

Ojo, K.K., Kehrenberg, C., Odelola, H.A., and Schwarz, S. (2003) Structural analysis of the tetracycline resistance gene region of a small multiresistance plasmid from

uropathogenic *Escherichia coli* isolated in Nigeria. *J Antimicrob Chemother* **52**: 1043-1044.

Okamoto, K., Gotoh, N., and Nishino, T. (2002a) Alterations of susceptibility of *Pseudomonas aeruginosa* by overproduction of multidrug efflux systems, MexAB-OprM, MexCD-OprJ, and MexXY/OprM to carbapenems: substrate specificities of the efflux systems. *J Infect Chemother* **8**: 371-373.

Okamoto, K., Gotoh, N., and Nishino, T. (2002b) Extrusion of penem antibiotics by multicomponent efflux systems MexAB-OprM, MexCD-OprJ, and MexXY-OprM of Pseudomonas aeruginosa. *Antimicrob Agents Chemother* **46**: 2696-2699.

O'Neill, A.J., Bostock, J.M., Moita, A.M., and Chopra, I. (2002) Antimicrobial activity and mechanisms of resistance to cephalosporin P1, an antibiotic related to fusidic acid. *J Antimicrob Chemother* **50**: 839-848.

Pan, W., and Spratt, B.G. (1994) Regulation of the permeability of the gonococcal cell envelope by the *mtr* system. *Mol Microbiol* **11**: 769-775.

Parker, W.L., Rathnum, M.L., Seiner, V., Trejo, W.H., Principe, P.A., and Sykes, R.B. (1984) Cepacin A and cepacin B, two new antibiotics produced by *Pseudomonas cepacia*. *J Antibiot (Tokyo)* **37**: 431-440.

Parr, T.R., Jr., Moore, R.A., Moore, L.V., and Hancock, R.E. (1987) Role of porins in intrinsic antibiotic resistance of *Pseudomonas cepacia*. *Antimicrob Agents Chemother* **31**: 121-123.

Pegues, D.A., Carson, L.A., Anderson, R.L., Norgard, M.J., Argent, T.A., Jarvis, W.R., and Woernle, C.H. (1993) Outbreak of *Pseudomonas cepacia* bacteremia in oncology patients. *Clin Infect Dis* **16**: 407-411.

Plesiat, P., and Nikaido, H. (1992) Outer membranes of gram-negative bacteria are permeable to steroid probes. *Mol Microbiol* **6**: 1323-1333.

Poole, K., Heinrichs, D.E., and Neshat, S. (1993a) Cloning and sequence analysis of an EnvCD homologue in *Pseudomonas aeruginosa*: regulation by iron and possible involvement in the secretion of the siderophore pyoverdine. *Mol Microbiol* **10**: 529-544.

Poole, K., Krebes, K., McNally, C., and Neshat, S. (1993b) Multiple antibiotic resistance in *Pseudomonas aeruginosa*: evidence for involvement of an efflux operon. *J Bacteriol* **175**: 7363-7372.

Poole, K., Gotoh, N., Tsujimoto, H., Zhao, Q., Wada, A., Yamasaki, T., Neshat, S., Yamagishi, J., Li, X.Z., and Nishino, T. (1996a) Overexpression of the *mexC-*

mexD-oprJ efflux operon in *nfxB*-type multidrug-resistant strains of *Pseudomonas aeruginosa*. *Mol Microbiol* **21**: 713-724.

Poole, K., Tetro, K., Zhao, Q., Neshat, S., Heinrichs, D.E., and Bianco, N. (1996b) Expression of the multidrug resistance operon *mexA-mexB-oprM* in *Pseudomonas aeruginosa*: *mexR* encodes a regulator of operon expression. *Antimicrob Agents Chemother* **40**: 2021-2028.

Poole, K. (2004) Efflux-mediated multiresistance in Gram-negative bacteria. *Clin Microbiol Infect* **10**: 12-26.

Postle, K. (1993) TonB protein and energy transduction between membranes. *J Bioenerg Biomembr* **25**: 591-601.

Price, C.T., O'Brien, F.G., Shelton, B.P., Warmington, J.R., Grubb, W.B., and Gustafson, J.E. (1999) Effects of salicylate and related compounds on fusidic acid MICs in *Staphylococcus aureus*. *J Antimicrob Chemother* **44**: 57-64.

Prince, A., Wood, M.S., Cacalano, G.S., and Chin, N.X. (1988) Isolation and characterization of a penicillinase from *Pseudomonas cepacia* 249. *Antimicrob Agents Chemother* **32**: 838-843.

Pujol, M., Corbella, X., Carratala, J., and Gudiol, F. (1992) Community-acquired bacteremic *Pseudomonas cepacia* pneumonia in an immunocompetent host. *Clin Infect Dis* **15**: 887-888.

Pumbwe, L., and Piddock, L.J. (2000) Two efflux systems expressed simultaneously in multidrug-resistant *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* **44**: 2861-2864.

Radstrom, P., Swedberg, G., and Skold, O. (1991) Genetic analyses of sulfonamide resistance and its dissemination in gram-negative bacteria illustrate new aspects of R plasmid evolution. *Antimicrob Agents Chemother* **35**: 1840-1848.

Rahmati, S., Yang, S., Davidson, A.L., and Zechiedrich, E.L. (2002) Control of the AcrAB multidrug efflux pump by quorum-sensing regulator SdiA. *Mol Microbiol* **43**: 677-685.

Rand, J.D., Danby, S.G., Greenway, D.L., and England, R.R. (2002) Increased expression of the multidrug efflux genes *acrAB* occurs during slow growth of *Escherichia coli*. *FEMS Microbiol Lett* **207**: 91-95.

Rensing, C., Pribyl, T., and Nies, D.H. (1997) New functions for the three subunits of the CzcCBA cation-proton antiporter. *J Bacteriol* **179**: 6871-6879.

Ribbons, D.W., Keyser, P., Kunz, D.A., Taylor, B.F., Eaton, R.W., and Anderson, B.N. (1984) Microbial degradation of phthalate. In *Microbial Degradation of Organic Compounds*. Gibson, D.T. (ed). New York: Marcel Dekker, pp. 371-397.

Riedel, K., Hentzer, M., Geisenberger, O., Huber, B., Steidle, A., Wu, H., Hoiby, N., Givskov, M., Molin, S., and Eberl, L. (2001) N-acylhomoserine-lactone-mediated communication between *Pseudomonas aeruginosa* and *Burkholderia cepacia* in mixed biofilms. *Microbiology* **147**: 3249-3262.

Roitman, J.N., Mahoney, N.E., Janisiewicz, W.J., and Benson, M. (1990) A new chlorinated phenylpyrrole antibiotic produced by the antifungal bacterium *Pseudomonas cepacia*. *J Agric Food Chem* **38**: 538-541.

Rosenberg, E.Y., Ma, D., and Nikaido, H. (2000) AcrD of *Escherichia coli* is an aminoglycoside efflux pump. *J Bacteriol* **182**: 1754-1756.

Rosenberg, E.Y., Bertenthal, D., Nilles, M.L., Bertrand, K.P., and Nikaido, H. (2003) Bile salts and fatty acids induce the expression of *Escherichia coli* AcrAB multidrug efflux pump through their interaction with Rob regulatory protein. *Mol Microbiol* **48**: 1609-1619.

Rouquette, C., Harmon, J.B., and Shafer, W.M. (1999) Induction of the *mtrCDE*-encoded efflux pump system of *Neisseria gonorrhoeae* requires MtrA, an AraC-like protein. *Mol Microbiol* **33**: 651-658.

Rouquette-Loughlin, C., Stojiljkovic, I., Hrobowski, T., Balthazar, J.T., and Shafer, W.M. (2002) Inducible, but not constitutive, resistance of gonococci to hydrophobic agents due to the MtrC-MtrD-MtrE efflux pump requires TonB-ExbB-ExbD proteins. *Antimicrob Agents Chemother* **46**: 561-565.

Saier, M.H., Jr., Tam, R., Reizer, A., and Reizer, J. (1994) Two novel families of bacterial membrane proteins concerned with nodulation, cell division and transport. *Mol Microbiol* **11**: 841-847.

Saier, M.H., Jr., Paulsen, I.T., Sliwinski, M.K., Pao, S.S., Skurray, R.A., and Nikaido, H. (1998) Evolutionary origins of multidrug and drug-specific efflux pumps in bacteria. *Faseb J* **12**: 265-274.

Saito, K., Yoneyama, H., and Nakae, T. (1999) *nalB*-type mutations causing the overexpression of the MexAB-OprM efflux pump are located in the *mexR* gene of the *Pseudomonas aeruginosa* chromosome. *FEMS Microbiol Lett* **179**: 67-72.

Sambrook, J., Fritsch, E.F., and Maniatis, T. (1989) *Molecular cloning: a laboratory manual.* Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press.

Sanchez, P., Linares, J.F., Ruiz-Diez, B., Campanario, E., Navas, A., Baquero, F., and Martinez, J.L. (2002a) Fitness of *in vitro* selected *Pseudomonas aeruginosa nalB* and *nfxB* multidrug resistant mutants. *J Antimicrob Chemother* **50**: 657-664.

Sanchez, P., Rojo, F., and Martinez, J.L. (2002b) Transcriptional regulation of *mexR*, the repressor of Pseudomonas aeruginosa *mexAB-oprM* multidrug efflux pump. *FEMS Microbiol Lett* **207**: 63-68.

Sangodkar, U.M., Chapman, P.J., and Chakrabarty, A.M. (1988) Cloning, physical mapping and expression of chromosomal genes specifying degradation of the herbicide 2,4,5-T by *Pseudomonas cepacia* AC1100. *Gene* **71**: 267-277.

Sawada, I., Maseda, H., Nakae, T., Uchiyama, H., and Nomura, N. (2004) A quorum-sensing autoinducer enhances the *mexAB-oprM* efflux-pump expression without the MexR-mediated regulation in *Pseudomonas aeruginosa*. *Microbiol Immunol* **48**: 435-439.

Schaller, A., Sun, Z., Yang, Y., Somoskovi, A., and Zhang, Y. (2002) Salicylate reduces susceptibility of *Mycobacterium tuberculosis* to multiple antituberculosis drugs. *Antimicrob Agents Chemother* **46**: 2636-2639.

Schell, M.A. (1993) Molecular biology of the LysR family of transcriptional regulators. *Annu Rev Microbiol* **47**: 597-626.

Scholz, P., Haring, V., Wittmann-Liebold, B., Ashman, K., Bagdasarian, M., and Scherzinger, E. (1989) Complete nucleotide sequence and gene organization of the broad-host-range plasmid RSF1010. *Gene* **75**: 271-288.

Schuldiner, S., Granot, D., Steiner, S., Ninio, S., Rotem, D., Soskin, M., and Yerushalmi, H. (2001) Precious things come in little packages. *J Mol Microbiol Biotechnol* **3**: 155-162.

Schweizer, H.P. (1998) Intrinsic resistance to inhibitors of fatty acid biosynthesis in *Pseudomonas aeruginosa* is due to efflux: application of a novel technique for generation of unmarked chromosomal mutations for the study of efflux systems. *Antimicrob Agents Chemother* **42**: 394-398.

Schweizer, H.P. (2003) Efflux as a mechanism of resistance to antimicrobials in *Pseudomonas aeruginosa* and related bacteria: unanswered questions. *Genet Mol Res* **2**: 48-62.

Sekiya, H., Mima, T., Morita, Y., Kuroda, T., Mizushima, T., and Tsuchiya, T. (2003) Functional cloning and characterization of a multidrug efflux pump, *mexHI-opmD*, from a *Pseudomonas aeruginosa* mutant. *Antimicrob Agents Chemother* **47**: 2990-2992.

Seoane, A.S., and Levy, S.B. (1995) Characterization of MarR, the repressor of the multiple antibiotic resistance (*mar*) operon in *Escherichia coli*. *J Bacteriol* **177**: 3414-3419.

Shiba, T., Ishiguro, K., Takemoto, N., Koibuchi, H., and Sugimoto, K. (1995) Purification and characterization of the *Pseudomonas aeruginosa* NfxB protein, the negative regulator of the *nfxB* gene. *J Bacteriol* **177**: 5872-5877.

Shields, M.S., and Reagin, M.J. (1992) Selection of a *Pseudomonas cepacia* strain constitutive for the degradation of trichloroethylene. *Appl Environ Microbiol* **58**: 3977-3983.

Shimomura, H., Matsuura, M., Saito, S., Hirai, Y., Isshiki, Y., and Kawahara, K. (2003) Unusual interaction of a lipopolysaccharide isolated from *Burkholderia cepacia* with polymyxin B. *Infect Immun* **71**: 5225-5230.

Sobel, M.L., Neshat, S., and Poole, K. (2005) Mutations in PA2491 (*mexS*) promote MexT-dependent *mexEF-oprN* expression and multidrug resistance in a clinical strain of *Pseudomonas aeruginosa*. *J Bacteriol* **187**: 1246-1253.

Sokol, P.A., Darling, P., Woods, D.E., Mahenthiralingam, E., and Kooi, C. (1999) Role of ornibactin biosynthesis in the virulence of *Burkholderia cepacia*: characterization of *pvdA*, the gene encoding L-ornithine N(5)-oxygenase. *Infect Immun* **67**: 4443-4455.

Srikumar, R., Li, X.Z., and Poole, K. (1997) Inner membrane efflux components are responsible for beta-lactam specificity of multidrug efflux pumps in *Pseudomonas aeruginosa*. *J Bacteriol* **179**: 7875-7881.

Srikumar, R., Paul, C.J., and Poole, K. (2000) Influence of mutations in the *mexR* repressor gene on expression of the MexA-MexB-OprM multidrug efflux system of *Pseudomonas aeruginosa*. *J Bacteriol* **182**: 1410-1414.

Stock, A.M., Robinson, V.L., and Goudreau, P.N. (2000) Two-component signal transduction. *Annu Rev Biochem* **69**: 183-215.

Stoker, N.G., Fairweather, N.F., and Spratt, B.G. (1982) Versatile low-copy-number plasmid vectors for cloning in *Escherichia coli*. *Gene* **18**: 335-341.

Stover, C.K., Pham, X.Q., Erwin, A.L., Mizoguchi, S.D., Warrener, P., Hickey, M.J., Brinkman, F.S., Hufnagle, W.O., Kowalik, D.J., Lagrou, M., Garber, R.L., Goltry, L., Tolentino, E., Westbrock-Wadman, S., Yuan, Y., Brody, L.L., Coulter, S.N., Folger, K.R., Kas, A., Larbig, K., Lim, R., Smith, K., Spencer, D., Wong, G.K., Wu, Z., Paulsen, I.T., Reizer, J., Saier, M.H., Hancock, R.E., Lory, S., and Olson, M.V. (2000) Complete genome sequence of *Pseudomonas aeruginosa* PA01, an opportunistic pathogen. *Nature* **406**: 959-964.

Sulavik, M.C., Houseweart, C., Cramer, C., Jiwani, N., Murgolo, N., Greene, J., DiDomenico, B., Shaw, K.J., Miller, G.H., Hare, R., and Shimer, G. (2001) Antibiotic susceptibility profiles of *Escherichia coli* strains lacking multidrug efflux pump genes. *Antimicrob Agents Chemother* **45**: 1126-1136.

Sumita, Y., and Fukasawa, M. (1993) Transient carbapenem resistance induced by salicylate in *Pseudomonas aeruginosa* associated with suppression of outer membrane protein D2 synthesis. *Antimicrob Agents Chemother* **37**: 2743-2746.

Taplin, D., Bassett, D.C., and Mertz, P.M. (1971) Foot lesions associated with *Pseudomonas cepacia*. *Lancet* **2**: 568-571.

Thanabalu, T., Koronakis, E., Hughes, C., and Koronakis, V. (1998) Substrate-induced assembly of a contiguous channel for protein export from *E.coli*: reversible bridging of an inner-membrane translocase to an outer membrane exit pore. *Embo J* **17**: 6487-6496.

Tikhonova, E.B., Wang, Q., and Zgurskaya, H.I. (2002) Chimeric analysis of the multicomponent multidrug efflux transporters from gram-negative bacteria. *J Bacteriol* **184**: 6499-6507.

Tomlin, K.L., Coll, O.P., and Ceri, H. (2001) Interspecies biofilms of *Pseudomonas aeruginosa* and *Burkholderia cepacia*. *Can J Microbiol* **47**: 949-954.

Touze, T., Eswaran, J., Bokma, E., Koronakis, E., Hughes, C., and Koronakis, V. (2004) Interactions underlying assembly of the *Escherichia coli* AcrAB-TolC multidrug efflux system. *Mol Microbiol* **53**: 697-706.

Tran Van, V., Berge, O., Ngo, S.K., Balandreau, J., and Heulin, T. (2000) Repeated beneficial effects of rice inoculation with a strain of *Burkholderia vietnamiensis* on early and late yield components in low fertility sulphate acid soils of Vietnam. *Plant Soil* **218**: 273-284.

Trepanier, S., Prince, A., and Huletsky, A. (1997) Characterization of the *penA* and *penR* genes of *Burkholderia cepacia* 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator. *Antimicrob Agents Chemother* **41**: 2399-2405.

Tsukagoshi, N., and Aono, R. (2000) Entry into and release of solvents by *Escherichia coli* in an organic-aqueous two-liquid-phase system and substrate specificity of the AcrAB-TolC solvent-extruding pump. *J Bacteriol* **182**: 4803-4810.

van der Lelie, D., Schwuchow, T., Schwidetzky, U., Wuertz, S., Baeyens, W., Mergeay, M., and Nies, D.H. (1997) Two-component regulatory system involved in transcriptional control of heavy-metal homoeostasis in *Alcaligenes eutrophus*. *Mol Microbiol* **23**: 493-503.

van Treeck, U., Schmidt, F., and Wiedemann, B. (1981) Molecular nature of a streptomycin and sulfonamide resistance plasmid (pBP1) prevalent in clinical *Escherichia coli* strains and integration of an ampicillin resistance transposon (TnA). *Antimicrob Agents Chemother* **19**: 371-380.

van Veen, H.W., Venema, K., Bolhuis, H., Oussenko, I., Kok, J., Poolman, B., Driessen, A.J., and Konings, W.N. (1996) Multidrug resistance mediated by a bacterial homolog of the human multidrug transporter MDR1. *Proc Natl Acad Sci U S A* **93**: 10668-10672.

Vandamme, P., Holmes, B., Vancanneyt, M., Coenye, T., Hoste, B., Coopman, R., Revets, H., Lauwers, S., Gillis, M., Kersters, K., and Govan, J.R. (1997) Occurrence of multiple genomovars of *Burkholderia cepacia* in cystic fibrosis patients and proposal of *Burkholderia multivorans* sp. nov. *Int J Syst Bacteriol* **47**: 1188-1200.

Vandamme, P., Mahenthiralingam, E., Holmes, B., Coenye, T., Hoste, B., De Vos, P., Henry, D., and Speert, D.P. (2000) Identification and population structure of *Burkholderia stabilis* sp. nov. (formerly *Burkholderia cepacia* genomovar IV). *J Clin Microbiol* **38**: 1042-1047.

Vandamme, P., Henry, D., Coenye, T., Nzula, S., Vancanneyt, M., LiPuma, J.J., Speert, D.P., Govan, J.R., and Mahenthiralingam, E. (2002) *Burkholderia anthina* sp. nov. and *Burkholderia pyrrocinia*, two additional *Burkholderia cepacia* complex bacteria, may confound results of new molecular diagnostic tools. *FEMS Immunol Med Microbiol* **33**: 143-149.

Vandamme, P., Holmes, B., Coenye, T., Goris, J., Mahenthiralingam, E., LiPuma, J.J., and Govan, J.R. (2003) *Burkholderia cenocepacia* sp. nov.--a new twist to an old story. *Res Microbiol* **154**: 91-96.

Veal, W.L., Yellen, A., Balthazar, J.T., Pan, W., Spratt, B.G., and Shafer, W.M. (1998) Loss-of-function mutations in the *mtr* efflux system of *Neisseria gonorrhoeae*. *Microbiology* **144 (Pt 3)**: 621-627.

Verghese, A., al-Samman, M., Nabhan, D., Naylor, A.D., and Rivera, M. (1994) Bacterial bronchitis and bronchiectasis in human immunodeficiency virus infection. *Arch Intern Med* **154**: 2086-2091.

Vermis, K., Coenye, T., LiPuma, J.J., Mahenthiralingam, E., Nelis, H.J., and Vandamme, P. (2004) Proposal to accommodate *Burkholderia cepacia* genomovar VI as *Burkholderia dolosa* sp. nov. *Int J Syst Evol Microbiol* **54**: 689-691.

Viallard, V., Poirier, I., Cournoyer, B., Haurat, J., Wiebkin, S., Ophel-Keller, K., and Balandreau, J. (1998) *Burkholderia graminis* sp. nov., a rhizospheric *Burkholderia* species, and reassessment of [*Pseudomonas*] *phenazinium*,

[*Pseudomonas*] *pyrrocinia* and [*Pseudomonas*] *glathei* as *Burkholderia*. *Int J Syst Bacteriol* **48 Pt 2**: 549-563.

Vogne, C., Aires, J.R., Bailly, C., Hocquet, D., and Plesiat, P. (2004) Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among *Pseudomonas aeruginosa* isolates from patients with cystic fibrosis. *Antimicrob Agents Chemother* **48**: 1676-1680.

Westbrock-Wadman, S., Sherman, D.R., Hickey, M.J., Coulter, S.N., Zhu, Y.Q., Warrener, P., Nguyen, L.Y., Shawar, R.M., Folger, K.R., and Stover, C.K. (1999) Characterization of a *Pseudomonas aeruginosa* efflux pump contributing to aminoglycoside impermeability. *Antimicrob Agents Chemother* **43**: 2975-2983.

White, D.G., Goldman, J.D., Demple, B., and Levy, S.B. (1997) Role of the *acrAB* locus in organic solvent tolerance mediated by expression of *marA*, *soxS*, or *robA* in *Escherichia coli*. *J Bacteriol* **179**: 6122-6126.

Whiteley, M., Lee, K.M., and Greenberg, E.P. (1999) Identification of genes controlled by quorum sensing in *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A* **96**: 13904-13909.

Whiteley, M., Bangera, M.G., Bumgarner, R.E., Parsek, M.R., Teitzel, G.M., Lory, S., and Greenberg, E.P. (2001) Gene expression in *Pseudomonas aeruginosa* biofilms. *Nature* **413**: 860-864.

Wigfield, S.M., Rigg, G.P., Kavari, M., Webb, A.K., Matthews, R.C., and Burnie, J.P. (2002) Identification of an immunodominant drug efflux pump in *Burkholderia cepacia*. *J Antimicrob Chemother* **49**: 619-624.

Wong, K.K., and Hancock, R.E. (2000) Insertion mutagenesis and membrane topology model of the *Pseudomonas aeruginosa* outer membrane protein OprM. *J Bacteriol* **182**: 2402-2410.

Wong, S.N., Tam, A.Y., Yung, R.W., Kwan, E.Y., and Tsoi, N.N. (1991) *Pseudomonas* septicaemia in apparently healthy children. *Acta Paediatr Scand* **80**: 515-520.

Yabuuchi, E., Kosako, Y., Oyaizu, H., Yano, I., Hotta, H., Hashimoto, Y., Ezaki, T., and Arakawa, M. (1992) Proposal of *Burkholderia* gen. nov. and transfer of seven species of the genus *Pseudomonas* homology group II to the new genus, with the type species *Burkholderia cepacia* (Palleroni and Holmes 1981) comb. nov. *Microbiol Immunol* **36**: 1251-1275.

Yerushalmi, H., Lebendiker, M., and Schuldiner, S. (1996) Negative dominance studies demonstrate the oligomeric structure of EmrE, a multidrug antiporter from *Escherichia coli*. *J Biol Chem* **271**: 31044-31048.

Yoneda, K., Chikumi, H., Murata, T., Gotoh, N., Yamamoto, H., Fujiwara, H., Nishino, T., and Shimizu, E. (2005) Measurement of *Pseudomonas aeruginosa* multidrug efflux pumps by quantitative real-time polymerase chain reaction. *FEMS Microbiol Lett* **243**: 125-131.

Yoneyama, H., Ocaktan, A., Gotoh, N., Nishino, T., and Nakae, T. (1998) Subunit swapping in the Mex-extrusion pumps in *Pseudomonas aeruginosa*. *Biochem Biophys Res Commun* **244**: 898-902.

Yoneyama, H., Maseda, H., Kamiguchi, H., and Nakae, T. (2000) Function of the membrane fusion protein, MexA, of the MexA, B-OprM efflux pump in *Pseudomonas aeruginosa* without an anchoring membrane. *J Biol Chem* **275**: 4628-4634.

Yoshihara, E., Maseda, H., and Saito, K. (2002) The outer membrane component of the multidrug efflux pump from *Pseudomonas aeruginosa* may be a gated channel. *Eur J Biochem* **269**: 4738-4745.

Yu, E.W., McDermott, G., Zgurskaya, H.I., Nikaido, H., and Koshland, D.E., Jr. (2003) Structural basis of multiple drug-binding capacity of the AcrB multidrug efflux pump. *Science* **300**: 976-980.

Zarantonelli, L., Borthagaray, G., Lee, E.H., and Shafer, W.M. (1999) Decreased azithromycin susceptibility of *Neisseria gonorrhoeae* due to *mtrR* mutations. *Antimicrob Agents Chemother* **43**: 2468-2472.

Zgurskaya, H.I., and Nikaido, H. (1999a) AcrA is a highly asymmetric protein capable of spanning the periplasm. *J Mol Biol* **285**: 409-420.

Zgurskaya, H.I., and Nikaido, H. (1999b) Bypassing the periplasm: reconstitution of the AcrAB multidrug efflux pump of *Escherichia coli*. *Proc Natl Acad Sci U S A* **96**: 7190-7195.

Zgurskaya, H.I., and Nikaido, H. (2000) Cross-linked complex between oligomeric periplasmic lipoprotein AcrA and the inner-membrane-associated multidrug efflux pump AcrB from *Escherichia coli*. *J Bacteriol* **182**: 4264-4267.

Zhao, Q., Li, X.Z., Mistry, A., Srikumar, R., Zhang, L., Lomovskaya, O., and Poole, K. (1998) Influence of the TonB energy-coupling protein on efflux-mediated multidrug resistance in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother* **42**: 2225-2231.

Ziha-Zarifi, I., Llanes, C., Kohler, T., Pechere, J.C., and Plesiat, P. (1999) *In vivo* emergence of multidrug-resistant mutants of *Pseudomonas aeruginosa* overexpressing the active efflux system MexA-MexB-OprM. *Antimicrob Agents Chemother* **43**: 287-291.

Zinner, S.H. (1999) Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. *Clin Infect Dis* **29**: 490-494.

Chapter 6: Appendix

6. APPENDIX: Contribution of p6148 to antibiotic resistance in enteropathogenic *E. coli*

6.1 Introduction

Clinical isolates of *E. coli* are known to contain multiple plasmids. Many of these are small, cryptic plasmids (SCPs) that are maintained despite the fact that they carry very little genetic information (Burian *et al.*, 1997). Some of these small, cryptic plasmids carry antibiotic resistance genes. For example, sulphonamide resistance in *E. coli* usually stems from the acquisition of *sul1* or *sul2* genes, encoding alternate forms of dihydropteroate synthase that are not inhibited by the drug. The *sulI* gene is almost always found on large conjugative plasmids within type I integrons (Radstrom *et al.*, 1991). The *sul2* gene, however, is found on small non-conjugative plasmids in association with streptomycin resistance genes *strA* and *strB* (Radstrom *et al.*, 1991). Among other organisms, the *strA strB sul2* gene cluster can be found on plasmids of clinical *E.coli* and *Shigella* spp. isolates and in large conjugative elements of clinical *Vibrio cholerae* isolates (Enne *et al.*, 2001; Hartman *et al.*, 2003; Hochhut *et al.*, 2001; Ojo *et al.*, 2003). The presence of *sul2*-containing plasmids persists despite a significant decrease in sulphonamide use during the 1990s (Enne *et al.*, 2001). One study suggests that maintenance of *sul2*-plasmids is due to a slight but consistent growth-enhancing effect (Enne *et al.*, 2004).

Two small, cryptic plasmids of unknown function, p6148 and p5218 with sizes of 6.2 kb and 5.0 kb respectively, were isolated from enteropathogenic *E. coli* E2348/69. Sequencing of p6148 revealed the presence of *strA*, *strB*, and *sul2* resistance determinants as shown in Figure 6.1 (J.J. Dennis, personal communication). The objectives of this



Figure 6.1 Physical map of antibiotic resistance genes carried on p6148, a 6.2 kb plasmid from EPEC E2348/69.

study were to examine the role of p6148 in streptomycin and sulphonamide resistance and to determine if the presence of p6148 confers a growth advantage.

6.2 Materials and Methods

6.2.1 Bacterial strains and plasmids

E. coli strains used in this study are listed in Table 6.1. Cloning vectors and recombinant plasmids are given, along with their relevant characteristics, in Table 6.1.

6.2.2 Growth Conditions

Bacterial strains were routinely grown in LB medium or M63 minimal medium (Sambrook *et al.*, 1989) at 37°C with shaking at 250 rpm. When necessary, the following concentrations of antibiotics were used: 100 μg/mL ampicillin, 50 μg/mL kanamycin, 30 μg/mL streptomycin, and 25 μg/mL tetracycline.

6.2.3 Transformation of E. coli JPN15

Cultures of *E. coli* JPN15 were grown in LB medium to an OD_{600} of approximately 0.8. The culture was then divided into 25 mL portions which were kept on ice for 20 minutes then centrifuged for 15 minutes at 4°C. The resulting pellets were washed three times with ice cold sterile water and then resuspended in 100 μL cold 10% glycerol. Cells were kept on ice for immediate use or stored at -80°C. For electroporation, cells were mixed with an appropriate volume of plasmid DNA, transferred into chilled 0.1 cm cuvettes and electroporated using the BIO-RAD (Hercules, CA) MicroPulser setting Ec1 (1.8 kV). After electroporation, cells were immediately

Table 6.1 Bacterial strains and plasmids

***E. coli* Strain**	**Relevant Characteristics**	**Reference or Source**
DH5α	F^- Φ80d*lac*ZΔM15 Δ(*lac*ZYA-*arg*F) U169 *rec*A1 *end*A1 *hsd*R17(r_k^-, m_k^+) *pho*A *sup*E44 λ^- *thi*-1 *gyr*A96 *rel*A1	Invitrogen
E2348/69	Prototypic EPEC isolate (O127 H6)	(Levine *et al.*, 1985)
JPN15	Plasmid-cured derivative of E2348/69, lacking p6148 and the EPEC adherence factor (EAF) plasmid.	(Levine *et al.*, 1985)

Plasmid	**Relevant Characteristics**	**Reference or Source**
p34S-Km3	Source of kanamycin resistance cassette	(Dennis and Zylstra, 1998)
p6148	6.2 kb plasmid from E2348/69 containing *strAB* and *sul2* antibiotic resistance genes	J.J. Dennis, personal communication
p6148-Km (*Kpn*I)	p6148 with the kanamycin resistance cassette from p34S-Km3 inserted into the *Kpn*I site	This study
p6148-Km (*Sac*I)	p6148 with the kanamycin resistance cassette from p34S-Km3 inserted into the *Sac*I site	J.J. Dennis, personal communication
p6148-pUC19 (*Sac*I)	p6148 with pUC19 iserted into the *Sac*I site	J.J. Dennis, personal communication
pLG339	Low copy number cloning vector conferring kanamycin resistance and tetracycline resistance.	(Stoker *et al.*, 1982)
pUC19	High copy number cloning vector conferring ampicillin resistance.	Invitrogen

resuspended in 500 μL SOC, a nutrient rich medium (Sambrook *et al.*, 1989) and incubated for 1 hour at 37°C. Following incubation, cells were plated in 100 μL volumes on LB agar containing selective antibiotics.

6.2.4 DNA analysis

All DNA isolation and general molecular biology techniques were performed as described in Section 2.3.

6.2.5 Overexpression of the sul2 gene

The *sul2* gene was amplified by PCR using p6148 plasmid DNA as template and a 60°C annealing temperature according to the standard PCR reaction described in Section 2.3. The primers *sul*1.L AAGGATCCAAACTCGTCGTTATG and *sul*1.R AAGGATCCAGTCAGAATGCGATT contained engineered *Bam*HI restriction endonuclease sites (underlined) that were used for restriction digestion and ligation of the purified PCR product into the cloning vectors pUC19 and pLG339.

Primers *sul*2.L AAGGATCC**AGGAG**TCGTTATGCATTCGGT and *sul*2.R ACGGATCCAGTTTTCTGATGAAGCG were used to amplify *sul2* from p6148 plasmid DNA, while adding an engineered Shine Dalgarno sequence (bold) that was closer to the *E. coli* consensus. *Bam*HI sites (underlined) were used to clone the resulting PCR product into pLG339.

6.2.6 Minimum inhibitory concentration (MIC) assay

In general, MIC assays were performed as described in Section 2.5. *E. coli* cultures were grown in LB at 37°C to a final OD_{600} of 1.2. Then, 5 µL/well of this culture was used to inoculate 96 well plates containing consecutive two-fold dilutions of an antibiotic stock solution. When a narrower range of antibiotic concentrations was desired, a difference of 250 µg/mL between consecutive wells was used. Following inoculation, the 96 well plates were incubated at 37°C overnight with shaking at 250 rpm. The minimum inhibitory concentration was determined as the lowest concentration that completely inhibited growth, as indicated by OD_{600} measurements.

6.2.7 Growth curves

A single colony of *E. coli* was used to inoculate 5 mL of M63 minimal medium and grown overnight at 37°C. The resulting overnight culture was used to inoculate M63 minimal medium to a final OD_{600} of 0.02. Cultures were incubated at 37°C with shaking at 250 rpm, with OD_{600} readings taken every hour until the culture reached stationary phase.

6.3 Results and Discussion

6.3.1 Effect of p6148 on E. coli streptomycin resistance

The p6148 plasmid contains *strA* and *strB* genes which encode a streptomycin-inactivating phosphotransferase (J.J. Dennis, personal communication). Therefore, this plasmid was expected to confer resistance to streptomycin. To determine if this was the case, the p6148 plasmid from resistant EPEC strain E2348/69 was introduced into *E. coli* JPN15, an isogenic strain that lacks both p6148 and the EPEC adherence factor (EAF)

plasmid. Minimum inhibitory concentration assays were performed (Table 6.2). The concentration of streptomycin needed to completely inhibit growth of E2348/69 is approximately 100 times greater than the MIC for JPN15. When p6148 was introduced into JPN15, the streptomycin resistance levels increased to the level of E2348/69 resistance. This result demonstrates that p6148 does confer resistance to streptomycin, and could account for the level of resistance observed in E2348/69.

To determine if the *strA* and *strB* genes were involved in the observed streptomycin resistance, p6148 was interrupted with a kanamycin resistance cassette (p6148-Km(*Sac*I)) or pUC19 plasmid (p6148-pUC19) inserted into the *Sac*I restriction site in the putative *strAB* promoter. The resulting constructs were used to transform JPN15. The MIC of streptomycin on JPN15 carrying p6148-Km(*Sac*I) was identical to that of JPN15. However, when p6148-pUC19 was introduced into JPN15, streptomycin resistance levels were partially restored, approximately 4.5 times that of JPN15 alone (Table 6.2). The above results suggest that the *strA* and *strB* genes are responsible for the streptomycin resistance conferred by p6148. The increased MIC value when p6148-pUC19 is present indicates that some expression of *strA* and *strB* is being driven from a pUC19 promoter. This could be confirmed by performing RT-PCR on the *str* genes.

6.3.2 Effect of p6148 on E. coli sulphonamide resistance

Along with the streptomycin resistance genes, p6148 also contains a *sul2* gene, encoding a sulphonamide resistant form of dihydropteroate synthase (J.J. Dennis, personal communication). To examine the importance of p6148 in EPEC sulphonamide

Table 6.2 The impact of p6148 on streptomycin resistance in *E. coli* JPN15. The values below are the average of three experiments comparing the minimum inhibitory concentration of streptomycin on *E. coli* E2348/69 (the source of p6148), JPN15 (lacks p6148), a pUC19 vector control, and JPN15 that has been transformed with p6148 or interrupted versions of p6148. The plasmids p6148-Km and p6148-pUC19 have a kanamycin resistance cassette or pUC19 inserted into the putative *strAB* promoter.

Strain	**MIC of Streptomycin (μg/mL)**
E2348/69	1000
JPN15	7.8
JPN15 + pUC19	10.4
JPN15 + p6148	1000
JPN15 + p6148-Km (*Sac*I)	7.8
JPN15 + p6148-pUC19 (*Sac*I)	41.6

resistance, minimum inhibitory concentration assays were performed (Table 6.3). The p6148-lacking strain JPN15 was equally resistant to sulphonamides as was EPEC strain E2348/69. The MICs of sulfisoxazole and sulfamethoxazole were 1000 μg/mL, greater than the NCCLS resistance breakpoint of ≥512 μg/mL (Enne *et al.*, 2001). The introduction of p6148 or p6148-Km(*Kpn*I) had no impact on the MIC of either sulphonamide antibiotic, sulfisoxazole or sulfamethoxazole.

To ensure that a small change in resistance was not being missed, MIC assays were repeated using a much narrower range of sulphonamide concentrations (Table 6.4). Again, no differences in the MICs of sulfisoxazole or sulfamethoxale were observed between JPN15 and the p6148-bearing strains. The above results indicate that p6148, and the *sul2* gene, do not contribute to sulphonamide resistance.

The lack of increase in sulphonamide resistance in the presence of p6148 could be the result of a weak or dysfunctional *sul*2 promoter. To address this possibility, the *sul2* gene from p6148 was cloned in both orientations into high copy number plasmid pUC19, placing it under the control of the strong *lac* promoter. The construct was then introduced into *E. coli* DH5α. MIC experiments were performed to determine if the *sul2* gene was capable of conferring sulphonamide resistance (Table 6.5). Rather than increasing resistance, the presence of *sul2* in both orientations actually decreased the MIC of sulphonamides as compared to the wild-type and vector control strains. However, the cells carrying pUC19-*sul2* grew much slower than DH5α with pUC19 alone (data not shown). Thus, it is likely that the decreased resistance is due to a toxic effect rather than an actual sensitivity to sulphonamides. Since the toxic effect was seen even when the

Table 6.3 The impact of p6148 on sulphonamide resistance in *E. coli* JPN15. The values below are the average of three experiments comparing the minimum inhibitory concentration of sulphonamides on *E. coli* E2348/69 (the source of p6148), JPN15 (lacks p6148), and JPN15 that has been transformed with p6148 or p6148 marked with a kanamycin resistance gene.

	MICs (µg/mL)	
Strain	**Sulfisoxazole**	**Sulfamethoxazole**
E2348/69	1000	1000
JPN15	1000	833.3
JPN15 + p6148	833.3	833.3
JPN15 + p6148-Km(*Kpn*I)	833.3	666.7

Table 6.4 The impact of p6148 on sulphonamide resistance in *E. coli* JPN15 measured over a narrow concentration range. The minimum inhibitory concentration of sulphonamides on *E. coli* E2348/69 (the source of p6148), JPN15 (lacks p6148), and JPN15 that has been transformed with p6148 or p6148 marked with a kanamycin resistance gene was determined. A narrow range of sulphonamide concentrations was used, with each consecutive well decreasing by 250 μg/mL. Values are an average of three replicates.

	MICs (μg/mL)	
Strain	**Sulfisoxazole**	**Sulfamethoxazole**
E2348/69	500	500
JPN15	583.3	500
JPN15 + p6148	500	500
JPN15 + p6148-Km(*Kpn*I)	500	500

Table 6.5 Overexpression of the p6148 *sul2* gene from high copy number plasmid pUC19. The *sul2* gene was cloned into the *Bam*HI site of pUC19 and transformed into *E. coli* DH5α. The impact on sulphonamide resistance was determined by comparing the minimum inhibitory concentration of sulfisoxazole and sulfamethoxazole on DH5α, a vector control, and DH5α carrying the *sul2* gene cloned into pUC19 in the same (L-R) or opposite (R-L) orientation as the promoter. Values below are the average of two replicates. Although multiple *sul2* clones were tested, only one representative of each orientation is shown below. However, MIC values were similar for all clones.

	MICs (μg/mL)	
Strain	**Sulfisoxazole**	**Sulfamethoxazole**
DH5α	187.5	312.5
DH5α + pUC19	187.5	187.5
DH5α + pUC19-*sul2* (L-R)	23.4	39.1
DH5α + pUC19-*sul2* (R-L)	31.3	31.3

sul2 gene was cloned in the opposite orientation as the *lac* promoter, there is likely some expression from another pUC19 promoter.

It appeared that the high level of *sul2* expressed from pUC19 was in some way toxic to the cells. To address this concern, we cloned *sul2* into the low copy number plasmid pLG339 and repeated the MIC experiment as described above. Although the growth rate of the *sul2*-bearing cells improved (data not shown), no meaningful increase in sulphonamide resistance was observed (Table 6.6).

Another possible explanation for the lack of change in sulphonamide resistance is that a defective Shine Dalgarno sequence could interfere with translation of *sul2* mRNA. Oligonucleotide primers containing an engineered Shine Dalgarno consensus sequence were used to amplify and clone the *sul2* gene into pLG339. The MICs of sulfisoxazole and sulfamethoxazole were determined for wild-type DH5α, the vector control, and DH5α containing pLG339-*sul2* with the modified Shine Dalgarno sequence (Table 6.7). However, the *sul2* gene was still unable to provide resistance to either sulphonamide antibiotic. The results of *sul2* overexpression experiments demonstrate that neither the promoter nor ribosome binding site is responsible for the lack of sulphonamide resistance. Rather it appears that the *sul2* gene itself is not functional, possibly due to an inactivating mutation.

This result was surprising given the high degree of conservation of *strA strB sul2* gene clusters. For example, *sul2* genes found on several *E. coli* small multicopy plasmids (Enne *et al.*, 2004; Scholz *et al.*, 1989; van Treeck *et al.*, 1981) and on a large, conjugative element (SXT constin) in *Vibrio cholerae* are identical (Hochhut *et al.*, 2001). Isolation of subclones from a *V. cholerae* cosmid library demonstrated that the

Table 6.6 Overexpression of the p6148 *sul2* gene from low copy number plasmid pLG339. The *sul2* gene was cloned into the *Bam*HI site of pLG339 and transformed into *E. coli* DH5α. The impact on sulphonamide resistance was determined by comparing the minimum inhibitory concentration of sulfisoxazole and sulfamethoxazole on DH5α, a vector control, and DH5α carrying the *sul2* gene cloned into pLG339 in the same (L-R) or opposite (R-L) orientation as the promoter. Values below are the average of three replicates. Although multiple *sul2* clones were tested, only one representative of each orientation is shown below. However, MIC values were similar for all clones.

	MICs (μg/mL)	
Strain	**Sulfisoxazole**	**Sulfamethoxazole**
DH5α	250	250
DH5α + pLG339	250	250
DH5α + pLG339-*sul2* (L-R)	333.3	250
DH5α + pLG339-*sul2* (R-L)	583.3	416.7

Table 6.7 Overexpression of the p6148 *sul2* with a modified ribosome binding site from low copy number plasmid pLG339. The *sul2* gene was amplified using primers with an engineered ribosome binding site, cloned into the *Bam*HI site of pLG339, and transformed into *E. coli* DH5α. The impact on sulphonamide resistance was determined by comparing the minimum inhibitory concentration of sulfisoxazole and sulfamethoxazole on DH5α, a vector control, and DH5α carrying the *sul2* gene cloned into pLG339 in the same (L-R) or opposite (R-L) orientation as the promoter. Values below are the average of three replicates. Although multiple *sul2* clones were tested, only one representative of each orientation is shown below. However, MIC values were similar for all clones.

	MICs (μg/mL)	
Strain	**Sulfisoxazole**	**Sulfamethoxazole**
DH5α	250	250
DH5α + pLG339	250	250
DH5α + pLG339-*sul2* (L-R)	250	250
DH5α + pLG339-*sul2* (R-L)	250	416.7

sul2 gene from this organism is able to confer sulphonamide resistance (Hochhut *et al.*, 2001). A comparison of the *sul2* gene sequences from p6148 and the previously characterized elements was needed. Pairwise BLAST searches (http://www.ncbi.nlm.nih.gov/BLAST/) found that p6148 and p9123 (accession number AY360321) are 99% identical at the DNA level. Their respective *sul2* sequences were even more similar, showing 100% identity. However, one striking difference was observed. The putative p6148 *sul2* ORF, starting at position 429 in Figure 6.2, is only 434 bp long, much shorter than the 816 bp functional *sul2* sequence from p9123 and SXT^{MO10} (accession number AY034138).

A likely explanation for this difference would be the presence of a premature stop codon in the p6148 *sul2* sequence resulting in a partial ORF of only 434 bp. To assess this possibility, a multiple alignment (Gene Tool 2.0, BioTools, Edmonton) of the *sul2* ORFS from p6148, p9123 and SXT^{MO10} was performed (Figure 6.2). As expected, the p6148 *sul2* sequence was almost identical to the ORFs from p9123 and SXT^{MO10}. However, the alignment shows three frameshift mutations (a 1 bp deletion and two 1 bp insertions) and premature stop codons in the p6148 *sul2* region. As a result, the partial *sul2* ORF from p6148 is much smaller than those from p9123 and SXT^{MO10}. This finding explains why addition of p6148 and overexpression of the partial *sul2* ORF did not increase sulphonamide resistance in *E. coli* strains.

6.3.3 Effect of p6148 on the growth rate of E. coli

In 2004, Enne *et al.* reported that the presence of the small plasmid p9123, which carries the *strA strB sul2* gene cluster provided a 3% decrease in logarithmic phase

Figure 6.2 Alignment of the *sul2* sequences and promoter regions from p6148, p9123, and SXT^{M010}. The *sul2* sequence from *E. coli* E2348/69 (p6148) was compared to the characterized *sul2* genes from clinical *E. coli* isolate 91-23 (p9123) and *V. cholerae* (SXT^{M010}). Alignment of these sequences reveals a 1 bp deletion and two 1 bp insertions (dark gray boxes) in the p6148 *sul2* region. These mutations shift the reading frame and create stop codons (* and light gray boxes). As a result, the putative p6148 *sul2* ORF begins with the start codon at postion 429 (underlined).

```
                                                                M  N
p6148 ATCCGTATGAGACTCATGCTCGATTATTATTATTATAGAAGCCCCCATGAATA 53
                                                                M  N
p9123 ATCCGTATGAGACTCATGCTCGATTATTATTATTATAGAAGCCCCCATGAATA 53
                                                                M  N
SXT^M010 ATCCGTATGAGACTCATGCTCGATTATTATTATTATAGAAGCCCCCATGAATA 53

      K  S  L  I  I  F  G  I  V  N  I  T  S  D  S  F  S  D
p6148 AATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGAT 106
      K  S  L  I  I  F  G  I  V  N  I  T  S  D  S  F  S  D
p9123 AATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGAT 106
      K  S  L  I  I  F  G  I  V  N  I  T  S  D  S  F  S  D
SXT^M010 AATCGCTCATCATTTTCGGCATCGTCAACATAACCTCGGACAGTTTCTCCGAT 106

       G  G  R  I  W  R  Q  T  Q  P  L  R  R  R  V  S  *
p6148 GGAGGCC▮GTATCTGGCGCCAGACGCAGCCATTGCGCAGGCGCGTAAGCTGAT 158
       G  G  R  Y  L  A  P  D  A  A  I  A  Q  A  R  K  L  M
p9123 GGAGGCC▮GTATCTGGCGCCAGACGCAGCCATTGCGCAGGCGCGTAAGCTGAT 159
       G  G  R  Y  L  A  P  D  A  A  I  A  Q  A  R  K  L  M
SXT^M010 GGAGGCC▮GTATCTGGCGCCAGACGCAGCCATTGCGCAGGCGCGTAAGCTGAT 159

      W  P  R  G  P  E  C  D  R  P  R  S  G  I  Q  Q  S  R
p6148 GGCCGAGGGGG▮CAG▮ATGTGATCGACCTCGGTCCGGCATCCAGCAATCCCGA 211
        A  E  G  A  D  V  I  D  L  G  P  A  S  S  N  P  D
p9123 GGCCGAGGGGG▮CAG▮ATGTGATCGACCTCGGTCCGGCATCCAGCAATCCCGA 210
        A  E  G  A  D  V  I  D  L  G  P  A  S  S  N  P  D
SXT^M010 GGCCGAGGGGG▮CAG▮ATGTGATCGACCTCGGTCCGGCATCCAGCAATCCCGA 210

       R  R  A  C  F  V  R  H  R  N  R  A  Y  R  A  G  A  G
p6148 CGCCGCGCCTGTTTCGTCCGACACAGAAATCGCGCGTATCGCGCCGGTGCTGG 264
        A  A  P  V  S  S  D  T  E  I  A  R  I  A  P  V  L
p9123 CGCCGCGCCTGTTTCGTCCGACACAGAAATCGCGCGTATCGCGCCGGTGCTGG 263
        A  A  P  V  S  S  D  T  E  I  A  R  I  A  P  V  L
SXT^M010 CGCCGCGCCTGTTTCGTCCGACACAGAAATCGCGCGTATCGCGCCGGTGCTGG 263

        R  A  Q  G  R  W  H  S  R  L  A  R  Q  L  S  T  R
p6148 ACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCAACCCGCG 317
      D  A  L  K  A  D  G  I  P  V  S  L  D  S  Y  Q  P  A
p9123 ACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCAACCCGCG 316
      D  A  L  K  A  D  G  I  P  V  S  L  D  S  Y  Q  P  A
SXT^M010 ACGCGCTCAAGGCAGATGGCATTCCCGTCTCGCTCGACAGTTATCAACCCGCG 316

      D  A  S  L  C  L  V  A  W  C  G  L  S  Q  *  Y  S  R
p6148 ACGCAAGCCTATGCCTTGTCGCGTGGTGTGGCCTATCTCAATGATATTCGCGG 370
       T  Q  A  Y  A  L  S  R  G  V  A  Y  L  N  D  I  R  G
p9123 ACGCAAGCCTATGCCTTGTCGCGTGGTGTGGCCTATCTCAATGATATTCGCGG 369
       T  Q  A  Y  A  L  S  R  G  V  A  Y  L  N  D  I  R  G
SXT^M010 ACGCAAGCCTATGCCTTGTCGCGTGGTGTGGCCTATCTCAATGATATTCGCGG 369
```

```
          F  S  R  R  C  V  L  S  A  I  G  E  I  I  C  Q  T  R
p6148 TTTTCCAGACGCTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCG 423
          F  P  D  A  A  F  Y  P  Q  L  A  K  S  S  A  K  L
p9123 TTTTCCAGACGCTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCG 422
          F  P  D  A  A  F  Y  P  Q  L  A  K  S  S  A  K  L
SXTM010 TTTTCCAGACGCTGCGTTCTATCCGCAATTGGCGAAATCATCTGCCAAACTCG 422

          R  Y  A  F  G  A  R  R  A  G  R  S  A  R  G  T  R
p6148 TCGTTATGCATTCGGTGCAAGACGGGCAGGCAGATCGGCGCGAGGCACCCGCT 476
       V  V  M  H  S  V  Q  D  G  Q  A  D  R  R  E  A  P  A
p9123 TCGTTATGCATTCGGTGCAAGACGGGCAGGCAGATCGGCGCGAGGCACCCGCT 475
       V  V  M  H  S  V  Q  D  G  Q  A  D  R  R  E  A  P  A
SXTM010 TCGTTATGCATTCGGTGCAAGACGGGCAGGCAGATCGGCGCGAGGCACCCGCT 475

       W  R  H  H  G  S  H  C  G  V  L  *  R  A  H  R  G  A
p6148 GGCGACATCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCT 529
          G  D  I  M  D  H  I  A  A  F  F  D  A  R  I  A  A  L
p9123 GGCGACATCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCT 528
          G  D  I  M  D  H  I  A  A  F  F  D  A  R  I  A  A  L
SXTM010 GGCGACATCATGGATCACATTGCGGCGTTCTTTGACGCGCGCATCGCGGCGCT 528

          D  G  C  R  Y  Q  T  Q  P  P  C  P  *  S  R  H  G  V
p6148 GACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGGT 582
          T  G  A  G  I  K  R  N  R  L  V  L  D  P  G  M  G
p9123 GACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGGT 581
          T  G  A  G  I  K  R  N  R  L  V  L  D  P  G  M  G
SXTM010 GACGGGTGCCGGTATCAAACGCAACCGCCTTGTCCTTGATCCCGGCATGGGGT 581

          F  S  G  G  C  S  R  N  L  A  L  G  A  G  A  V  R
p6148 TTTTTCTGGGGGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGAT 635
       F  F  L  G  A  A  P  E  T  S  L  S  V  L  A  R  F  D
p9123 TTTTTCTGGGGGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGAT 634
       F  F  L  G  A  A  P  E  T  S  L  S  V  L  A  R  F  D
SXTM010 TTTTTCTGGGGGCTGCTCCCGAAACCTCGCTCTCGGTGCTGGCGCGGTTCGAT 634

       *  I  A  A  A  L  R  F  A  G  A  S  V  C  F  A  Q  I
p6148 GAATTGCGGCTGCGCTTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATC 688
          E  L  R  L  R  F  D  L  P  V  L  L  S  V  S  R  K  S
p9123 GAATTGCGGCTGCGCTTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATC 687
          E  L  R  L  R  F  D  L  P  V  L  L  S  V  S  R  K  S
SXTM010 GAATTGCGGCTGCGCTTCGATTTGCCGGTGCTTCTGTCTGTTTCGCGCAAATC 687

          L  S  A  R  A  H  R  P  W  S  G  G  C  R  G  R  D  T
p6148 CTTTCTGCGCGCGCTCACAGGCCGTGGTCCGGGGGATGTCGGGGCCGCGACAC 741
          F  L  R  A  L  T  G  R  G  P  G  D  V  G  A  A  T
p9123 CTTTCTGCGCGCGCTCACAGGCCGTGGTCCGGGGGATGTCGGGGCCGCGACAC 740
          F  L  R  A  L  T  G  R  G  P  G  D  V  G  A  A  T
SXTM010 CTTTCTGCGCGCGCTCACAGGCCGTGGTCCGGGGGATGTCGGGGCCGCGACAC 740
```

```
        R  C  R  A  C  R  R  R  R  W  S  *  L  H  P  H  T
p6148 TCGCTGCAGAGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCATCCGCACACAC 794
      L  A  A  E  L  A  A  A  A  G  G  A  D  F  I  R  T  H
p9123 TCGCTGCAGAGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCATCCGCACACAC 793
      L  A  A  E  L  A  A  A  A  G  G  A  D  F  I  R  T  H
SXTM010 TCGCTGCAGAGCTTGCCGCCGCCGCAGGTGGAGCTGACTTCATCCGCACACAC 793

      R  A  A  P  L  A  R  R  A  G  G  I  G  G  A  E  R  N
p6148 GAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTGAAAGAAAC 847
       E  P  R  P  L  R  D  G  L  A  V  L  A  A  L  K  E  T
p9123 GAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTGAAAGAAAC 846
       E  P  R  P  L  R  D  G  L  A  V  L  A  A  L  K  E  T
SXTM010 GAGCCGCGCCCCTTGCGCGACGGGCTGGCGGTATTGGCGGCGCTGAAAGAAAC 846

       R  K  N  S  L
p6148 CGCAAGAATTCGTTA                                        862
        A  R  I  R  *
p9123 CGCAAGAATTCGTTA                                        861
        A  R  I  R  *
SXTM010 CGCAAGAATTCGTTA                                      861
```

generation time as compared to plasmid-free strains. This was observed even when the plasmid was introduced into a naïve host that was not given a chance to adapt to the plasmid. This growth-enhancing effect was not statistically significant, but was observed consistently (Enne *et al.*, 2004). Using similar conditions to those described by Enne *et al.* (2004), we looked for a corresponding growth-enhancing effect from p6148.

Growth curves were performed in M63 minimal media with OD_{600} readings taken every hour (Figure 6.3). Throughout logarithmic phase growth, the p6148-containing E2348/69 grew slightly faster than the other strains. However, there was no difference between the growth rates of JPN15 and JPN15 containing intact p6148. JPN15 carrying the interrupted p6148-Km(*Kpn*I) grew more slowly than the other strains. Based on these results, we conclude that the introduction of p6148 does not provide a growth advantage to *E. coli* JPN15. Although this result contradicts the finding by Enne *et al.* (2004), it is in agreement with the majority of the literature. In general, resistance plasmids impose a fitness cost on their host (Enne *et al.*, 2004; Helling *et al.*, 1981; Johnsen *et al.*, 2002; Lenski *et al.*, 1994; McDermott *et al.*, 1993). Over many generations of co-evolution a plasmid-carrying host may develop compensatory mutations. As a result of these mutations, the plasmid-carrying strain becomes fitter than the plasmid-free strain (Lenski *et al.*, 1994; McDermott *et al.*, 1993). Therefore the introduction of a resistance plasmid into a naïve, plasmid free host, such as JPN15, would not be expected to increase growth rate.

6.4 Conclusions



Figure 6.3 Impact of p6148 on the growth of *E. coli*. The p6148 plasmid, intact (triangle) and interrupted with a kanamycin resistance cassette in the *Kpn*I site (X), were transformed into JPN15. Growth in minimal medium was measured for the p6148 containing strains, E2348/69, the source of p6148 (diamond), and JPN15, a strain that lacks p6148 (square). The above graph shows the results of three replicates.

The results of this study have shown conclusively that the p6148 plasmid from *E. coli* E2348/69 confers resistance to streptomycin. Streptomycin resistance was attributed to the presence of *strA* and *strB*, encoding streptomycin phosphotransferase. On the other hand, the *sul2* ORF from p6148 was unable to confer sulphonamide resistance when expressed from p6148 or from cloning vectors pUC19 and pLG339. The lack of sulphonamide resistance was later explained by the presence of a frameshift mutation and premature stop codon upstream of *sul2*. In addition, the reported growth-enhancing effect conferred by p9123, which is 99% identical to p6148, was not observed upon introduction of p6148 into *E. coli* JPN15.